0001628280-24-037202.txt : 20240814 0001628280-24-037202.hdr.sgml : 20240814 20240814161620 ACCESSION NUMBER: 0001628280-24-037202 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 45 CONFORMED PERIOD OF REPORT: 20240630 FILED AS OF DATE: 20240814 DATE AS OF CHANGE: 20240814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HeartBeam, Inc. CENTRAL INDEX KEY: 0001779372 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 474881450 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-41060 FILM NUMBER: 241208126 BUSINESS ADDRESS: STREET 1: 2118 WALSH AVE., SUITE 210 CITY: SANTA CLARA STATE: CA ZIP: 95050 BUSINESS PHONE: 408-899-4443 MAIL ADDRESS: STREET 1: 2118 WALSH AVE., SUITE 210 CITY: SANTA CLARA STATE: CA ZIP: 95050 10-Q 1 beat-20240630.htm 10-Q beat-20240630
0001779372December 312024Q2FALSExbrli:sharesiso4217:USDiso4217:USDxbrli:sharesbeat:segmentxbrli:purebeat:directorbeat:site00017793722024-01-012024-06-300001779372us-gaap:CommonClassAMember2024-01-012024-06-300001779372us-gaap:WarrantMember2024-01-012024-06-3000017793722024-08-1200017793722024-06-3000017793722023-12-310001779372us-gaap:RelatedPartyMember2024-06-300001779372us-gaap:RelatedPartyMember2023-12-3100017793722024-04-012024-06-3000017793722023-04-012023-06-3000017793722023-01-012023-06-300001779372us-gaap:CommonStockMember2024-03-310001779372us-gaap:AdditionalPaidInCapitalMember2024-03-310001779372us-gaap:RetainedEarningsMember2024-03-3100017793722024-03-310001779372us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001779372us-gaap:CommonStockMember2024-04-012024-06-300001779372us-gaap:RetainedEarningsMember2024-04-012024-06-300001779372us-gaap:CommonStockMember2024-06-300001779372us-gaap:AdditionalPaidInCapitalMember2024-06-300001779372us-gaap:RetainedEarningsMember2024-06-300001779372us-gaap:CommonStockMember2023-03-310001779372us-gaap:AdditionalPaidInCapitalMember2023-03-310001779372us-gaap:RetainedEarningsMember2023-03-3100017793722023-03-310001779372us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001779372us-gaap:CommonStockMember2023-04-012023-06-300001779372us-gaap:RetainedEarningsMember2023-04-012023-06-300001779372us-gaap:CommonStockMember2023-06-300001779372us-gaap:AdditionalPaidInCapitalMember2023-06-300001779372us-gaap:RetainedEarningsMember2023-06-3000017793722023-06-300001779372us-gaap:CommonStockMember2023-12-310001779372us-gaap:AdditionalPaidInCapitalMember2023-12-310001779372us-gaap:RetainedEarningsMember2023-12-310001779372us-gaap:AdditionalPaidInCapitalMember2024-01-012024-06-300001779372us-gaap:CommonStockMember2024-01-012024-06-300001779372us-gaap:RetainedEarningsMember2024-01-012024-06-300001779372us-gaap:CommonStockMember2022-12-310001779372us-gaap:AdditionalPaidInCapitalMember2022-12-310001779372us-gaap:RetainedEarningsMember2022-12-3100017793722022-12-310001779372us-gaap:AdditionalPaidInCapitalMember2023-01-012023-06-300001779372us-gaap:CommonStockMember2023-01-012023-06-300001779372us-gaap:RetainedEarningsMember2023-01-012023-06-300001779372us-gaap:PrivatePlacementMemberbeat:PublicVenturesLLCMember2024-05-020001779372us-gaap:PrivatePlacementMemberbeat:PublicVenturesLLCMember2024-04-012024-06-300001779372us-gaap:PrivatePlacementMemberbeat:PublicVenturesLLCMember2024-06-300001779372us-gaap:StockOptionMember2024-01-012024-06-300001779372us-gaap:StockOptionMember2024-04-012024-06-300001779372us-gaap:StockOptionMember2023-04-012023-06-300001779372us-gaap:StockOptionMember2023-01-012023-06-300001779372us-gaap:RestrictedStockMember2024-04-012024-06-300001779372us-gaap:RestrictedStockMember2024-01-012024-06-300001779372us-gaap:RestrictedStockMember2023-01-012023-06-300001779372us-gaap:RestrictedStockMember2023-04-012023-06-300001779372us-gaap:WarrantMember2024-04-012024-06-300001779372us-gaap:WarrantMember2024-01-012024-06-300001779372us-gaap:WarrantMember2023-01-012023-06-300001779372us-gaap:WarrantMember2023-04-012023-06-3000017793722023-01-012023-12-310001779372beat:A2022EquityPlanMember2024-05-310001779372beat:A2022EquityPlanMember2024-06-300001779372us-gaap:EmployeeStockOptionMembersrt:MinimumMember2024-01-012024-06-300001779372us-gaap:EmployeeStockOptionMembersrt:MaximumMember2024-01-012024-06-300001779372us-gaap:EmployeeStockOptionMembersrt:MinimumMember2023-01-012023-06-300001779372us-gaap:EmployeeStockOptionMembersrt:MaximumMember2023-01-012023-06-300001779372us-gaap:EmployeeStockOptionMember2024-01-012024-06-300001779372us-gaap:EmployeeStockOptionMember2023-01-012023-06-300001779372us-gaap:RestrictedStockUnitsRSUMember2023-12-310001779372us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-06-300001779372us-gaap:RestrictedStockUnitsRSUMember2024-06-300001779372us-gaap:EmployeeStockOptionMemberus-gaap:GeneralAndAdministrativeExpenseMember2024-04-012024-06-300001779372us-gaap:EmployeeStockOptionMemberus-gaap:GeneralAndAdministrativeExpenseMember2023-04-012023-06-300001779372us-gaap:EmployeeStockOptionMemberus-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-06-300001779372us-gaap:EmployeeStockOptionMemberus-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-06-300001779372us-gaap:RestrictedStockUnitsRSUMemberus-gaap:GeneralAndAdministrativeExpenseMember2024-04-012024-06-300001779372us-gaap:RestrictedStockUnitsRSUMemberus-gaap:GeneralAndAdministrativeExpenseMember2023-04-012023-06-300001779372us-gaap:RestrictedStockUnitsRSUMemberus-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-06-300001779372us-gaap:RestrictedStockUnitsRSUMemberus-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-06-300001779372us-gaap:GeneralAndAdministrativeExpenseMember2024-04-012024-06-300001779372us-gaap:GeneralAndAdministrativeExpenseMember2023-04-012023-06-300001779372us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-06-300001779372us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-06-300001779372us-gaap:EmployeeStockOptionMemberus-gaap:ResearchAndDevelopmentExpenseMember2024-04-012024-06-300001779372us-gaap:EmployeeStockOptionMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-04-012023-06-300001779372us-gaap:EmployeeStockOptionMemberus-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-06-300001779372us-gaap:EmployeeStockOptionMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-06-300001779372us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ResearchAndDevelopmentExpenseMember2024-04-012024-06-300001779372us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-04-012023-06-300001779372us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-06-300001779372us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-06-300001779372us-gaap:ResearchAndDevelopmentExpenseMember2024-04-012024-06-300001779372us-gaap:ResearchAndDevelopmentExpenseMember2023-04-012023-06-300001779372us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-06-300001779372us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-06-300001779372beat:ExecutivesAndEmployeesMember2023-01-012023-06-300001779372us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedCompensationAwardTrancheOneMemberbeat:ExecutivesAndEmployeesMember2023-01-012023-06-300001779372us-gaap:ShareBasedCompensationAwardTrancheTwoMemberbeat:ExecutivesAndEmployeesMember2023-01-012023-06-3000017793722024-04-3000017793722024-04-012024-04-300001779372us-gaap:RelatedPartyMember2024-04-012024-04-300001779372us-gaap:EmployeeStockOptionMemberus-gaap:RelatedPartyMember2024-04-012024-04-300001779372us-gaap:RelatedPartyMember2024-04-012024-06-3000017793722024-01-312024-01-3100017793722024-02-010001779372beat:TripleRingTechnologiesMember2022-03-310001779372beat:TripleRingTechnologiesMember2024-04-012024-06-300001779372beat:TripleRingTechnologiesMember2024-01-012024-06-300001779372beat:TripleRingTechnologiesMember2023-04-012023-06-300001779372beat:TripleRingTechnologiesMember2023-01-012023-06-300001779372beat:TripleRingTechnologiesMember2024-06-300001779372beat:ClinicalResearchOrganizationMember2024-03-080001779372beat:ClinicalResearchOrganizationMember2024-04-012024-06-300001779372beat:ClinicalResearchOrganizationMember2024-01-012024-06-300001779372beat:ClinicalResearchOrganizationMember2024-06-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2024
or
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ___________ to ___________
Commission File Number: 001-41060
HEARTBEAM, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware47-4881450
State or Other Jurisdiction of
Incorporation or Organization
I.R.S. Employer
Identification No.
2118 Walsh Avenue, Suite 210
Santa Clara, CA
95050
Address of Principal Executive OfficesZip Code
(408) 899-4443
Registrant’s Telephone Number, Including Area Code
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common StockBEATNASDAQ
WarrantsBEATWNASDAQ
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐
Accelerated filer ☐
Non-accelerated filer ☒
Smaller reporting company ☒
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒
Number of shares of common stock outstanding as of August 12, 2024 was 26,562,111.

HEARTBEAM, INC.
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”). In particular, statements contained in this Quarterly Report on Form 10-Q, including but not limited to, statements regarding the sufficiency of our cash, our ability to finance our operations and business initiatives and obtain funding for such activities; our future results of operations and financial position, business strategy and plan prospects, or costs and objectives of management for future acquisitions, are forward looking statements. These forward-looking statements relate to our future plans, objectives, expectations and intentions and may be identified by words such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “intends,” ’‘targets,” “projects,” “contemplates,” ’‘believes,” “seeks,” “goals,” “estimates,” ’‘predicts,” ’‘potential” and “continue” or similar words. Readers are cautioned that these forward-looking statements are based on our current beliefs, expectations and assumptions and are subject to risks, uncertainties, and assumptions that are difficult to predict, including those identified below, under Part II, Item lA. “Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q and those risks identified under Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission on March 20, 2024. Therefore, actual results may differ materially and adversely from those expressed, projected or implied in any forward-looking statements. We undertake no obligation to revise or update any forward-looking statements for any reason.

NOTE REGARDING COMPANY REFERENCES
Throughout this Quarterly Report on Form 10-Q, “HeartBeam,” “Company,” “we,” “us” and “our” refer to HeartBeam, Inc.

FORM 10-Q
TABLE OF CONTENTS

Page
17
17

19
19
19
19
19
19
19
20
21

PART I - FINANCIAL INFORMATION
Item 1. Condensed Unaudited Financial Statements
HEARTBEAM, INC.
Condensed Balance Sheets (Unaudited)
(In thousands, except share data)
June 30,
2024		December 31,
2023
Assets
Current Assets:
Cash and cash equivalents
$9,157 $16,189 
Prepaid expenses and other current assets
544 636 
Total Current Assets9,701 16,825 
Property and equipment, net370 256 
Other assets55 50 
Total Assets$10,126 $17,131 
Liabilities and Stockholders’ Equity
Current Liabilities:
Accounts payable and accrued expenses (includes related party $- and $2, respectively)
$1,420 $1,194 
Total Current Liabilities1,420 1,194 
Total Liabilities
1,420 1,194 
Commitments (Note 7)


Stockholders’ Equity
Preferred stock - $0.0001 par value; 10,000,000 authorized; 0 shares outstanding at June 30, 2024 and December 31, 2023
— — 
Common stock - $0.0001 par value 100,000,000 shares authorized; 26,562,111 and 26,329,032 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively
3 3 
Additional paid in capital
55,090 52,759 
Accumulated deficit
(46,387)(36,825)
Total Stockholders’ Equity
8,706 15,937 
Total Liabilities and Stockholders’ Equity
$10,126 $17,131 
See accompanying notes to the condensed unaudited financial statements
1
HEARTBEAM, INC.
Condensed Statements of Operations (Unaudited)
(In thousands, except share and per share data)
Three months ended June 30,Six months ended June 30,
2024202320242023
Operating Expenses:
General and administrative
$2,246 $1,828 $4,602 $4,303 
Research and development
2,844 1,484 5,272 3,165 
Total operating expenses
5,090 3,312 9,874 7,468 
Loss from operations(5,090)(3,312)(9,874)(7,468)
Other Income
Interest income134 158 312 178 
Total other income 134 158 312 178 
Loss before provision for income taxes(4,956)(3,154)(9,562)(7,290)
Income tax provision— — — — 
Net Loss$(4,956)$(3,154)$(9,562)$(7,290)
Net loss per share, basic and diluted$(0.19)$(0.16)$(0.36)$(0.52)
Weighted average common shares outstanding, basic and diluted26,566,832 19,690,251 26,538,863 13,910,365 
See accompanying notes to the condensed unaudited financial statements
2
HEARTBEAM, INC.
Condensed Statement of Changes in Stockholders’ Equity (Unaudited)
(In thousands, except share data)
Three months ended June 30, 2024
Common StockAdditional
Paid-in
Capital		Accumulated
Deficit		Total
Stockholders'
Equity
SharesAmount
Balance - April 1, 202426,329,032 $3 $53,966 $(41,431)$12,538 
Stock based compensation expense— — 1,040 — 1,040 
Sale of Common Stock under ATM, net of issuance costs50,000 — 76 — 76 
Stock issuance upon exercise of stock options5,252 — 8 — 8 
Stock issuance upon vesting of restricted stock units177,827 — — — — 
Net loss— — — (4,956)(4,956)
Balance – June 30, 2024
26,562,111 $3 $55,090 $(46,387)$8,706 
Three months ended June 30, 2023
Common StockAdditional
Paid-in
Capital		Accumulated
Deficit		Total
Stockholders'
Equity
SharesAmount
Balance – April 1, 20238,227,074 $1 $25,462 $(26,322)$(859)
Stock based compensation expense— — 702 — 702 
Sale of Common Stock, net of issuance costs17,666,666 2 24,268 — 24,270 
Stock issuance upon exercise of stock options88,026 — 103 — 103 
Stock issuance upon vesting of restricted stock units8,750 — — — — 
Net loss— — — (3,154)(3,154)
Balance – June 30, 202325,990,516 $3 $50,535 $(29,476)$21,062 








3
Six months ended June 30, 2024
Common StockAdditional
Paid-in
Capital		Accumulated
Deficit		Total
Stockholders'
Equity
SharesAmount
Balance - January 1, 202426,329,032 $3 $52,759 $(36,825)$15,937 
Stock based compensation expense— — 2,247 — 2,247 
Sale of Common Stock under ATM, net of issuance costs50,000 — 76 — 76 
Stock issuance upon exercise of stock options5,252 — 8 — 8 
Stock issuance upon vesting of restricted stock units177,827 — — — — 
Net loss— — — (9,562)(9,562)
Balance - June 30, 202426,562,111 $3 $55,090 $(46,387)$8,706 
Six months ended June 30, 2023
Common StockAdditional
Paid-in
Capital		Accumulated
Deficit		Total
Stockholders'
Equity
SharesAmount
Balance - January 1, 20238,009,743 $1 $24,559 $(22,186)$2,374 
Stock based compensation expense— — 1,095 — 1,095 
Sale of Common Stock under ATM, net of issuance costs17,872,955 2 24,762 — 24,764 
Stock issuance upon exercise of stock options88,026 — 103 — 103 
Stock issuance upon vesting of restricted stock units12,500 — — — — 
Stock issuance upon exercise of warrants7,292 — 16 — 16 
Net loss— — — (7,290)(7,290)
Balance – June 30, 202325,990,516 $3 $50,535 $(29,476)$21,062 
See accompanying notes to the condensed unaudited financial statements
4
HEARTBEAM, INC.
Condensed Statements of Cash Flows (Unaudited)
(In thousands)
Six months ended June 30,
20242023
Cash Flows From Operating Activities
Net loss$(9,562)$(7,290)
Adjustments to reconcile net loss to net cash used in operating activities

Stock based compensation expense2,247 1,095 
Changes in operating assets and liabilities:
Prepaid expenses and other current assets92 152 
Accounts payable and accrued expenses210 (1,094)
Net cash used in operating activities(7,013)(7,137)

Cash Flows From Investing Activities
Purchase of property and equipment(98)— 
Purchase of short-term investments— (3,939)
Net cash used in investing activities(98)(3,939)
Cash Flows From Financing Activities
Proceeds from sale of equity, net of issuance costs76 24,764 
Proceeds from exercise of stock options8 103 
Proceeds from exercise of warrants— 16 
Net cash provided by financing activities84 24,883 
Net increase (decrease) in cash and restricted cash(7,027)13,807 
Cash, cash equivalents and restricted cash – Beginning of period16,239 3,594 
Cash, cash equivalents and restricted cash – Ending of period$9,212 $17,401 
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents$9,157 $17,401 
Restricted cash (included in other assets)55— 
Total cash, cash equivalents and restricted cash$9,212 $17,401 
Supplemental Disclosures of Cash Flow Information:
Purchase of property and equipment in accounts payable$16 $— 
Taxes paid$— $— 
See accompanying notes to the condensed unaudited financial statements
5
HEARTBEAM, INC.
NOTES TO CONDENSED UNAUDITED FINANCIAL STATEMENTS
NOTE 1 – ORGANIZATION AND OPERATIONS
HeartBeam, Inc. (“HeartBeam” or the “Company”) is a cardiac technology company focusing on developing and commercializing higher resolution ambulatory Electrocardiogram (“ECG”) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company’s ability to develop higher resolution ECG solutions is achieved through the development of the Company’s proprietary and patented Vector Electrocardiography (“VECG”) technology platform. HeartBeam’s VECG is capable of developing three-dimensional (3D) representations of cardiac electrical activity by displaying the spatial locations of ECG waveforms that demonstrated in early studies to deliver diagnostic capability equal or superior to traditional hospital-based ECG systems.

The Company has validated this technology and is seeking U.S. Food and Drug Administration (“FDA”) clearance of its initial telehealth products. The Company filed a 510(k) submission in 2023 for its initial product, a patient-held VECG device, which is planned, with a second submission, to become an ambulatory device, carried by patients, which can synthesize a 12L ECG for physician review.

The Company was incorporated in 2015 as a Delaware corporation. The Company’s operations are based in Santa Clara, California and operates as one segment.

NOTE 2 – GOING CONCERN AND OTHER UNCERTAINTIES

The Company is subject to a number of risks similar to those of early stage medical device companies, including dependence on key individuals and products, the inherent uncertainties with regulatory approvals, the difficulties inherent in the development of a commercial market, the potential need to obtain additional capital, competition from larger companies, other technology companies and other technologies.

The Company has incurred losses each year since inception and has experienced negative cash flows from operations in each year since inception. As of June 30, 2024 the Company has a cash and cash equivalents balance of approximately $9.2 million. Based on its current business plan assumptions and expected cash burn rate, the Company believes that the existing cash is insufficient to fund operations for the next twelve months following the issuance of these financial statements. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern.

On May 2, 2024, the Company entered into a Sales Agreement (“PV Sales Agreement”) with Public Ventures, LLC, as sales agent (“Public Ventures” or “Agent”), pursuant to which the Company may sell up to an aggregate of approximately $17 million of shares of the Company’s common stock. There were 50,000 shares issued under the At The Market (“ATM”) during the three months ended June 30, 2024. As of June 30, 2024, there was approximately $16.9 million available for issuance under the ATM.

The Company’s continued operations will depend on its ability to raise additional capital through various potential sources, such as equity and/or debt financings, strategic relationships until FDA clearance is obtained for the Company’s initial telehealth product and sufficient revenue can be generated to achieve positive cash flow from operations. The Company expects no material commercial revenue in 2024. Management can provide no assurance that such financing or strategic relationships will be available on acceptable terms, or at all, which would likely have a material adverse effect on the Company and its financial statements.

The accompanying unaudited condensed financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that may result should the Company be unable to continue as a going concern.

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

BASIS OF PRESENTATION

The accompanying condensed unaudited financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("US GAAP") and in conformity with the instructions on Form 10-Q and Rule 8-03 of Regulation S-X and the related rules and regulations of the Securities and Exchange Commission (“SEC”) and have been prepared on a basis which assumes that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business.
6
In the opinion of management, the unaudited interim condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results of operations for the periods presented. The interim operating results are not necessarily indicative of results that may be expected for any subsequent period. The accompanying condensed unaudited financial statements should be read in conjunction with the Company’s audited annual financial statements and notes thereto included in the Company’s Form 10-K filed with the SEC on March 20, 2024 (“2023 Annual Report”).

CASH, CASH EQUIVALENTS AND RESTRICTED CASH

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash deposits. The Company maintains its cash in institutions insured by the Federal Deposit Insurance Corporation (“FDIC”) and has cash balances in accounts which exceed the federally insured limits as of June 30, 2024 and December 31, 2023. The Company has made a deposit to the bank for their credit cards in the amount of $55,000 and is classified as restricted cash included in other assets as of June 30, 2024.

USE OF ESTIMATES

The preparation of financial statements in conformity with US GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be based on amounts that differ from those estimates.

PROPERTY AND EQUIPMENT, NET

Property and equipment are stated at cost less accumulated depreciation. Depreciation of property and equipment is calculated using the straight-line method over the estimated useful lives of the assets. The Company regularly evaluates the estimated remaining useful lives of the Company’s property and equipment, net, to determine whether events or changes in circumstances warrant a revision to the remaining period of depreciation. Maintenance and repairs are expensed as incurred. As of June 30, 2024, property and equipment, net represents construction-in-progress of $370,000 related to tooling development that has not been placed into service. Construction-in-progress amounts are not subject to depreciation as such assets are not yet available for their intended use.

NET LOSS PER COMMON SHARE

Basic net loss per share excludes the effect of dilution and is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding.

Diluted net loss per share is computed by giving effect to all potential shares of common stock, including stock options and warrants to the extent dilutive. Basic net loss per share was the same as diluted net loss per share for the three and six months ended June 30, 2024 and 2023 as the inclusion of all potential common shares outstanding would have an anti-dilutive effect.

In accordance with ASC 260-10-45-13, exercisable penny options are included in the calculation of weighted average basic and diluted earnings per share. As of June 30, 2024, 182,169 penny options have been included in the calculation of weighted average basic and diluted earnings per share.

The following is a summary of awards outstanding as of June 30, 2024 and 2023, which are not included in the computation of basic and diluted weighted average shares:
7
Three and Six months ended
June 30,
20242023
Stock options (excluding exercisable penny stock options)5,993,356 2,851,383 
Restricted stock units283,411 246,470 
Warrants5,152,397 5,152,397 
Total11,429,164 8,250,250 

RECENTLY ISSUED ACCOUNTING STANDARDS

Not Yet Adopted as of June 30, 2024:

In November 2023, the Financial Standards Accounting Board (FASB) issued Accounting Standards Update (ASU) 2023-07 "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures" which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 is effective for the Company’s annual periods beginning January 1, 2024, and for interim periods beginning January 1, 2025, with early adoption permitted. The Company does not expect that the updated standard will have a significant impact on the Company’s financial statement disclosures.

In December 2023, the FASB issued ASU 2023-09 "Income Taxes (Topics 740): Improvements to Income Tax Disclosures" to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. ASU 2023-09 is effective for the Company’s annual periods beginning January 1, 2025, with early adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on the Company’s financial statement disclosures.

In March 2024, the FASB issued ASU 2024-02 “Codification Improvements – Amendments to Remove References to the Concepts Statements.” This amendments to the Codification that remove references to various Concepts Statement. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2024. Early application of the amendments in this update is permitted for all entities, for any fiscal year or interim period for which financial statements have not yet been issued (or made available for issuance). If an entity adopts the amendments in an interim period, it must adopt them as of the beginning of the fiscal year that includes that interim period. The Company is currently evaluating the impact that the adoption of this standard will have on the Company’s financial statement disclosures.

NOTE 4 – STOCKHOLDERS’ EQUITY

WARRANTS

The following is a summary of warrant activity during the six months ended June 30, 2024:
Number of
shares		Weighted
average exercise
price		Weighted
average
remaining life (years)		Aggregate
intrinsic value
(in thousands)
Outstanding and exercisable - December 31, 2023
5,152,397 $4.71 3.35$792
Exercised— — — — 
Expired— — — — 
Outstanding and exercisable – June 30, 2024
5,152,397 $4.71 2.85$1,158 


8
NOTE 5 – STOCK-BASED COMPENSATION

At the June 2024 annual stockholders’ meeting the 2022 Equity Incentive Plan was amended to increase the number of authorized shares from 5,900,000 shares to 8,900,000.
STOCK OPTIONS
The following is a summary of stock option activity during the six months ended June 30, 2024:
Number of
options
outstanding		Weighted
average
exercise
price		Average
remaining
contractual life
(in years)		Aggregate
intrinsic value
(in thousands)
Outstanding – December 31, 2023
6,092,525 $2.22 8.7$2,945 
Options granted
114,000 2.27 
Options exercised
(5,252)1.54 
Options cancelled(25,748)2.41 
Outstanding – June 30, 2024
6,175,525 $2.23 8.4$3,692 
Exercisable – June 30, 2024
1,748,660 $1.90 7.4$1,687 
The Company estimates the fair values of stock options using the Black-Scholes option-pricing model on the date of grant. For the six months ended June 30, 2024 and 2023, the assumptions used in the Black-Scholes option pricing model, which was used to estimate the grant date fair value per option, were as follows:

Six months ended June 30,
20242023
Weighted-average Black-Scholes option pricing model assumptions:
Volatility
125.89% - 128.74%
110.23% - 111.73%
Expected term (in years)
6.02 - 7.00
5.71 - 6.07
Risk-free rate
4.50% - 4.60%
3.54% - 3.80%
Expected dividend yield$— $— 
Weighted average grant date fair value per share
$1.81 - $2.48
$1.73 - $3.38

RESTRICTED STOCK UNITS
The following is a summary of RSU’s awards activity:
Six months ended June 30, 2024
Numbers of SharesWeighted Average Grant Date Fair value
Non-Vested at beginning of period217,881 $3.12 
Shares granted243,357 2.26 
Shares vested(177,827)3.13 
Non-vested at the end of period283,411 $2.38 
9

STOCK BASED COMPENSATION

The following is a summary of stock-based compensation expense:
Three months ended June 30,Six months ended June 30,
2024202320242023
General and administrative
Stock options602,000 507,200 1,338,000 707,200 
RSU’s142,000 116,400 283,000 217,400 
Total general and administrative744,000 623,600 1,621,000 924,600 
Research and development
Stock options287,000 78,800 607,000 170,800 
  RSU’s 9,000 — 19,000 — 
Total research and development296,000 78,800 626,000 170,800 
Total1,040,000 702,400 2,247,000 1,095,400 

During the six months ended 2023, the Company granted 2,208,000 options to various executives and employees. Sixty percent (60%) of these options vest based on FDA Clearance for marketing of HeartBeam’s synthesized 12L product and the remaining forty percent (40%) vest monthly over a period of 48 months.

The Company calculated the fair value for each of these grants using the Black-Scholes option pricing model and the performance-based options are expensed beginning from date of grant to the expected FDA clearance, which is based on management’s probability assessment performed on a quarterly basis.

As of June 30, 2024, total compensation cost not yet recognized related to unvested stock options and unvested RSUs was approximately $6.4 million and $0.6 million, respectively, which is expected to be recognized over a weighted-average period of 2.4 years and 1.08 years, respectively.

NOTE 6 – RELATED PARTY TRANSACTIONS

During the course of business, the Company obtains accounting services from CTRLCFO, a firm in which an executive of the Company has significant influence. On December 29, 2023, this executive, informed the Company of his plans to retire from his position as of February 1, 2024 and as such ceased to be a related party as of February 1, 2024. The Company had balances due to this firm amounting to approximately $2,000 as of December 31, 2023.

During April 2024, the Company entered into consulting agreement with one of the independent Board of Directors to provide business development consulting services. For these consulting services, the Company agreed to pay $5,000 per month as remuneration and granted 70,000 options to vest during over a period of 36 months. During the three months ended June 30, 2024, the Company recognized $24,500 related to these consulting services, which includes stock based compensation expense of $9,500.

NOTE 7 – COMMITMENTS

Lease Obligations

Prior to February 1, 2024, the Company was in a month-to-month lease agreement for its headquarters. The agreement was for an undefined term that could be cancelled at any time, given one month’s notice by either party. The Company’s monthly rent expense associated with this agreement was approximately $1,800. This headquarters lease was in the name of the Company’s Chief Executive Officer, and the cost was reimbursed monthly to CEO until January 31, 2024 when the Company terminated the month-to-month lease, and entered into a new lease in name of the Company with the same landlord. The new lease commenced on February 1, 2024, for initial period of 3 years. The Company performed an assessment and concluded that amount of operating lease right-of-use, or ROU assets was below the Company’s capitalization thresholds set in accordance with ASC 842. For the three and six months ended June 30, 2024 rent was approximately $5,400 and $10,440, respectively. For the three and six months ended June 30, 2023, rent expense was approximately $4,000 and $8,000, respectively.

10
Professional Services Agreement

In March 2022, the Company entered into a professional services agreement with Triple Ring Technologies, Inc. (“TRT”), a co-development company, to assist in the design and development of the Company’s telehealth complete solution 3D vector ECG collection device for remote heart attack or MI monitoring. This agreement was followed by several amendments. The agreement with TRT includes a commitment totaling $1.7 million. For the three and six months ended June 30, 2024, the Company has expensed approximately $0.1 million and $0.2 million, respectively. For the three and six months ended June 30, 2023, the Company has expensed approximately $0.4 million and $0.6 million, respectively.

As of June 30, 2024, the Company has a remaining commitment of $0.2 million.

Clinical Research Organization

On March 8, 2024, the Company has entered into an agreement with Clinical Research Organization (CRO) to perform certain services related to project set up, clinical trial management and monitoring during next six months. As per terms of the agreement, the Company will pay CRO approximately $0.5 million for these services. Additionally, the Company has signed a Clinical Study Agreement with first of five sites to carry out the clinical study for which CRO will act as Company sponsor in relation to payment for these services. The total cost of the clinical trial including the CRO cost is expected to approximate $0.8 million. For the three months and six months ended June 30, 2024, the Company has expensed $0.3 million and $0.7 million based on actual services performed by the CRO and clinical sites, of which $0.2 million was accrued as of June 30, 2024. As of June 30, 2024, the Company has a remaining commitment of $0.1 million.



11
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following management’s discussion and analysis is intended as a review of significant factors affecting our financial condition and results of operations for the periods indicated. The discussion should be read in conjunction with our condensed unaudited financial statements and the notes presented herein included in this Form 10-Q and the audited financial statements and the other information set forth in the 2023 Form 10-K. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. In addition to historical information, the following Management’s Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements that involve risks and uncertainties including, but not limited to, those set forth below under “Risk Factors” and elsewhere herein, and those identified under Part I, Item 1A of our 2023 Form 10-K. Our actual results could differ significantly from those anticipated in these forward-looking statements as a result of certain factors discussed herein and any other periodic reports filed and to be filed with the Securities and Exchange Commission.

Overview

We are a medical technology company focused on transforming cardiac care through the power of personalized insights. Our aim is to deliver innovative, higher resolution ambulatory cardiac monitoring solutions that can be used by patients anywhere to enable the detection and monitoring of cardiac disease outside of a healthcare facility. Our ability to develop higher resolution Electrocardiogram (“ECG”) solutions is achieved through the development of our proprietary and patented Vector Electrocardiography (“VECG”) technology platform. Our VECG technology is capable of capturing 3D vector signals of the heart’s electrical activity and synthesizing a 12-Lead (“12L”) ECG from these signals. In early studies, our approach demonstrated equal or superior diagnostic capability than traditional hospital-based 12L ECG systems.

Our Products (“Product” or “Products”) require FDA clearance and have not been cleared for marketing.

We believe our Products and services will benefit many stakeholders, including patients, healthcare providers, and healthcare payors. We are developing our telehealth Product, (“HeartBeam AIMIGo™” or “AIMIGo™”), to address the rapidly growing field of ambulatory cardiac health monitoring. HeartBeam AIMIGo is comprised of a credit card sized electrocardiogram device, a patient application, a physician portal, and powerful cloud-based algorithms. We believe that we are uniquely positioned to play a central role in ambulatory cardiac monitoring including high-risk Coronary Artery Disease (“CAD”) patients, because the initial studies have shown that our ischemia detection system may be more accurate than existing ambulatory monitoring solutions. CAD patients are at increased risk for a heart attack or Myocardial Infarction (“MI”).

To date, we have developed a working prototype for HeartBeam AIMIGo and have filed a 510(k) submission with the FDA. This submission is for the initial Product, a device which is a 3 lead (3L) X, Y, Z vector VECG. We are in the substantive review phase of answering questions posed by the FDA on this submission. We have clarified the information requested in meetings with FDA representatives and are finalizing our official responses. During the second quarter of 2024 we received additional questions from FDA, have provided answers and additional data, and are engaged in productive discussions to finalize the clearance. If cleared as anticipated, we believe this will be the first patient-held VECG device to be cleared by the FDA and this will be a major milestone for the company.

Following the FDA clearance of the AIMIGo 3L device, we plan to file a submission for the software algorithms that synthesize a 12L ECG from the HeartBeam AIMIGo device. We have held two Pre-submission meetings with FDA on this 12L synthesis submission. These meetings have been focused primarily on the performance goals of our clinical study that is designed to demonstrate the similarity between our synthesized 12L signal and the output of a standard 12L ECG. Based on feedback from FDA and our clinical experts, we have designed our clinical study, “Clinical Validation of AIMIGo 12 Lead ECG Synthesis Software for Arrhythmia Detection: A Prospective Multicenter Pivotal Study,” (the “VALID-ECG Study”).

On June 20, 2024, we completed patient enrollment in the VALID-ECG study. The VALID-ECG study is a prospective single-arm multicenter trial designed with the goal to validate the AIMIGo 12L ECG Synthesis Software by comparing its results with those of a standard FDA-cleared 12L ECG using both quantitative and qualitative assessment methodologies. We enrolled a total of 198 patients presenting to an outpatient cardiology clinic or arrhythmia center for symptoms suggestive of cardiac arrhythmia or for routine checkup of previously diagnosed arrhythmia. The study included five sites. The primary objective is to demonstrate the equivalence of ECG waveforms between AIMIGo Synthesized 12L ECG and Standard 12L ECG, recorded simultaneously in each subject, by assessing intervals and amplitudes.
12

We are currently analyzing the data and working on the other components of the second 510(k) application. We anticipate submitting this 510(k) application in the second half of 2024. The result of these two 510(k) submissions, when cleared by the FDA as anticipated, will be an ambulatory device, carried by patients, which can synthesize a 12L ECG for physician review.

We continue to anticipate that our limited launch of AIMIGo will occur by the end of 2024. This limited launch, focused on the AIMIGo 3L system, will provide the company with valuable feedback on the user experience and functionality of the system in a real world setting. We do not anticipate that the AIMIGo 3L system clearance will generate significant revenue before the 12L clearance.

We also have an active AI program underway. Our AI team includes 5 PhDs. The leadership has deep AI expertise, including prior positions at Apple, Microsoft and Google. We have acquired approximately one million 12L ECGs from various sources, a key element in our fast-paced AI development efforts.

We have developed initial deep learning algorithms, focused on the ability to detect various cardiac arrhythmias. HeartBeam has had data on its deep learning algorithm accepted and presented at two prestigious Electrophysiology conferences. Data were presented at the European Heart Rhythm Association in Berlin, Germany in April 2024 and at the Heart Rhythm Society, in Boston MA in May 2024. We believe that, when combined with our Products, HeartBeam’s AI will provide additional value to patients and physicians in several ways, including:

•Providing automated classification of cardiac conditions, including common arrhythmias,
•The potential to further enhance user experience and simplify the onboarding process, and
•In the longer run, we believe that applying deep learning algorithms on top of the rich VECG data, especially with the longitudinal dataset from patients taking repeated readings, may result in unsurpassed predictive and diagnostic capabilities.

The custom software and hardware of our Products are classified as Class II medical devices by the FDA, running on an FDA registered Class I software platform. Premarket review and clearance by the FDA for Class II devices is generally accomplished through the 510(k) premarket notification process or De Novo process. Given the proposed intended use of our device, the 510(k) submission is expected to require clinical data to support FDA clearance.

A landmark clinical study on the HeartBeam technology was published in the August 2023 issue of the journal JACC: Advances. The publication, “Coronary Artery Occlusion Detection Using 3-Lead ECG System Suitable for Credit Card-Size Personal Device Integration” demonstrated that HeartBeam’s VECG technology detects the presence of a coronary occlusion, the cause of heart attacks, with the same accuracy as a standard 12L ECG.

The study showed that the automated analysis of the VECG and 12L ECG signals had similar performance in determining whether a coronary artery was occluded. Also in the study, the human interpretation of the 12L ECGs had significant intra- and inter-observer variability, which does not occur with automated readings. The study also showed that the presence of the “normal baseline” recording, a novel feature that is integral to HeartBeam’s VECG technology, dramatically improved the accuracy of interpretation, increasing the Area Under the Curve (“AUC”), a standard measure of diagnostic performance, from 0.72 to 0.95. This is particularly important since physicians who are analyzing 12L ECGs often do not have access to a normal baseline, implying that the HeartBeam system could outperform this approach.

The study was a collaboration of Harvard Medical School Faculty at Beth Israel Deaconess Medical Center in Boston, Massachusetts, and Clinical Center of Serbia in Belgrade.

As of June 30, 2024, we had 15 employees. We intend to hire or engage additional full-time professionals, employees, and / or consultants in alignment with our growth strategy. Although the market is highly competitive for attracting and retaining highly qualified professionals in our industry, we continue our endeavor to find such candidates for our Company. Our management team and additional personnel that we may hire in the future will be primarily responsible for executing and implementing growth opportunities, making tactical decisions related to our strategy and pursuing opportunities to invest in new technologies through strategic partnerships and acquisitions.



13
Recent Developments

New Patent Assignments

Thus far in 2024, we have been granted two new U.S. patents:

•One patent covers apparatuses and methods that facilitate the comparison of cardiac signals over time for the automated or assisted detection of heart attacks. The other covers methods and apparatuses around HeartBeam’s wrist-based ECG system.

•We now have 13 issued U.S. patents and ten pending U.S applications. Outside of the U.S., we have four issued patents in Germany, France, Netherlands and United Kingdom and nineteen pending applications in Canada, China, the European Union, Japan, South Korea and Australia. We also have one pending Patent Cooperation Treaty application. The issued patents are predicted to expire between April 11, 2036 and March 4, 2044.

Interactions with Industrial Players

We believe that our VECG technology has the potential to be the most advanced ambulatory cardiac monitoring solution and is applicable in a number of form factors. In anticipation of FDA clearance, we are refining our go-to-market strategy and are encouraged by our early discussions with industry players and their interest in our technology.

At-the-Market Offering

On May 2, 2024, we entered into the PV Sales Agreement with Public Ventures, pursuant to which we may offer and sell from time to time, at our option, through or to Public Ventures, up to an aggregate of approximately $17 million of shares of the Company’s common stock, $0.0001 par value per share (the “Shares”). We will pay Public Ventures a commission at a fixed rate of 3.0% of the aggregate gross proceeds from each sale of the Shares under the PV Sales Agreement. There were 50,000 shares issued under the ATM during the three months ended June 30, 2024. As of June 30, 2024, there was approximately $16.9 million available for issuance under the ATM following the use of the shelf registration on Form S-3 for the Agreements and the ATM during the quarter.

Any Shares to be offered and sold under the PV Sales Agreement will be issued and sold pursuant to our Registration Statement on Form S-3 (File No. 333-269520), filed with the Securities and Exchange Commission on February 1, 2023 and the prospectus supplement included therein, relating to the Offering, by methods deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, or if specified by us, by any other method permitted by law.

In order to proceed with the PV Sales Agreement, we terminated the prior Sales Agreement with A.G.P/Alliance Global Partners.

MedTech Breakthrough Award

On May 13, 2024, we were selected as the winner of the “Best New ECG Technology Solution” award in the 8th annual MedTech Breakthrough Awards program. This awards program is conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global digital health and medical technology market.

14
Results of operations

The following table summarizes our results of operations for the periods presented on our statement of operations data.

For three months ended June 30For six months ended June 30
20242023Change% Change20242023Change% Change
(In thousands, except percentages)
Operating expenses:
General and administrative$2,246 $1,828 $418 23 %$4,602 $4,303 $299 7 %
Research and development2,844 1,484 1,360 92 %5,272 3,165 2,107 67 %
Total operating expenses5,090 3,312 1,778 54 %9,874 7,468 2,406 32 %
Loss from operations(5,090)(3,312)(1,778)54 %(9,874)(7,468)(2,406)32 %
Interest income (expense)134 158 (24)(15)%312 178 134 75 %
Income tax provision— — — — %— — — — %
Net loss$(4,956)$(3,154)$(1,802)57 %$(9,562)$(7,290)$(2,272)31 %

Summary of Statements of Operations for the three and six months ended June 30, 2024 compared with the three and six months ended June 30, 2023:

General and administrative (“G&A”) expenses increased by approximately $0.4 million or 23% during the three months ended June 30, 2024 as compared to the three months ended June 30, 2023. The increase in G&A expense is primarily related to non-cash stock-based compensation expense amounting to $0.1 million associated with additional awards granted since June 30, 2023, higher consultants costs of $0.3 million primarily offset by lower legal costs in this quarter compared to the prior period.

General and administrative (“G&A”) expenses increased by approximately $0.3 million or 7% during the six months ended June 30, 2024. The increase in G&A expense is primarily related to non-cash stock-based compensation expense amounting to $0.7 million associated with additional awards granted since June 30, 2023, higher consulting costs of $0.3 million related to finance consultants, primarily offset by decrease in payroll cost of $0.5 million related to lower costs associated with transitioning our commercial team, decrease in lower investor relation costs, and legal costs incurred in this period compared to the prior period.

Research and development expenses (“R&D”) expenses increased by approximately $1.4 million or 92% during the three months ended June 30, 2024 as compared to the three months ended June 30, 2023. The increase in R&D expense is primarily related to increase in headcount of $0.4 million, increase of clinical and AI related costs of $0.7 million, increase in consulting spend of $0.3 million offset by decrease in product development consulting cost of $0.4 million primarily driven by completion of milestone projects in prior period.

Research and development expenses (“R&D”) expenses increased by approximately $2.1 million or 67% during the six months ended June 30, 2024 as compared to the six months ended June 30, 2023. The increase in R&D expense is primarily related to increase in headcount of $0.9 million and non-cash stock-based compensation expense amounting to $0.4 million associated with additional awards granted since June 30, 2023, increase of clinical and AI related costs of $1.2 million, increase in consulting spend of $0.2 million offset by decrease in product development consulting cost of $0.9 million primarily driven by completion of milestone projects in prior period.

Other income during the three and six months ended June 30, 2024 and 2023 is related to interest earned on our cash balances.




15

Liquidity and Capital Resources

Our cash requirements are and will continue to be, dependent upon a variety of factors. We expect to continue devoting significant capital resources to R&D and go-to-market strategies.

We have incurred losses each year since inception and has experienced negative cash flows from operations in each year since inception. As of June 30, 2024, we have cash and cash equivalents balance of approximately $9.2 million. Based on our current business plan assumptions and expected cash burn rate, we believe that the existing cash is insufficient to fund operations for the next twelve months following the issuance of these financial statements. These factors raise substantial doubt regarding our ability to continue as a going concern.

Our continued operations will depend on the ability to raise additional capital through various potential sources, such as equity and/or debt financings, strategic relationships until sufficient revenue can be generated to achieve positive cash flow from operations. We expect no material commercial revenue in 2024 nor can we provide assurance that a financing or strategic relationships will be available on acceptable terms.

As of June 30, 2024, we had approximately $9.2 million in cash, a decrease of $7.0 million from $16.2 million as of December 31, 2023.

Our cash is as follows (in thousands):
June 30, 2024December 31, 2023
Cash and cash equivalents$9,157 $16,189 

Cash flows for the six months ended June 30, 2024 and 2023 (in thousands):
Six months ended June 30,
20242023
Net cash used in operating activities$(7,013)$(7,137)
Net cash used in investing activities(98)(3,939)
Net cash provided by financing activities84 24,883 

Operating Activities:

Net cash used in our operating activities of $7.0 million during the six months ended June 30, 2024, is primarily due to our net loss of $9.5 million less $2.2 million in non-cash expenses and $0.3 million of net changes in operating assets and liabilities.

Net cash used by our operating activities of $7.1 million during the six months ended June 30, 2023, is primarily due to our net loss of $7.3 million less $1.1 million in non-cash expenses, offset by $0.9 million of net changes in operating assets and liabilities.

Investing Activities:

Net cash used in investing activities during the six months ended June 30, 2024 of $0.1 million, is from the purchase of property and equipment.

Net cash used in investing activities during the six months ended June 30, 2023, of $3.9 million, is from the purchase of short-term investments.

Financing Activities

During the six months ended June 30, 2024, net cash provided by financing activities during the six months ended June 30, 2024, of $0.1 million is primarily from net proceeds from sale of equity, net of issuance costs.

Net cash provided by financing activities during the six months ended June 30, 2023, of $24.9 million, is primarily from net proceeds of $23.2 million from the issuance of common stock under the Placement Agency Agreement, $1.1 million net proceeds from the issuance of common stock under a registered direct offering and $0.5 million from the issuance of common stock under the SPA.
16


Critical Accounting Estimates

There have been no material changes to our critical accounting estimates from the information provided in Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” included in our 2023 Annual Report except as covered below:

Stock-based Compensation

The compensation cost for all stock-based awards is measured at the grant date, based on the fair value of the award, determined using a Black-Scholes option pricing model for stock options and fair value on the date of grant for non-vested restricted stock, and is recognized as an expense over the employee’s requisite service period (generally the vesting period of the equity award). Determining the fair value of stock-based awards at the grant date requires significant estimates and judgments. Management has determined the fair value and vesting period of stock-based compensation to be a critical accounting estimate due to certain options containing performance-based vesting condition.

Research and Development: Clinical and Manufacturing Accruals

We record accruals for estimated costs of research, preclinical studies and clinical trials, and manufacturing development, which are a significant component of research and development expenses. A substantial portion of our ongoing research and development activities are conducted by one CRO. Our contract with this CRO include pass-through fees such as regulatory expenses, investigator fees, travel costs and other miscellaneous costs. We accrue the costs incurred under agreements with CRO based on estimates of actual work completed in accordance with the CRO agreement. We determine the estimated costs based on actual services performed by the CRO and clinical sites as at each period end. As actual costs become known, we adjust our accruals. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in our reporting amounts that are too high or too low in any particular period.

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

We do not hold any derivative instruments and do not engage in any hedging activities.

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

We have adopted and maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in the reports filed under the Exchange Act, such as this Quarterly Report on Form 10-Q, is collected, recorded, processed, summarized and reported within the time periods specified in the rules of the SEC. Our disclosure controls and procedures are also designed to ensure that such information is accumulated and communicated to management to allow timely decisions regarding required disclosure. The material weaknesses previously identified but not yet remediated include (i) lack of proper approval processes and review processes and documentation for such reviews, (ii) insufficient number of staff to maintain optimal segregation of duties and levels of oversight, and (iii) lack of formal risk assessment under COSO framework. As of June 30, 2024, based on evaluation of our disclosure controls and procedures, management concluded that our disclosure controls and procedures were not effective.

Notwithstanding the material weaknesses described above, our management, including the Chief Executive Officer (our principal executive and accounting officer) have concluded that the condensed unaudited financial statements, and other financial information included in this quarterly report, fairly presents in all material respects our financial condition, results of operations, and cash flows as of and for the periods presented in this quarterly report.

Since the third quarter of 2023, we have undertaken specific remediation actions to address the material weaknesses in our financial reporting specifically remediating the material weakness as identified in the 2023 Form 10-K related to documentation of policies and procedures, and insufficient GAAP experience regarding complex transactions and reporting. These remediation actions included hiring a Controller in July 2023, who has extensive experience in developing and implementing internal controls and executing plans to remediate control deficiencies. We are establishing more robust
17
processes related to the review of complex accounting transactions, the preparation of account reconciliations and the review of journal entries. We will continue to assess the remaining weaknesses as we continue to implement and refine control policies and procedures.

Changes in Internal Control

Although, we have hired personnel with sufficient GAAP experience to address the material weaknesses, there has been no change in our internal control procedures over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during our fiscal quarter ended June 30, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
18
PART II-OTHER INFORMATION
Item 1. Legal Proceedings.

There are no actions, suits, proceedings, inquiries or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our Company or any of our subsidiaries, threatened against or affecting our Company, our common stock, any of our officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.

Item 1A. Risk Factors.

Not applicable as we are a smaller reporting company.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

(A) Unregistered Sales of Equity Securities

There were no sales of equity securities sold during the period covered by this Quarterly Report that were not registered under the Securities Act and were not previously reported in a Current Report on Form 8-K filed by the Company.

(B) Use of Proceeds

Not applicable.

(C) Issuer Purchases of Equity Securities

Not applicable.

Item 3. Defaults Upon Senior Securities.
Not applicable

Item 4. Mine Safety Disclosures (Removed and Reserved)
Not applicable.

Item 5. Other Information.
Not applicable.
19
Item 6. Exhibits
The exhibit index set forth below is incorporated by reference in response to this Item 6.
Exhibit
Number		Description of Exhibit
3.1
3.2
3.3
3.4
31.1*
32.1**
101.INSXBRL Instance Document+
101.SCHXBRL Taxonomy Extension Schema Document+
101.CALXBRL Taxonomy Extension Calculation Linkbase Document+
101.DEFXBRL Taxonomy Extension Definition Linkbase Document+
101.LABXBRL Taxonomy Extension Label Linkbase Document+
101.PREXBRL Taxonomy Extension Presentation Linkbase Document+
104Cover Page Interactive Data File - The cover page iXBRL tags are embedded within the inline XBRL document+
*Filed herewith.
**Furnished herewith.
+Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files in Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.



20
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
HEARTBEAM, Inc.
By:/s/ Branislav Vajdic
Name:Branislav Vajdic
Title:
Chief Executive Officer
Dated: August 14, 2024
(Principal Executive and Accounting Officer)

21
 EX-31.1 2 exhibit311-06302024.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION
I, Branislav Vajdic, certify that:

1.    I have reviewed this Quarterly Report on Form 10-Q of HeartBeam, Inc.;

2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: August 14, 2024By: /s/ Branislav Vajdic
Branislav Vajdic
(Chief Executive Officer)
(Principal Executive and Accounting Officer)

 EX-32.1 3 exhibit321-06302024.htm EX-32.1 Document

Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection with the Quarterly Report of HeartBeam, Inc. (the “Registrant”) on Form 10-Q for the period ending June 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Branislav Vajdic, Chief Executive Officer of the Registrant, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1)    The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.
Date: August 14, 2024By: /s/ Branislav Vajdic
Branislav Vajdic
(Chief Executive Officer)
(Principal Executive and Accounting Officer)



 EX-101.SCH 4 beat-20240630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - Condensed Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - Condensed Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - Condensed Statement of Changes in Stockholders’ Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 9952156 - Disclosure - ORGANIZATION AND OPERATIONS link:presentationLink link:calculationLink link:definitionLink 9952157 - Disclosure - GOING CONCERN AND OTHER UNCERTAINTIES link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - STOCKHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - COMMITMENTS link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - STOCKHOLDERS’ EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - ORGANIZATION AND OPERATIONS (Details) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - GOING CONCERN AND OTHER UNCERTAINTIES (Details) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - STOCKHOLDERS’ EQUITY - Schedule of Warrant Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock Option, Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - STOCK-BASED COMPENSATION - Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Nonvested Restricted Stock Units Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - STOCK-BASED COMPENSATION - Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - RELATED PARTY TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - COMMITMENTS (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 5 beat-20240630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 6 beat-20240630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 7 beat-20240630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Minimum Minimum [Member] Adjustments to reconcile net loss to net cash used in operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Triple Ring Technologies Triple Ring Technologies [Member] Triple Ring Technologies Exercisable Class of Warrant or Right, Exercisable, Aggregate Intrinsic Value, Outstanding Class of Warrant or Right, Exercisable, Aggregate Intrinsic Value, Outstanding Statistical Measurement [Domain] Statistical Measurement [Domain] RELATED PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] Related Party Transactions [Abstract] Number of independent Board of Directors members Related Party Transaction, Number Of Board Members Related Party Transaction, Number Of Board Members Cover [Abstract] Beginning balance (in dollars per share) Ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Outstanding Class of Warrant or Right, Aggregate Intrinsic Value, Outstanding Class of Warrant or Right, Aggregate Intrinsic Value, Outstanding Net increase (decrease) in cash and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Trading Symbol Trading Symbol Executives And Employees Executives And Employees [Member] Executives And Employees Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Outstanding Class Of Warrant Or Right, Weighted Average Remaining Life Class Of Warrant Or Right, Weighted Average Remaining Life Taxes paid Income Taxes Paid, Net Stock issuance upon exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Operating Expenses: Costs and Expenses [Abstract] Common Stock Common Class A [Member] Stock issuance upon exercise of warrants (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Stockholders’ Equity Equity, Attributable to Parent [Abstract] Shares granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value GOING CONCERN AND OTHER UNCERTAINTIES Substantial Doubt about Going Concern [Text Block] Number of shares Class of Warrant orRight [Roll Forward] Class of Warrant orRight NET LOSS PER COMMON SHARE Earnings Per Share, Policy [Policy Text Block] Stock issuance upon vesting of restricted stock units (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Proceeds from exercise of stock options Proceeds from Stock Options Exercised Schedule of Nonvested Restricted Stock Units Activity Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Rent expense Operating Lease, Cost Monthly rent expense Lessee, Operating Lease, Monthly Rent Expense Lessee, Operating Lease, Monthly Rent Expense Statement of Stockholders' Equity [Abstract] Number of options granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted Aggregate intrinsic value (in thousands) Class OF Warrant Or Right, Aggregate Intrinsic Value [Abstract] Class OF Warrant Or Right, Aggregate Intrinsic Value Plan Name [Domain] Plan Name [Domain] Cost not yet recognized, excluding options, amount Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Other assets Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Cash Flows From Operating Activities Net Cash Provided by (Used in) Operating Activities [Abstract] Related Party [Domain] Related and Nonrelated Parties [Domain] Accounts payable and accrued expenses (includes related party $- and $2, respectively) Due to related party Accrued liabilities Accounts Payable and Accrued Liabilities, Current Plan Name [Axis] Plan Name [Axis] Equity Components [Axis] Equity Components [Axis] Long-term Purchase Commitment [Line Items] Long-Term Purchase Commitment [Line Items] Local Phone Number Local Phone Number Total operating expenses Operating Expenses Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Risk-free rate, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum USE OF ESTIMATES Use of Estimates, Policy [Policy Text Block] Stock Options Additional Disclosures Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Aggregate intrinsic value, outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Remaining commitment Purchase Commitment, Remaining Minimum Amount Committed Monthly payment Related Party Transaction, Monthly Amount Of Transaction Related Party Transaction, Monthly Amount Of Transaction Clinical Research Organization Clinical Research Organization [Member] Clinical Research Organization Entity Small Business Entity Small Business Expired (in dollars per share) Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Expired Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Expired Income Statement Location [Axis] Statement of Income Location, Balance [Axis] Entity Ex Transition Period Entity Ex Transition Period Weighted average exercise price Class Of Warrant Or Right Outstanding, Weighted Average Exercise Price [Roll Forward] Class Of Warrant Or Right Outstanding, Weighted Average Exercise Price CASH, CASH EQUIVALENTS AND RESTRICTED CASH Cash and Cash Equivalents, Policy [Policy Text Block] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] COMMITMENTS Commitments and Contingencies Disclosure [Text Block] Common Stock Common Stock [Member] Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Share-Based Payment Arrangement, Tranche One Share-Based Payment Arrangement, Tranche One [Member] Sale of Common Stock under ATM, net of issuance costs (in shares) Stock Issued During Period, Shares, New Issues Weighted average remaining life (years) Class Of Warrant Or Right Outstanding, Weighted Average Remaining Life [Abstract] Class Of Warrant Or Right Outstanding, Weighted Average Remaining Life Entity Emerging Growth Company Entity Emerging Growth Company Cash, cash equivalents and restricted cash – Beginning of period Cash, cash equivalents and restricted cash – Ending of period Total cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Liquidity, Going Concern, and Other Uncertainties [Line Items] Liquidity, Going Concern, and Other Uncertainties [Line Items] Liquidity, Going Concern, and Other Uncertainties [Line Items] Entity Central Index Key Entity Central Index Key Exercisable beginning balance ( in dollars per share) Exercisable ending balance ( in dollars per share) Class of Warrant or Right, Exercisable, Exercise Price of Warrants or Rights Class of Warrant or Right, Exercisable, Exercise Price of Warrants or Rights General and administrative General and Administrative Expense [Member] Current Assets: Assets, Current [Abstract] Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend STOCKHOLDERS’ EQUITY Equity [Text Block] Accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Exercised (in dollars per share) Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Exercised Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Exercised Equity Component [Domain] Equity Component [Domain] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Reconciliation of cash, cash equivalents and restricted cash: Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] Stock options Share-Based Payment Arrangement, Option [Member] Shares vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Exercised (in shares) Class Of Warrant Or Right, Warrants Exercised Class Of Warrant Or Right, Warrants Exercised Stock based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Restricted stock units Restricted Stock [Member] Entity Shell Company Entity Shell Company Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Liquidity, Going Concern, and Other Uncertainties [Table] Liquidity, Going Concern, and Other Uncertainties [Table] Liquidity, Going Concern, and Other Uncertainties [Table] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Security Exchange Name Security Exchange Name Warrants Warrants Warrant [Member] Statement [Table] Statement [Table] Award Type [Axis] Award Type [Axis] Counterparty Name [Axis] Counterparty Name [Axis] Options exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price City Area Code City Area Code Current Liabilities: Liabilities, Current [Abstract] Expired (in shares) Class Of Warrant Or Right, Warrants Expired Class Of Warrant Or Right, Warrants Expired Numbers of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Property and equipment, net Property, Plant and Equipment, Net Total Liabilities Liabilities Exercisable, Weighted average exercise price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Purchase of short-term investments Payments to Acquire Short-Term Investments Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Research and development Research and Development Expense Total Current Assets Assets, Current Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Statement of Cash Flows [Abstract] Cash Flows From Investing Activities Net Cash Provided by (Used in) Investing Activities [Abstract] 2022 Equity Plan 2022 Equity Plan [Member] 2022 Equity Plan Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Common stock, shares issued (in shares) Common Stock, Shares, Issued Document Information [Line Items] Document Information [Line Items] Sale of stock, available for issuance under the ATM Sale Of Stock, Amount Remaining For Future Issuance, Value Sale Of Stock, Amount Remaining For Future Issuance, Value Weighted Average Grant Date Fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Weighted average grant date fair value per share (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Equity [Abstract] Accumulated deficit Retained Earnings (Accumulated Deficit) Stock issuance upon exercise of stock options (in shares) Options exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Class of Stock [Domain] Class of Stock [Domain] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Research and development Research and Development Expense [Member] Weighted average exercise price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] General and administrative Consulting service fees General and Administrative Expense Common stock, shares authorized (in shares) Common Stock, Shares Authorized Organization, Consolidation and Presentation of Financial Statements [Abstract] BASIS OF PRESENTATION Basis of Accounting, Policy [Policy Text Block] Weighted average common shares outstanding, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Total Stockholders’ Equity Beginning balance Ending balance Equity, Attributable to Parent Amendment Flag Amendment Flag Entity Registrant Name Entity Registrant Name Related Party Related Party [Member] Construction in progress Construction in Progress, Gross Operating lease, prior notice for cancellation Lessee, Operating Lease, Prior Notice For Cancellation Lessee, Operating Lease, Prior Notice For Cancellation Shares issued in at the market (ATM) (in shares) Sale of Stock, Number of Shares Issued in Transaction Options granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Sale of Common Stock under ATM, net of issuance costs Stock Issued During Period, Value, New Issues Number of shares authorized for issuance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Sale of Stock [Domain] Sale of Stock [Domain] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Schedule of Stock-Based Compensation Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Title of 12(b) Security Title of 12(b) Security Long-term Purchase Commitment [Table] Long-Term Purchase Commitment [Table] Common stock - $0.0001 par value 100,000,000 shares authorized; 26,562,111 and 26,329,032 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively Common Stock, Value, Issued Average remaining contractual life Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Assets Assets [Abstract] Share-Based Payment Arrangement [Abstract] Proceeds from exercise of warrants Proceeds from Warrant Exercises Document Type Document Type Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Exercisable, Average remaining contractual life Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Shares vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Sale of stock, maximum amount authorized Sale Of Stock, Value Authorized In Transaction Sale Of Stock, Value Authorized In Transaction Exercisable beginning balance (in shares) Exercisable ending balance (in shares) Class of Warrant or Right, Exercisable Class of Warrant or Right, Exercisable Cash Flows From Financing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Preferred stock - $0.0001 par value; 10,000,000 authorized; 0 shares outstanding at June 30, 2024 and December 31, 2023 Preferred Stock, Value, Issued Maximum Maximum [Member] Number of options outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Net loss per share, basic (in dollars per share) Earnings Per Share, Basic Antidilutive Securities [Axis] Antidilutive Securities [Axis] Accounting Policies [Abstract] Proceeds from sale of equity, net of issuance costs Proceeds from Issuance of Common Stock Amount to be paid to Clinical Research Organization (CRO) Contractual Obligation Stock options (excluding exercisable penny stock options) Equity Option [Member] Number of planned sites to carrying out the clinical study Research And Development, Number Of Clinical Study Sites Research And Development, Number Of Clinical Study Sites Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Purchase of property and equipment in accounts payable Capital Expenditures Incurred but Not yet Paid Statistical Measurement [Axis] Statistical Measurement [Axis] Outstanding, beginning balance (in shares) Outstanding, ending balance (in shares) Class of Warrant or Right, Outstanding PROPERTY AND EQUIPMENT, NET Property, Plant and Equipment, Policy [Policy Text Block] Loss before provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Research and development expense, expected cost Research And Development Expense, Expected Cost Research And Development Expense, Expected Cost Total Current Liabilities Liabilities, Current Vesting [Axis] Vesting [Axis] Award Type [Domain] Award Type [Domain] Cost not yet recognized, options, amount Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Total Assets Assets Volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Shares granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Incremental common shares attributable to dilutive effect of equity forward agreements (in shares) Incremental Common Shares Attributable to Dilutive Effect of Equity Forward Agreements Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment Title of Individual [Axis] Title and Position [Axis] Commitments (Note 7) Commitments and Contingencies Additional Paid-in Capital Additional Paid-in Capital [Member] Risk-free rate, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum ORGANIZATION AND OPERATIONS Nature of Operations [Text Block] Restricted cash (included in other assets) Restricted Cash, Noncurrent Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Table] Outstanding, beginning balance (in dollars per share) Outstanding, ending balance (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights RECENTLY ISSUED ACCOUNTING STANDARDS New Accounting Pronouncements, Policy [Policy Text Block] Net loss per share, diluted (in dollars per share) Earnings Per Share, Diluted Class of Stock [Axis] Class of Stock [Axis] STOCK-BASED COMPENSATION Share-Based Payment Arrangement [Text Block] Title of Individual [Domain] Title and Position [Domain] Counterparty Name [Domain] Counterparty Name [Domain] Entity Interactive Data Current Entity Interactive Data Current Entity Address, City or Town Entity Address, City or Town Schedule of Warrant Activity Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Percentage of share-based compensation arrangement vesting (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Schedule of Stock Option, Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Number of operating segments Number of Operating Segments Total Stock based compensation expense Share-Based Payment Arrangement, Expense Public Ventures, LLC Public Ventures, LLC [Member] Public Ventures, LLC Net Loss Net loss Net loss Net Income (Loss) Attributable to Parent Statement of Financial Position [Abstract] Stock issuance upon exercise of warrants Stock Issued During Period, Value, Conversion of Convertible Securities Options granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Stock based compensation expense Share-Based Payment Arrangement, Noncash Expense Entity File Number Entity File Number Share-Based Payment Arrangement, Tranche Two Share-Based Payment Arrangement, Tranche Two [Member] Income tax provision Income Tax Expense (Benefit) Other Income Nonoperating Income (Expense) [Abstract] Document Fiscal Year Focus Document Fiscal Year Focus Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Supplemental Disclosures of Cash Flow Information: Supplemental Cash Flow Information [Abstract] Lease commenced, initial period Lessee, Operating Lease, Term of Contract Exercisable, Aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Cost not yet recognized, period of recognition (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Document Period End Date Document Period End Date Sale of Stock [Axis] Sale of Stock [Axis] Total other income Nonoperating Income (Expense) Exercisable Class of Warrant or Right, Exercisable, Weighted Average Remaining Life Class of Warrant or Right, Exercisable, Weighted Average Remaining Life Non-vested, beginning balance (in shares) Non-vested, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Loss from operations Operating Income (Loss) Total Liabilities and Stockholders’ Equity Liabilities and Equity Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Additional paid in capital Additional Paid in Capital Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Commitments and Contingencies Disclosure [Abstract] Interest income Interest Income (Expense), Nonoperating Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Purchase commitments Purchase Obligation Entity Current Reporting Status Entity Current Reporting Status Accumulated Deficit Retained Earnings [Member] Options cancelled (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Expected term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Weighted average common shares outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Related Party [Axis] Related and Nonrelated Parties [Axis] Entity Address, State or Province Entity Address, State or Province Statement [Line Items] Statement [Line Items] Document Information [Table] Document Information [Table] RSU’s Restricted Stock Units (RSUs) [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Options cancelled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Vesting [Domain] Vesting [Domain] Non-Vested, beginning balance (in dollars per share) Non-vested, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Liabilities and Stockholders’ Equity Liabilities and Equity [Abstract] Entity Filer Category Entity Filer Category Income Statement Location [Domain] Statement of Income Location, Balance [Domain] Private Placement Private Placement [Member] EX-101.PRE 8 beat-20240630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 10 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Cover Page - shares
 6 Months Ended
Jun. 30, 2024
Aug. 12, 2024
Document Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Jun. 30, 2024  
Document Transition Report false  
Entity File Number 001-41060  
Entity Registrant Name HEARTBEAM, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 47-4881450  
Entity Address, Address Line One 2118 Walsh Avenue  
Entity Address, Address Line Two Suite 210  
Entity Address, City or Town Santa Clara  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 95050  
City Area Code 408  
Local Phone Number 899-4443  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   26,562,111
Entity Central Index Key 0001779372  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q2  
Amendment Flag false  
Common Stock    
Document Information [Line Items]    
Title of 12(b) Security Common Stock  
Trading Symbol BEAT  
Security Exchange Name NASDAQ  
Warrants    
Document Information [Line Items]    
Title of 12(b) Security Warrants  
Trading Symbol BEATW  
Security Exchange Name NASDAQ  
XML 11 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Condensed Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2024
Dec. 31, 2023
Current Assets:    
Cash and cash equivalents $ 9,157 $ 16,189
Prepaid expenses and other current assets 544 636
Total Current Assets 9,701 16,825
Property and equipment, net 370 256
Other assets 55 50
Total Assets 10,126 17,131
Current Liabilities:    
Accounts payable and accrued expenses (includes related party $- and $2, respectively) 1,420 1,194
Total Current Liabilities 1,420 1,194
Total Liabilities 1,420 1,194
Commitments (Note 7)
Stockholders’ Equity    
Preferred stock - $0.0001 par value; 10,000,000 authorized; 0 shares outstanding at June 30, 2024 and December 31, 2023 0 0
Common stock - $0.0001 par value 100,000,000 shares authorized; 26,562,111 and 26,329,032 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively 3 3
Additional paid in capital 55,090 52,759
Accumulated deficit (46,387) (36,825)
Total Stockholders’ Equity 8,706 15,937
Total Liabilities and Stockholders’ Equity $ 10,126 $ 17,131
XML 12 R3.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Condensed Balance Sheets (Unaudited) (Parenthetical) - USD ($)
$ in Thousands
Jun. 30, 2024
Dec. 31, 2023
Current Liabilities:    
Due to related party $ 1,420 $ 1,194
Stockholders’ Equity    
Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized (in shares) 10,000,000 10,000,000
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized (in shares) 100,000,000 100,000,000
Common stock, shares issued (in shares) 26,562,111 26,329,032
Common stock, shares outstanding (in shares) 26,562,111 26,329,032
Related Party    
Current Liabilities:    
Due to related party $ 0 $ 2
XML 13 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Condensed Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Operating Expenses:        
General and administrative $ 2,246 $ 1,828 $ 4,602 $ 4,303
Research and development 2,844 1,484 5,272 3,165
Total operating expenses 5,090 3,312 9,874 7,468
Loss from operations (5,090) (3,312) (9,874) (7,468)
Other Income        
Interest income 134 158 312 178
Total other income 134 158 312 178
Loss before provision for income taxes (4,956) (3,154) (9,562) (7,290)
Income tax provision 0 0 0 0
Net Loss $ (4,956) $ (3,154) $ (9,562) $ (7,290)
Net loss per share, basic (in dollars per share) $ (0.19) $ (0.16) $ (0.36) $ (0.52)
Net loss per share, diluted (in dollars per share) $ (0.19) $ (0.16) $ (0.36) $ (0.52)
Weighted average common shares outstanding, basic (in shares) 26,566,832 19,690,251 26,538,863 13,910,365
Weighted average common shares outstanding, diluted (in shares) 26,566,832 19,690,251 26,538,863 13,910,365
XML 14 R5.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Condensed Statement of Changes in Stockholders’ Equity (Unaudited) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2022   8,009,743    
Beginning balance at Dec. 31, 2022 $ 2,374 $ 1 $ 24,559 $ (22,186)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Stock based compensation expense 1,095   1,095  
Sale of Common Stock under ATM, net of issuance costs (in shares)   17,872,955    
Sale of Common Stock under ATM, net of issuance costs 24,764 $ 2 24,762  
Stock issuance upon exercise of stock options (in shares)   88,026    
Stock issuance upon exercise of stock options 103   103  
Stock issuance upon vesting of restricted stock units (in shares)   12,500    
Stock issuance upon exercise of warrants (in shares)   7,292    
Stock issuance upon exercise of warrants 16   16  
Net loss (7,290)     (7,290)
Ending balance (in shares) at Jun. 30, 2023   25,990,516    
Ending balance at Jun. 30, 2023 21,062 $ 3 50,535 (29,476)
Beginning balance (in shares) at Mar. 31, 2023   8,227,074    
Beginning balance at Mar. 31, 2023 (859) $ 1 25,462 (26,322)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Stock based compensation expense 702   702  
Sale of Common Stock under ATM, net of issuance costs (in shares)   17,666,666    
Sale of Common Stock under ATM, net of issuance costs 24,270 $ 2 24,268  
Stock issuance upon exercise of stock options (in shares)   88,026    
Stock issuance upon exercise of stock options 103   103  
Stock issuance upon vesting of restricted stock units (in shares)   8,750    
Net loss (3,154)     (3,154)
Ending balance (in shares) at Jun. 30, 2023   25,990,516    
Ending balance at Jun. 30, 2023 $ 21,062 $ 3 50,535 (29,476)
Beginning balance (in shares) at Dec. 31, 2023 26,329,032 26,329,032    
Beginning balance at Dec. 31, 2023 $ 15,937 $ 3 52,759 (36,825)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Stock based compensation expense 2,247   2,247  
Sale of Common Stock under ATM, net of issuance costs (in shares)   50,000    
Sale of Common Stock under ATM, net of issuance costs $ 76   76  
Stock issuance upon exercise of stock options (in shares) 5,252 5,252    
Stock issuance upon exercise of stock options $ 8   8  
Stock issuance upon vesting of restricted stock units (in shares)   177,827    
Net loss $ (9,562)     (9,562)
Ending balance (in shares) at Jun. 30, 2024 26,562,111 26,562,111    
Ending balance at Jun. 30, 2024 $ 8,706 $ 3 55,090 (46,387)
Beginning balance (in shares) at Mar. 31, 2024   26,329,032    
Beginning balance at Mar. 31, 2024 12,538 $ 3 53,966 (41,431)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Stock based compensation expense 1,040   1,040  
Sale of Common Stock under ATM, net of issuance costs (in shares)   50,000    
Sale of Common Stock under ATM, net of issuance costs 76   76  
Stock issuance upon exercise of stock options (in shares)   5,252    
Stock issuance upon exercise of stock options 8   8  
Stock issuance upon vesting of restricted stock units (in shares)   177,827    
Net loss $ (4,956)     (4,956)
Ending balance (in shares) at Jun. 30, 2024 26,562,111 26,562,111    
Ending balance at Jun. 30, 2024 $ 8,706 $ 3 $ 55,090 $ (46,387)
XML 15 R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Condensed Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Cash Flows From Operating Activities        
Net loss $ (4,956) $ (3,154) $ (9,562) $ (7,290)
Adjustments to reconcile net loss to net cash used in operating activities        
Stock based compensation expense     2,247 1,095
Changes in operating assets and liabilities:        
Prepaid expenses and other current assets     92 152
Accounts payable and accrued expenses     210 (1,094)
Net cash used in operating activities     (7,013) (7,137)
Cash Flows From Investing Activities        
Purchase of property and equipment     (98) 0
Purchase of short-term investments     0 (3,939)
Net cash used in investing activities     (98) (3,939)
Cash Flows From Financing Activities        
Proceeds from sale of equity, net of issuance costs     76 24,764
Proceeds from exercise of stock options     8 103
Proceeds from exercise of warrants     0 16
Net cash provided by financing activities     84 24,883
Net increase (decrease) in cash and restricted cash     (7,027) 13,807
Cash, cash equivalents and restricted cash – Beginning of period     16,239 3,594
Cash, cash equivalents and restricted cash – Ending of period 9,212 17,401 9,212 17,401
Reconciliation of cash, cash equivalents and restricted cash:        
Cash and cash equivalents 9,157 17,401 9,157 17,401
Restricted cash (included in other assets) 55 0 55 0
Total cash, cash equivalents and restricted cash $ 9,212 $ 17,401 9,212 17,401
Supplemental Disclosures of Cash Flow Information:        
Purchase of property and equipment in accounts payable     16 0
Taxes paid     $ 0 $ 0
XML 16 R7.htm IDEA: XBRL DOCUMENT v3.24.2.u1
ORGANIZATION AND OPERATIONS
 6 Months Ended
Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
ORGANIZATION AND OPERATIONS ORGANIZATION AND OPERATIONS
HeartBeam, Inc. (“HeartBeam” or the “Company”) is a cardiac technology company focusing on developing and commercializing higher resolution ambulatory Electrocardiogram (“ECG”) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company’s ability to develop higher resolution ECG solutions is achieved through the development of the Company’s proprietary and patented Vector Electrocardiography (“VECG”) technology platform. HeartBeam’s VECG is capable of developing three-dimensional (3D) representations of cardiac electrical activity by displaying the spatial locations of ECG waveforms that demonstrated in early studies to deliver diagnostic capability equal or superior to traditional hospital-based ECG systems.

The Company has validated this technology and is seeking U.S. Food and Drug Administration (“FDA”) clearance of its initial telehealth products. The Company filed a 510(k) submission in 2023 for its initial product, a patient-held VECG device, which is planned, with a second submission, to become an ambulatory device, carried by patients, which can synthesize a 12L ECG for physician review.

The Company was incorporated in 2015 as a Delaware corporation. The Company’s operations are based in Santa Clara, California and operates as one segment.
XML 17 R8.htm IDEA: XBRL DOCUMENT v3.24.2.u1
GOING CONCERN AND OTHER UNCERTAINTIES
 6 Months Ended
Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
GOING CONCERN AND OTHER UNCERTAINTIES GOING CONCERN AND OTHER UNCERTAINTIES
The Company is subject to a number of risks similar to those of early stage medical device companies, including dependence on key individuals and products, the inherent uncertainties with regulatory approvals, the difficulties inherent in the development of a commercial market, the potential need to obtain additional capital, competition from larger companies, other technology companies and other technologies.

The Company has incurred losses each year since inception and has experienced negative cash flows from operations in each year since inception. As of June 30, 2024 the Company has a cash and cash equivalents balance of approximately $9.2 million. Based on its current business plan assumptions and expected cash burn rate, the Company believes that the existing cash is insufficient to fund operations for the next twelve months following the issuance of these financial statements. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern.

On May 2, 2024, the Company entered into a Sales Agreement (“PV Sales Agreement”) with Public Ventures, LLC, as sales agent (“Public Ventures” or “Agent”), pursuant to which the Company may sell up to an aggregate of approximately $17 million of shares of the Company’s common stock. There were 50,000 shares issued under the At The Market (“ATM”) during the three months ended June 30, 2024. As of June 30, 2024, there was approximately $16.9 million available for issuance under the ATM.

The Company’s continued operations will depend on its ability to raise additional capital through various potential sources, such as equity and/or debt financings, strategic relationships until FDA clearance is obtained for the Company’s initial telehealth product and sufficient revenue can be generated to achieve positive cash flow from operations. The Company expects no material commercial revenue in 2024. Management can provide no assurance that such financing or strategic relationships will be available on acceptable terms, or at all, which would likely have a material adverse effect on the Company and its financial statements.
The accompanying unaudited condensed financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that may result should the Company be unable to continue as a going concern.
XML 18 R9.htm IDEA: XBRL DOCUMENT v3.24.2.u1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 6 Months Ended
Jun. 30, 2024
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
BASIS OF PRESENTATION

The accompanying condensed unaudited financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("US GAAP") and in conformity with the instructions on Form 10-Q and Rule 8-03 of Regulation S-X and the related rules and regulations of the Securities and Exchange Commission (“SEC”) and have been prepared on a basis which assumes that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business.
In the opinion of management, the unaudited interim condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results of operations for the periods presented. The interim operating results are not necessarily indicative of results that may be expected for any subsequent period. The accompanying condensed unaudited financial statements should be read in conjunction with the Company’s audited annual financial statements and notes thereto included in the Company’s Form 10-K filed with the SEC on March 20, 2024 (“2023 Annual Report”).

CASH, CASH EQUIVALENTS AND RESTRICTED CASH

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash deposits. The Company maintains its cash in institutions insured by the Federal Deposit Insurance Corporation (“FDIC”) and has cash balances in accounts which exceed the federally insured limits as of June 30, 2024 and December 31, 2023. The Company has made a deposit to the bank for their credit cards in the amount of $55,000 and is classified as restricted cash included in other assets as of June 30, 2024.

USE OF ESTIMATES

The preparation of financial statements in conformity with US GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be based on amounts that differ from those estimates.

PROPERTY AND EQUIPMENT, NET

Property and equipment are stated at cost less accumulated depreciation. Depreciation of property and equipment is calculated using the straight-line method over the estimated useful lives of the assets. The Company regularly evaluates the estimated remaining useful lives of the Company’s property and equipment, net, to determine whether events or changes in circumstances warrant a revision to the remaining period of depreciation. Maintenance and repairs are expensed as incurred. As of June 30, 2024, property and equipment, net represents construction-in-progress of $370,000 related to tooling development that has not been placed into service. Construction-in-progress amounts are not subject to depreciation as such assets are not yet available for their intended use.

NET LOSS PER COMMON SHARE

Basic net loss per share excludes the effect of dilution and is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding.

Diluted net loss per share is computed by giving effect to all potential shares of common stock, including stock options and warrants to the extent dilutive. Basic net loss per share was the same as diluted net loss per share for the three and six months ended June 30, 2024 and 2023 as the inclusion of all potential common shares outstanding would have an anti-dilutive effect.

In accordance with ASC 260-10-45-13, exercisable penny options are included in the calculation of weighted average basic and diluted earnings per share. As of June 30, 2024, 182,169 penny options have been included in the calculation of weighted average basic and diluted earnings per share.

The following is a summary of awards outstanding as of June 30, 2024 and 2023, which are not included in the computation of basic and diluted weighted average shares:
Three and Six months ended
June 30,
20242023
Stock options (excluding exercisable penny stock options)5,993,356 2,851,383 
Restricted stock units283,411 246,470 
Warrants5,152,397 5,152,397 
Total11,429,164 8,250,250 

RECENTLY ISSUED ACCOUNTING STANDARDS

Not Yet Adopted as of June 30, 2024:

In November 2023, the Financial Standards Accounting Board (FASB) issued Accounting Standards Update (ASU) 2023-07 "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures" which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 is effective for the Company’s annual periods beginning January 1, 2024, and for interim periods beginning January 1, 2025, with early adoption permitted. The Company does not expect that the updated standard will have a significant impact on the Company’s financial statement disclosures.

In December 2023, the FASB issued ASU 2023-09 "Income Taxes (Topics 740): Improvements to Income Tax Disclosures" to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. ASU 2023-09 is effective for the Company’s annual periods beginning January 1, 2025, with early adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on the Company’s financial statement disclosures.

In March 2024, the FASB issued ASU 2024-02 “Codification Improvements – Amendments to Remove References to the Concepts Statements.” This amendments to the Codification that remove references to various Concepts Statement. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2024. Early application of the amendments in this update is permitted for all entities, for any fiscal year or interim period for which financial statements have not yet been issued (or made available for issuance). If an entity adopts the amendments in an interim period, it must adopt them as of the beginning of the fiscal year that includes that interim period. The Company is currently evaluating the impact that the adoption of this standard will have on the Company’s financial statement disclosures.
XML 19 R10.htm IDEA: XBRL DOCUMENT v3.24.2.u1
STOCKHOLDERS’ EQUITY
 6 Months Ended
Jun. 30, 2024
Equity [Abstract]  
STOCKHOLDERS’ EQUITY STOCKHOLDERS’ EQUITY
WARRANTS

The following is a summary of warrant activity during the six months ended June 30, 2024:
Number of
shares		Weighted
average exercise
price		Weighted
average
remaining life (years)		Aggregate
intrinsic value
(in thousands)
Outstanding and exercisable - December 31, 2023
5,152,397 $4.71 3.35$792
Exercised— — — — 
Expired— — — — 
Outstanding and exercisable – June 30, 2024
5,152,397 $4.71 2.85$1,158 
XML 20 R11.htm IDEA: XBRL DOCUMENT v3.24.2.u1
STOCK-BASED COMPENSATION
 6 Months Ended
Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]  
STOCK-BASED COMPENSATION STOCK-BASED COMPENSATION
At the June 2024 annual stockholders’ meeting the 2022 Equity Incentive Plan was amended to increase the number of authorized shares from 5,900,000 shares to 8,900,000.
STOCK OPTIONS
The following is a summary of stock option activity during the six months ended June 30, 2024:
Number of
options
outstanding		Weighted
average
exercise
price		Average
remaining
contractual life
(in years)		Aggregate
intrinsic value
(in thousands)
Outstanding – December 31, 2023
6,092,525 $2.22 8.7$2,945 
Options granted
114,000 2.27 
Options exercised
(5,252)1.54 
Options cancelled(25,748)2.41 
Outstanding – June 30, 2024
6,175,525 $2.23 8.4$3,692 
Exercisable – June 30, 2024
1,748,660 $1.90 7.4$1,687 
The Company estimates the fair values of stock options using the Black-Scholes option-pricing model on the date of grant. For the six months ended June 30, 2024 and 2023, the assumptions used in the Black-Scholes option pricing model, which was used to estimate the grant date fair value per option, were as follows:

Six months ended June 30,
20242023
Weighted-average Black-Scholes option pricing model assumptions:
Volatility
125.89% - 128.74%
110.23% - 111.73%
Expected term (in years)
6.02 - 7.00
5.71 - 6.07
Risk-free rate
4.50% - 4.60%
3.54% - 3.80%
Expected dividend yield$— $— 
Weighted average grant date fair value per share
$1.81 - $2.48
$1.73 - $3.38

RESTRICTED STOCK UNITS
The following is a summary of RSU’s awards activity:
Six months ended June 30, 2024
Numbers of SharesWeighted Average Grant Date Fair value
Non-Vested at beginning of period217,881 $3.12 
Shares granted243,357 2.26 
Shares vested(177,827)3.13 
Non-vested at the end of period283,411 $2.38 
STOCK BASED COMPENSATION

The following is a summary of stock-based compensation expense:
Three months ended June 30,Six months ended June 30,
2024202320242023
General and administrative
Stock options602,000 507,200 1,338,000 707,200 
RSU’s142,000 116,400 283,000 217,400 
Total general and administrative744,000 623,600 1,621,000 924,600 
Research and development
Stock options287,000 78,800 607,000 170,800 
  RSU’s 9,000 — 19,000 — 
Total research and development296,000 78,800 626,000 170,800 
Total1,040,000 702,400 2,247,000 1,095,400 

During the six months ended 2023, the Company granted 2,208,000 options to various executives and employees. Sixty percent (60%) of these options vest based on FDA Clearance for marketing of HeartBeam’s synthesized 12L product and the remaining forty percent (40%) vest monthly over a period of 48 months.

The Company calculated the fair value for each of these grants using the Black-Scholes option pricing model and the performance-based options are expensed beginning from date of grant to the expected FDA clearance, which is based on management’s probability assessment performed on a quarterly basis.

As of June 30, 2024, total compensation cost not yet recognized related to unvested stock options and unvested RSUs was approximately $6.4 million and $0.6 million, respectively, which is expected to be recognized over a weighted-average period of 2.4 years and 1.08 years, respectively.
XML 21 R12.htm IDEA: XBRL DOCUMENT v3.24.2.u1
RELATED PARTY TRANSACTIONS
 6 Months Ended
Jun. 30, 2024
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS
During the course of business, the Company obtains accounting services from CTRLCFO, a firm in which an executive of the Company has significant influence. On December 29, 2023, this executive, informed the Company of his plans to retire from his position as of February 1, 2024 and as such ceased to be a related party as of February 1, 2024. The Company had balances due to this firm amounting to approximately $2,000 as of December 31, 2023.

During April 2024, the Company entered into consulting agreement with one of the independent Board of Directors to provide business development consulting services. For these consulting services, the Company agreed to pay $5,000 per month as remuneration and granted 70,000 options to vest during over a period of 36 months. During the three months ended June 30, 2024, the Company recognized $24,500 related to these consulting services, which includes stock based compensation expense of $9,500.
XML 22 R13.htm IDEA: XBRL DOCUMENT v3.24.2.u1
COMMITMENTS
 6 Months Ended
Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS COMMITMENTS
Lease Obligations

Prior to February 1, 2024, the Company was in a month-to-month lease agreement for its headquarters. The agreement was for an undefined term that could be cancelled at any time, given one month’s notice by either party. The Company’s monthly rent expense associated with this agreement was approximately $1,800. This headquarters lease was in the name of the Company’s Chief Executive Officer, and the cost was reimbursed monthly to CEO until January 31, 2024 when the Company terminated the month-to-month lease, and entered into a new lease in name of the Company with the same landlord. The new lease commenced on February 1, 2024, for initial period of 3 years. The Company performed an assessment and concluded that amount of operating lease right-of-use, or ROU assets was below the Company’s capitalization thresholds set in accordance with ASC 842. For the three and six months ended June 30, 2024 rent was approximately $5,400 and $10,440, respectively. For the three and six months ended June 30, 2023, rent expense was approximately $4,000 and $8,000, respectively.
Professional Services Agreement

In March 2022, the Company entered into a professional services agreement with Triple Ring Technologies, Inc. (“TRT”), a co-development company, to assist in the design and development of the Company’s telehealth complete solution 3D vector ECG collection device for remote heart attack or MI monitoring. This agreement was followed by several amendments. The agreement with TRT includes a commitment totaling $1.7 million. For the three and six months ended June 30, 2024, the Company has expensed approximately $0.1 million and $0.2 million, respectively. For the three and six months ended June 30, 2023, the Company has expensed approximately $0.4 million and $0.6 million, respectively.

As of June 30, 2024, the Company has a remaining commitment of $0.2 million.

Clinical Research Organization

On March 8, 2024, the Company has entered into an agreement with Clinical Research Organization (CRO) to perform certain services related to project set up, clinical trial management and monitoring during next six months. As per terms of the agreement, the Company will pay CRO approximately $0.5 million for these services. Additionally, the Company has signed a Clinical Study Agreement with first of five sites to carry out the clinical study for which CRO will act as Company sponsor in relation to payment for these services. The total cost of the clinical trial including the CRO cost is expected to approximate $0.8 million. For the three months and six months ended June 30, 2024, the Company has expensed $0.3 million and $0.7 million based on actual services performed by the CRO and clinical sites, of which $0.2 million was accrued as of June 30, 2024. As of June 30, 2024, the Company has a remaining commitment of $0.1 million.
XML 23 R14.htm IDEA: XBRL DOCUMENT v3.24.2.u1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 6 Months Ended
Jun. 30, 2024
Accounting Policies [Abstract]  
BASIS OF PRESENTATION
BASIS OF PRESENTATION

The accompanying condensed unaudited financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("US GAAP") and in conformity with the instructions on Form 10-Q and Rule 8-03 of Regulation S-X and the related rules and regulations of the Securities and Exchange Commission (“SEC”) and have been prepared on a basis which assumes that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business.
In the opinion of management, the unaudited interim condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results of operations for the periods presented. The interim operating results are not necessarily indicative of results that may be expected for any subsequent period. The accompanying condensed unaudited financial statements should be read in conjunction with the Company’s audited annual financial statements and notes thereto included in the Company’s Form 10-K filed with the SEC on March 20, 2024 (“2023 Annual Report”).
CASH, CASH EQUIVALENTS AND RESTRICTED CASH
CASH, CASH EQUIVALENTS AND RESTRICTED CASH
The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash deposits. The Company maintains its cash in institutions insured by the Federal Deposit Insurance Corporation (“FDIC”) and has cash balances in accounts which exceed the federally insured limits as of June 30, 2024 and December 31, 2023.
USE OF ESTIMATES
USE OF ESTIMATES

The preparation of financial statements in conformity with US GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be based on amounts that differ from those estimates.
PROPERTY AND EQUIPMENT, NET
PROPERTY AND EQUIPMENT, NET
Property and equipment are stated at cost less accumulated depreciation. Depreciation of property and equipment is calculated using the straight-line method over the estimated useful lives of the assets. The Company regularly evaluates the estimated remaining useful lives of the Company’s property and equipment, net, to determine whether events or changes in circumstances warrant a revision to the remaining period of depreciation. Maintenance and repairs are expensed as incurred.
NET LOSS PER COMMON SHARE
NET LOSS PER COMMON SHARE

Basic net loss per share excludes the effect of dilution and is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding.

Diluted net loss per share is computed by giving effect to all potential shares of common stock, including stock options and warrants to the extent dilutive. Basic net loss per share was the same as diluted net loss per share for the three and six months ended June 30, 2024 and 2023 as the inclusion of all potential common shares outstanding would have an anti-dilutive effect.
In accordance with ASC 260-10-45-13, exercisable penny options are included in the calculation of weighted average basic and diluted earnings per share.
RECENTLY ISSUED ACCOUNTING STANDARDS
RECENTLY ISSUED ACCOUNTING STANDARDS

Not Yet Adopted as of June 30, 2024:

In November 2023, the Financial Standards Accounting Board (FASB) issued Accounting Standards Update (ASU) 2023-07 "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures" which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 is effective for the Company’s annual periods beginning January 1, 2024, and for interim periods beginning January 1, 2025, with early adoption permitted. The Company does not expect that the updated standard will have a significant impact on the Company’s financial statement disclosures.

In December 2023, the FASB issued ASU 2023-09 "Income Taxes (Topics 740): Improvements to Income Tax Disclosures" to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. ASU 2023-09 is effective for the Company’s annual periods beginning January 1, 2025, with early adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on the Company’s financial statement disclosures.

In March 2024, the FASB issued ASU 2024-02 “Codification Improvements – Amendments to Remove References to the Concepts Statements.” This amendments to the Codification that remove references to various Concepts Statement. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2024. Early application of the amendments in this update is permitted for all entities, for any fiscal year or interim period for which financial statements have not yet been issued (or made available for issuance). If an entity adopts the amendments in an interim period, it must adopt them as of the beginning of the fiscal year that includes that interim period. The Company is currently evaluating the impact that the adoption of this standard will have on the Company’s financial statement disclosures.
XML 24 R15.htm IDEA: XBRL DOCUMENT v3.24.2.u1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 6 Months Ended
Jun. 30, 2024
Accounting Policies [Abstract]  
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
The following is a summary of awards outstanding as of June 30, 2024 and 2023, which are not included in the computation of basic and diluted weighted average shares:
Three and Six months ended
June 30,
20242023
Stock options (excluding exercisable penny stock options)5,993,356 2,851,383 
Restricted stock units283,411 246,470 
Warrants5,152,397 5,152,397 
Total11,429,164 8,250,250 
XML 25 R16.htm IDEA: XBRL DOCUMENT v3.24.2.u1
STOCKHOLDERS’ EQUITY (Tables)
 6 Months Ended
Jun. 30, 2024
Equity [Abstract]  
Schedule of Warrant Activity
The following is a summary of warrant activity during the six months ended June 30, 2024:
Number of
shares		Weighted
average exercise
price		Weighted
average
remaining life (years)		Aggregate
intrinsic value
(in thousands)
Outstanding and exercisable - December 31, 2023
5,152,397 $4.71 3.35$792
Exercised— — — — 
Expired— — — — 
Outstanding and exercisable – June 30, 2024
5,152,397 $4.71 2.85$1,158 
XML 26 R17.htm IDEA: XBRL DOCUMENT v3.24.2.u1
STOCK-BASED COMPENSATION (Tables)
 6 Months Ended
Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock Option, Activity
The following is a summary of stock option activity during the six months ended June 30, 2024:
Number of
options
outstanding		Weighted
average
exercise
price		Average
remaining
contractual life
(in years)		Aggregate
intrinsic value
(in thousands)
Outstanding – December 31, 2023
6,092,525 $2.22 8.7$2,945 
Options granted
114,000 2.27 
Options exercised
(5,252)1.54 
Options cancelled(25,748)2.41 
Outstanding – June 30, 2024
6,175,525 $2.23 8.4$3,692 
Exercisable – June 30, 2024
1,748,660 $1.90 7.4$1,687 
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions For the six months ended June 30, 2024 and 2023, the assumptions used in the Black-Scholes option pricing model, which was used to estimate the grant date fair value per option, were as follows:
Six months ended June 30,
20242023
Weighted-average Black-Scholes option pricing model assumptions:
Volatility
125.89% - 128.74%
110.23% - 111.73%
Expected term (in years)
6.02 - 7.00
5.71 - 6.07
Risk-free rate
4.50% - 4.60%
3.54% - 3.80%
Expected dividend yield$— $— 
Weighted average grant date fair value per share
$1.81 - $2.48
$1.73 - $3.38
Schedule of Nonvested Restricted Stock Units Activity
The following is a summary of RSU’s awards activity:
Six months ended June 30, 2024
Numbers of SharesWeighted Average Grant Date Fair value
Non-Vested at beginning of period217,881 $3.12 
Shares granted243,357 2.26 
Shares vested(177,827)3.13 
Non-vested at the end of period283,411 $2.38 
Schedule of Stock-Based Compensation
The following is a summary of stock-based compensation expense:
Three months ended June 30,Six months ended June 30,
2024202320242023
General and administrative
Stock options602,000 507,200 1,338,000 707,200 
RSU’s142,000 116,400 283,000 217,400 
Total general and administrative744,000 623,600 1,621,000 924,600 
Research and development
Stock options287,000 78,800 607,000 170,800 
  RSU’s 9,000 — 19,000 — 
Total research and development296,000 78,800 626,000 170,800 
Total1,040,000 702,400 2,247,000 1,095,400 
XML 27 R18.htm IDEA: XBRL DOCUMENT v3.24.2.u1
ORGANIZATION AND OPERATIONS (Details)
 6 Months Ended
Jun. 30, 2024
segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Number of operating segments 1
XML 28 R19.htm IDEA: XBRL DOCUMENT v3.24.2.u1
GOING CONCERN AND OTHER UNCERTAINTIES (Details) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Jun. 30, 2024
May 02, 2024
Dec. 31, 2023
Jun. 30, 2023
Liquidity, Going Concern, and Other Uncertainties [Line Items]        
Cash and cash equivalents $ 9,157   $ 16,189 $ 17,401
Public Ventures, LLC | Private Placement        
Liquidity, Going Concern, and Other Uncertainties [Line Items]        
Sale of stock, maximum amount authorized   $ 17,000    
Shares issued in at the market (ATM) (in shares) 50      
Sale of stock, available for issuance under the ATM $ 16,900      
XML 29 R20.htm IDEA: XBRL DOCUMENT v3.24.2.u1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Accounting Policies [Abstract]    
Restricted cash (included in other assets) $ 55 $ 0
Construction in progress $ 370  
Incremental common shares attributable to dilutive effect of equity forward agreements (in shares) 182,169  
XML 30 R21.htm IDEA: XBRL DOCUMENT v3.24.2.u1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of earnings per share (in shares) 11,429,164 8,250,250 11,429,164 8,250,250
Stock options (excluding exercisable penny stock options)        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of earnings per share (in shares) 5,993,356 2,851,383 5,993,356 2,851,383
Restricted stock units        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of earnings per share (in shares) 283,411 246,470 283,411 246,470
Warrants        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of earnings per share (in shares) 5,152,397 5,152,397 5,152,397 5,152,397
XML 31 R22.htm IDEA: XBRL DOCUMENT v3.24.2.u1
STOCKHOLDERS’ EQUITY - Schedule of Warrant Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
 6 Months Ended 12 Months Ended
Jun. 30, 2024
Dec. 31, 2023
Number of shares    
Outstanding, beginning balance (in shares) 5,152,397  
Exercisable beginning balance (in shares) 5,152,397  
Exercised (in shares) 0  
Expired (in shares) 0  
Outstanding, ending balance (in shares) 5,152,397 5,152,397
Exercisable ending balance (in shares) 5,152,397 5,152,397
Weighted average exercise price    
Outstanding, beginning balance (in dollars per share) $ 4.71  
Exercisable beginning balance ( in dollars per share) 4.71  
Exercised (in dollars per share) 0  
Expired (in dollars per share) 0  
Outstanding, ending balance (in dollars per share) 4.71 $ 4.71
Exercisable ending balance ( in dollars per share) $ 4.71 $ 4.71
Weighted average remaining life (years)    
Outstanding 2 years 10 months 6 days 3 years 4 months 6 days
Exercisable 2 years 10 months 6 days 3 years 4 months 6 days
Aggregate intrinsic value (in thousands)    
Outstanding $ 1,158 $ 792
Exercisable $ 1,158 $ 792
XML 32 R23.htm IDEA: XBRL DOCUMENT v3.24.2.u1
STOCK-BASED COMPENSATION - Narrative (Details) - USD ($)
$ in Millions
 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
May 31, 2024
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Cost not yet recognized, options, amount $ 6.4    
Cost not yet recognized, excluding options, amount $ 0.6    
Stock options      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Cost not yet recognized, period of recognition (in years) 2 years 4 months 24 days    
RSU’s      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Cost not yet recognized, period of recognition (in years) 1 year 29 days    
Executives And Employees      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of options granted (in shares)   2,208,000  
Executives And Employees | Share-Based Payment Arrangement, Tranche Two      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Percentage of share-based compensation arrangement vesting (as a percent)   40.00%  
Vesting period   48 months  
Executives And Employees | Stock options | Share-Based Payment Arrangement, Tranche One      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Percentage of share-based compensation arrangement vesting (as a percent)   60.00%  
2022 Equity Plan      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of shares authorized for issuance (in shares) 8,900,000   5,900,000
XML 33 R24.htm IDEA: XBRL DOCUMENT v3.24.2.u1
STOCK-BASED COMPENSATION - Schedule of Stock Option, Activity (Details)
$ / shares in Units, $ in Thousands
 6 Months Ended 12 Months Ended
Jun. 30, 2024
USD ($)
$ / shares
shares
Dec. 31, 2023
USD ($)
$ / shares
shares
Number of options outstanding    
Beginning balance (in shares) | shares 6,092,525  
Options granted (in shares) | shares 114,000  
Options exercised (in shares) | shares (5,252)  
Options cancelled (in shares) | shares (25,748)  
Ending balance (in shares) | shares 6,175,525 6,092,525
Weighted average exercise price    
Beginning balance (in dollars per share) | $ / shares $ 2.22  
Options granted (in dollars per share) | $ / shares 2.27  
Options exercised (in dollars per share) | $ / shares 1.54  
Options cancelled (in dollars per share) | $ / shares 2.41  
Ending balance (in dollars per share) | $ / shares $ 2.23 $ 2.22
Stock Options Additional Disclosures    
Average remaining contractual life 8 years 4 months 24 days 8 years 8 months 12 days
Aggregate intrinsic value, outstanding | $ $ 3,692 $ 2,945
Exercisable (in shares) | shares 1,748,660  
Exercisable, Weighted average exercise price (in dollars per share) | $ / shares $ 1.90  
Exercisable, Average remaining contractual life 7 years 4 months 24 days  
Exercisable, Aggregate intrinsic value | $ $ 1,687  
XML 34 R25.htm IDEA: XBRL DOCUMENT v3.24.2.u1
STOCK-BASED COMPENSATION - Assumptions (Details) - Stock options - USD ($)
 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Risk-free rate, minimum 4.50% 3.54%
Risk-free rate, maximum 4.60% 3.80%
Expected dividend yield $ 0 $ 0
Minimum    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Volatility 125.89% 110.23%
Expected term (in years) 6 years 7 days 5 years 8 months 15 days
Weighted average grant date fair value per share (in dollars per share) $ 1.81 $ 1.73
Maximum    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Volatility 128.74% 111.73%
Expected term (in years) 7 years 6 years 25 days
Weighted average grant date fair value per share (in dollars per share) $ 2.48 $ 3.38
XML 35 R26.htm IDEA: XBRL DOCUMENT v3.24.2.u1
STOCK-BASED COMPENSATION - Schedule of Nonvested Restricted Stock Units Activity (Details) - RSU’s
 6 Months Ended
Jun. 30, 2024
$ / shares
shares
Numbers of Shares  
Non-vested, beginning balance (in shares) | shares 217,881
Shares granted (in shares) | shares 243,357
Shares vested (in shares) | shares (177,827)
Non-vested, ending balance (in shares) | shares 283,411
Weighted Average Grant Date Fair value  
Non-Vested, beginning balance (in dollars per share) | $ / shares $ 3.12
Shares granted (in dollars per share) | $ / shares 2.26
Shares vested (in dollars per share) | $ / shares 3.13
Non-vested, ending balance (in dollars per share) | $ / shares $ 2.38
XML 36 R27.htm IDEA: XBRL DOCUMENT v3.24.2.u1
STOCK-BASED COMPENSATION - Stock-Based Compensation (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total $ 1,040,000 $ 702,400 $ 2,247,000 $ 1,095,400
General and administrative        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total 744,000 623,600 1,621,000 924,600
General and administrative | Stock options        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total 602,000 507,200 1,338,000 707,200
General and administrative | RSU’s        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total 142,000 116,400 283,000 217,400
Research and development        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total 296,000 78,800 626,000 170,800
Research and development | Stock options        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total 287,000 78,800 607,000 170,800
Research and development | RSU’s        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total $ 9,000 $ 0 $ 19,000 $ 0
XML 37 R28.htm IDEA: XBRL DOCUMENT v3.24.2.u1
RELATED PARTY TRANSACTIONS (Details)
 1 Months Ended 3 Months Ended 6 Months Ended
Apr. 30, 2024
USD ($)
director
shares
Jun. 30, 2024
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2024
USD ($)
shares
Jun. 30, 2023
USD ($)
Dec. 31, 2023
USD ($)
Related Party Transaction [Line Items]            
Due to related party   $ 1,420,000   $ 1,420,000   $ 1,194,000
Number of independent Board of Directors members | director 1          
Monthly payment $ 5,000          
Options granted (in shares) | shares       114,000    
Consulting service fees   2,246,000 $ 1,828,000 $ 4,602,000 $ 4,303,000  
Stock based compensation expense   1,040,000 $ 702,400 2,247,000 $ 1,095,400  
Related Party            
Related Party Transaction [Line Items]            
Due to related party   0   $ 0   $ 2,000
Options granted (in shares) | shares 70,000          
Consulting service fees   24,500        
Stock based compensation expense   $ 9,500        
Related Party | Stock options            
Related Party Transaction [Line Items]            
Vesting period 36 months          
XML 38 R29.htm IDEA: XBRL DOCUMENT v3.24.2.u1
COMMITMENTS (Details)
 3 Months Ended 6 Months Ended
Jan. 31, 2024
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2023
USD ($)
Mar. 08, 2024
USD ($)
site
Feb. 01, 2024
Dec. 31, 2023
USD ($)
Mar. 31, 2022
USD ($)
Long-term Purchase Commitment [Line Items]                  
Operating lease, prior notice for cancellation 1 month                
Monthly rent expense $ 1,800                
Lease commenced, initial period             3 years    
Rent expense   $ 5,400 $ 4,000 $ 10,440 $ 8,000        
Research and development   2,844,000 1,484,000 5,272,000 3,165,000        
Accrued liabilities   1,420,000   1,420,000       $ 1,194,000  
Triple Ring Technologies                  
Long-term Purchase Commitment [Line Items]                  
Purchase commitments                 $ 1,700,000
Research and development   100,000 $ 400,000 200,000 $ 600,000        
Remaining commitment   200,000   200,000          
Clinical Research Organization                  
Long-term Purchase Commitment [Line Items]                  
Research and development   300,000   700,000          
Remaining commitment   100,000   100,000          
Amount to be paid to Clinical Research Organization (CRO)           $ 500,000      
Number of planned sites to carrying out the clinical study | site           5      
Research and development expense, expected cost           $ 800,000      
Accrued liabilities   $ 200,000   $ 200,000          
EXCEL 39 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 40 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 41 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 43 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 116 173 1 false 23 0 false 7 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.heartbeam.com/role/CoverPage Cover Page Cover 1 false false R2.htm 9952151 - Statement - Condensed Balance Sheets (Unaudited) Sheet http://www.heartbeam.com/role/CondensedBalanceSheetsUnaudited Condensed Balance Sheets (Unaudited) Statements 2 false false R3.htm 9952152 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical) Sheet http://www.heartbeam.com/role/CondensedBalanceSheetsUnauditedParenthetical Condensed Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 9952153 - Statement - Condensed Statements of Operations (Unaudited) Sheet http://www.heartbeam.com/role/CondensedStatementsofOperationsUnaudited Condensed Statements of Operations (Unaudited) Statements 4 false false R5.htm 9952154 - Statement - Condensed Statement of Changes in Stockholders??? Equity (Unaudited) Sheet http://www.heartbeam.com/role/CondensedStatementofChangesinStockholdersEquityUnaudited Condensed Statement of Changes in Stockholders??? Equity (Unaudited) Statements 5 false false R6.htm 9952155 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://www.heartbeam.com/role/CondensedStatementsofCashFlowsUnaudited Condensed Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 9952156 - Disclosure - ORGANIZATION AND OPERATIONS Sheet http://www.heartbeam.com/role/ORGANIZATIONANDOPERATIONS ORGANIZATION AND OPERATIONS Notes 7 false false R8.htm 9952157 - Disclosure - GOING CONCERN AND OTHER UNCERTAINTIES Sheet http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIES GOING CONCERN AND OTHER UNCERTAINTIES Notes 8 false false R9.htm 9952158 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 9952159 - Disclosure - STOCKHOLDERS??? EQUITY Sheet http://www.heartbeam.com/role/STOCKHOLDERSEQUITY STOCKHOLDERS??? EQUITY Notes 10 false false R11.htm 9952160 - Disclosure - STOCK-BASED COMPENSATION Sheet http://www.heartbeam.com/role/STOCKBASEDCOMPENSATION STOCK-BASED COMPENSATION Notes 11 false false R12.htm 9952161 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://www.heartbeam.com/role/RELATEDPARTYTRANSACTIONS RELATED PARTY TRANSACTIONS Notes 12 false false R13.htm 9952162 - Disclosure - COMMITMENTS Sheet http://www.heartbeam.com/role/COMMITMENTS COMMITMENTS Notes 13 false false R14.htm 9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 14 false false R15.htm 9954472 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES 15 false false R16.htm 9954473 - Disclosure - STOCKHOLDERS??? EQUITY (Tables) Sheet http://www.heartbeam.com/role/STOCKHOLDERSEQUITYTables STOCKHOLDERS??? EQUITY (Tables) Tables http://www.heartbeam.com/role/STOCKHOLDERSEQUITY 16 false false R17.htm 9954474 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONTables STOCK-BASED COMPENSATION (Tables) Tables http://www.heartbeam.com/role/STOCKBASEDCOMPENSATION 17 false false R18.htm 9954475 - Disclosure - ORGANIZATION AND OPERATIONS (Details) Sheet http://www.heartbeam.com/role/ORGANIZATIONANDOPERATIONSDetails ORGANIZATION AND OPERATIONS (Details) Details http://www.heartbeam.com/role/ORGANIZATIONANDOPERATIONS 18 false false R19.htm 9954476 - Disclosure - GOING CONCERN AND OTHER UNCERTAINTIES (Details) Sheet http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIESDetails GOING CONCERN AND OTHER UNCERTAINTIES (Details) Details http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIES 19 false false R20.htm 9954477 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) Sheet http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) Details 20 false false R21.htm 9954478 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Sheet http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Details 21 false false R22.htm 9954479 - Disclosure - STOCKHOLDERS??? EQUITY - Schedule of Warrant Activity (Details) Sheet http://www.heartbeam.com/role/STOCKHOLDERSEQUITYScheduleofWarrantActivityDetails STOCKHOLDERS??? EQUITY - Schedule of Warrant Activity (Details) Details 22 false false R23.htm 9954480 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details) Sheet http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails STOCK-BASED COMPENSATION - Narrative (Details) Details 23 false false R24.htm 9954481 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock Option, Activity (Details) Sheet http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails STOCK-BASED COMPENSATION - Schedule of Stock Option, Activity (Details) Details 24 false false R25.htm 9954482 - Disclosure - STOCK-BASED COMPENSATION - Assumptions (Details) Sheet http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONAssumptionsDetails STOCK-BASED COMPENSATION - Assumptions (Details) Details 25 false false R26.htm 9954483 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Nonvested Restricted Stock Units Activity (Details) Sheet http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONScheduleofNonvestedRestrictedStockUnitsActivityDetails STOCK-BASED COMPENSATION - Schedule of Nonvested Restricted Stock Units Activity (Details) Details 26 false false R27.htm 9954484 - Disclosure - STOCK-BASED COMPENSATION - Stock-Based Compensation (Details) Sheet http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationDetails STOCK-BASED COMPENSATION - Stock-Based Compensation (Details) Details 27 false false R28.htm 9954485 - Disclosure - RELATED PARTY TRANSACTIONS (Details) Sheet http://www.heartbeam.com/role/RELATEDPARTYTRANSACTIONSDetails RELATED PARTY TRANSACTIONS (Details) Details http://www.heartbeam.com/role/RELATEDPARTYTRANSACTIONS 28 false false R29.htm 9954486 - Disclosure - COMMITMENTS (Details) Sheet http://www.heartbeam.com/role/COMMITMENTSDetails COMMITMENTS (Details) Details http://www.heartbeam.com/role/COMMITMENTS 29 false false All Reports Book All Reports beat-20240630.htm beat-20240630.xsd beat-20240630_cal.xml beat-20240630_def.xml beat-20240630_lab.xml beat-20240630_pre.xml http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 true true JSON 45 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "beat-20240630.htm": { "nsprefix": "beat", "nsuri": "http://www.heartbeam.com/20240630", "dts": { "inline": { "local": [ "beat-20240630.htm" ] }, "schema": { "local": [ "beat-20240630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "beat-20240630_cal.xml" ] }, "definitionLink": { "local": [ "beat-20240630_def.xml" ] }, "labelLink": { "local": [ "beat-20240630_lab.xml" ] }, "presentationLink": { "local": [ "beat-20240630_pre.xml" ] } }, "keyStandard": 155, "keyCustom": 18, "axisStandard": 12, "axisCustom": 0, "memberStandard": 17, "memberCustom": 5, "hidden": { "total": 5, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 116, "entityCount": 1, "segmentCount": 23, "elementCount": 268, "unitCount": 7, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 377, "http://xbrl.sec.gov/dei/2024": 34 }, "report": { "R1": { "role": "http://www.heartbeam.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.heartbeam.com/role/CondensedBalanceSheetsUnaudited", "longName": "9952151 - Statement - Condensed Balance Sheets (Unaudited)", "shortName": "Condensed Balance Sheets (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "unique": true } }, "R3": { "role": "http://www.heartbeam.com/role/CondensedBalanceSheetsUnauditedParenthetical", "longName": "9952152 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical)", "shortName": "Condensed Balance Sheets (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "unique": true } }, "R4": { "role": "http://www.heartbeam.com/role/CondensedStatementsofOperationsUnaudited", "longName": "9952153 - Statement - Condensed Statements of Operations (Unaudited)", "shortName": "Condensed Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-9", "name": "us-gaap:OperatingExpenses", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "unique": true } }, "R5": { "role": "http://www.heartbeam.com/role/CondensedStatementofChangesinStockholdersEquityUnaudited", "longName": "9952154 - Statement - Condensed Statement of Changes in Stockholders\u2019 Equity (Unaudited)", "shortName": "Condensed Statement of Changes in Stockholders\u2019 Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-39", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-39", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.heartbeam.com/role/CondensedStatementsofCashFlowsUnaudited", "longName": "9952155 - Statement - Condensed Statements of Cash Flows (Unaudited)", "shortName": "Condensed Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "unique": true } }, "R7": { "role": "http://www.heartbeam.com/role/ORGANIZATIONANDOPERATIONS", "longName": "9952156 - Disclosure - ORGANIZATION AND OPERATIONS", "shortName": "ORGANIZATION AND OPERATIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIES", "longName": "9952157 - Disclosure - GOING CONCERN AND OTHER UNCERTAINTIES", "shortName": "GOING CONCERN AND OTHER UNCERTAINTIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "longName": "9952158 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.heartbeam.com/role/STOCKHOLDERSEQUITY", "longName": "9952159 - Disclosure - STOCKHOLDERS\u2019 EQUITY", "shortName": "STOCKHOLDERS\u2019 EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATION", "longName": "9952160 - Disclosure - STOCK-BASED COMPENSATION", "shortName": "STOCK-BASED COMPENSATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.heartbeam.com/role/RELATEDPARTYTRANSACTIONS", "longName": "9952161 - Disclosure - RELATED PARTY TRANSACTIONS", "shortName": "RELATED PARTY TRANSACTIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.heartbeam.com/role/COMMITMENTS", "longName": "9952162 - Disclosure - COMMITMENTS", "shortName": "COMMITMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "longName": "9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables", "longName": "9954472 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYTables", "longName": "9954473 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Tables)", "shortName": "STOCKHOLDERS\u2019 EQUITY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONTables", "longName": "9954474 - Disclosure - STOCK-BASED COMPENSATION (Tables)", "shortName": "STOCK-BASED COMPENSATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.heartbeam.com/role/ORGANIZATIONANDOPERATIONSDetails", "longName": "9954475 - Disclosure - ORGANIZATION AND OPERATIONS (Details)", "shortName": "ORGANIZATION AND OPERATIONS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIESDetails", "longName": "9954476 - Disclosure - GOING CONCERN AND OTHER UNCERTAINTIES (Details)", "shortName": "GOING CONCERN AND OTHER UNCERTAINTIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "19", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-46", "name": "beat:SaleOfStockValueAuthorizedInTransaction", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "unique": true } }, "R20": { "role": "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "longName": "9954477 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "20", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:RestrictedCashNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:ConstructionInProgressGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "unique": true } }, "R21": { "role": "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails", "longName": "9954478 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "21", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-9", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYScheduleofWarrantActivityDetails", "longName": "9954479 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Schedule of Warrant Activity (Details)", "shortName": "STOCKHOLDERS\u2019 EQUITY - Schedule of Warrant Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "22", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "beat:ClassOfWarrantOrRightWarrantsExercised", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "unique": true } }, "R23": { "role": "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "longName": "9954480 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)", "shortName": "STOCK-BASED COMPENSATION - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "23", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails", "longName": "9954481 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock Option, Activity (Details)", "shortName": "STOCK-BASED COMPENSATION - Schedule of Stock Option, Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "unique": true } }, "R25": { "role": "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONAssumptionsDetails", "longName": "9954482 - Disclosure - STOCK-BASED COMPENSATION - Assumptions (Details)", "shortName": "STOCK-BASED COMPENSATION - Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "c-68", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-68", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONScheduleofNonvestedRestrictedStockUnitsActivityDetails", "longName": "9954483 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Nonvested Restricted Stock Units Activity (Details)", "shortName": "STOCK-BASED COMPENSATION - Schedule of Nonvested Restricted Stock Units Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "c-70", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-70", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationDetails", "longName": "9954484 - Disclosure - STOCK-BASED COMPENSATION - Stock-Based Compensation (Details)", "shortName": "STOCK-BASED COMPENSATION - Stock-Based Compensation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-81", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "unique": true } }, "R28": { "role": "http://www.heartbeam.com/role/RELATEDPARTYTRANSACTIONSDetails", "longName": "9954485 - Disclosure - RELATED PARTY TRANSACTIONS (Details)", "shortName": "RELATED PARTY TRANSACTIONS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-100", "name": "beat:RelatedPartyTransactionNumberOfBoardMembers", "unitRef": "director", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "unique": true } }, "R29": { "role": "http://www.heartbeam.com/role/COMMITMENTSDetails", "longName": "9954486 - Disclosure - COMMITMENTS (Details)", "shortName": "COMMITMENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "c-105", "name": "beat:LesseeOperatingLeasePriorNoticeForCancellation", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-105", "name": "beat:LesseeOperatingLeasePriorNoticeForCancellation", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "beat-20240630.htm", "first": true, "unique": true } } }, "tag": { "beat_A2022EquityPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.heartbeam.com/20240630", "localname": "A2022EquityPlanMember", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2022 Equity Plan", "label": "2022 Equity Plan [Member]", "documentation": "2022 Equity Plan" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.heartbeam.com/role/CondensedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.heartbeam.com/role/COMMITMENTSDetails", "http://www.heartbeam.com/role/CondensedBalanceSheetsUnaudited", "http://www.heartbeam.com/role/CondensedBalanceSheetsUnauditedParenthetical", "http://www.heartbeam.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued expenses (includes related party $- and $2, respectively)", "verboseLabel": "Due to related party", "netLabel": "Accrued liabilities", "label": "Accounts Payable and Accrued Liabilities, Current", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r31", "r32" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.heartbeam.com/role/CondensedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.heartbeam.com/role/CondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r40", "r433", "r525" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.heartbeam.com/role/CondensedStatementofChangesinStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r323", "r462", "r463", "r464", "r465", "r508", "r526" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.heartbeam.com/role/CondensedStatementofChangesinStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stock based compensation expense", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r25", "r26", "r191" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.heartbeam.com/role/CondensedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.heartbeam.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total", "verboseLabel": "Stock based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r220", "r225" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.heartbeam.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r133" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r16" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r16" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.heartbeam.com/role/CondensedBalanceSheetsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.heartbeam.com/role/CondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total Assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r66", "r72", "r91", "r106", "r136", "r140", "r142", "r143", "r145", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r242", "r244", "r260", "r289", "r357", "r419", "r420", "r433", "r445", "r478", "r479", "r514" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://www.heartbeam.com/role/CondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.heartbeam.com/role/CondensedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.heartbeam.com/role/CondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total Current Assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r87", "r95", "r106", "r145", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r242", "r244", "r260", "r433", "r478", "r479", "r514" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.heartbeam.com/role/CondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current Assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://www.heartbeam.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONAssumptionsDetails", "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONScheduleofNonvestedRestrictedStockUnitsActivityDetails", "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "BASIS\u00a0OF PRESENTATION", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://www.heartbeam.com/role/CondensedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase of property and equipment in accounts payable", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r13", "r14", "r15" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.heartbeam.com/role/CondensedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.heartbeam.com/role/CondensedBalanceSheetsUnaudited", "http://www.heartbeam.com/role/CondensedStatementsofCashFlowsUnaudited", "http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r10", "r89", "r411" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r11" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.heartbeam.com/role/CondensedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents and restricted cash \u2013 Beginning of period", "periodEndLabel": "Cash, cash equivalents and restricted cash \u2013 Ending of period", "terseLabel": "Total cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r10", "r51", "r104" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "presentation": [ "http://www.heartbeam.com/role/CondensedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash:", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.heartbeam.com/role/CondensedStatementsofCashFlowsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.heartbeam.com/role/CondensedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r51" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.heartbeam.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "beat_ClassOFWarrantOrRightAggregateIntrinsicValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.heartbeam.com/20240630", "localname": "ClassOFWarrantOrRightAggregateIntrinsicValueAbstract", "presentation": [ "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYScheduleofWarrantActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate intrinsic value (in thousands)", "label": "Class OF Warrant Or Right, Aggregate Intrinsic Value [Abstract]", "documentation": "Class OF Warrant Or Right, Aggregate Intrinsic Value" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [ "http://www.heartbeam.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r84", "r92", "r93", "r94", "r106", "r127", "r128", "r130", "r132", "r138", "r139", "r145", "r158", "r160", "r161", "r162", "r165", "r166", "r170", "r171", "r174", "r177", "r183", "r260", "r315", "r316", "r317", "r318", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r345", "r366", "r388", "r401", "r402", "r403", "r404", "r405", "r453", "r459", "r466" ] }, "beat_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://www.heartbeam.com/20240630", "localname": "ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding", "crdr": "debit", "presentation": [ "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYScheduleofWarrantActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding", "label": "Class of Warrant or Right, Aggregate Intrinsic Value, Outstanding", "documentation": "Class of Warrant or Right, Aggregate Intrinsic Value, Outstanding" } } }, "auth_ref": [] }, "beat_ClassOfWarrantOrRightExercisable": { "xbrltype": "sharesItemType", "nsuri": "http://www.heartbeam.com/20240630", "localname": "ClassOfWarrantOrRightExercisable", "presentation": [ "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYScheduleofWarrantActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Exercisable beginning balance (in shares)", "periodEndLabel": "Exercisable ending balance (in shares)", "label": "Class of Warrant or Right, Exercisable", "documentation": "Class of Warrant or Right, Exercisable" } } }, "auth_ref": [] }, "beat_ClassOfWarrantOrRightExercisableAggregateIntrinsicValueOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://www.heartbeam.com/20240630", "localname": "ClassOfWarrantOrRightExercisableAggregateIntrinsicValueOutstanding", "crdr": "debit", "presentation": [ "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYScheduleofWarrantActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable", "label": "Class of Warrant or Right, Exercisable, Aggregate Intrinsic Value, Outstanding", "documentation": "Class of Warrant or Right, Exercisable, Aggregate Intrinsic Value, Outstanding" } } }, "auth_ref": [] }, "beat_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights": { "xbrltype": "perShareItemType", "nsuri": "http://www.heartbeam.com/20240630", "localname": "ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights", "presentation": [ "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYScheduleofWarrantActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Exercisable beginning balance ( in dollars per share)", "periodEndLabel": "Exercisable ending balance ( in dollars per share)", "label": "Class of Warrant or Right, Exercisable, Exercise Price of Warrants or Rights", "documentation": "Class of Warrant or Right, Exercisable, Exercise Price of Warrants or Rights" } } }, "auth_ref": [] }, "beat_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife": { "xbrltype": "durationItemType", "nsuri": "http://www.heartbeam.com/20240630", "localname": "ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife", "presentation": [ "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYScheduleofWarrantActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable", "label": "Class of Warrant or Right, Exercisable, Weighted Average Remaining Life", "documentation": "Class of Warrant or Right, Exercisable, Weighted Average Remaining Life" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYScheduleofWarrantActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, beginning balance (in dollars per share)", "periodEndLabel": "Outstanding, ending balance (in dollars per share)", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r184" ] }, "beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised": { "xbrltype": "perShareItemType", "nsuri": "http://www.heartbeam.com/20240630", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised", "presentation": [ "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYScheduleofWarrantActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised (in dollars per share)", "label": "Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Exercised", "documentation": "Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Exercised" } } }, "auth_ref": [] }, "beat_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired": { "xbrltype": "perShareItemType", "nsuri": "http://www.heartbeam.com/20240630", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired", "presentation": [ "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYScheduleofWarrantActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expired (in dollars per share)", "label": "Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Expired", "documentation": "Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Expired" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYScheduleofWarrantActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, beginning balance (in shares)", "periodEndLabel": "Outstanding, ending balance (in shares)", "label": "Class of Warrant or Right, Outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "beat_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.heartbeam.com/20240630", "localname": "ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward", "presentation": [ "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYScheduleofWarrantActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price", "label": "Class Of Warrant Or Right Outstanding, Weighted Average Exercise Price [Roll Forward]", "documentation": "Class Of Warrant Or Right Outstanding, Weighted Average Exercise Price" } } }, "auth_ref": [] }, "beat_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLifeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.heartbeam.com/20240630", "localname": "ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLifeAbstract", "presentation": [ "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYScheduleofWarrantActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining life (years)", "label": "Class Of Warrant Or Right Outstanding, Weighted Average Remaining Life [Abstract]", "documentation": "Class Of Warrant Or Right Outstanding, Weighted Average Remaining Life" } } }, "auth_ref": [] }, "beat_ClassOfWarrantOrRightRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.heartbeam.com/20240630", "localname": "ClassOfWarrantOrRightRollForward", "presentation": [ "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYScheduleofWarrantActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares", "label": "Class of Warrant orRight [Roll Forward]", "documentation": "Class of Warrant orRight" } } }, "auth_ref": [] }, "beat_ClassOfWarrantOrRightWarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.heartbeam.com/20240630", "localname": "ClassOfWarrantOrRightWarrantsExercised", "presentation": [ "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYScheduleofWarrantActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Exercised (in shares)", "label": "Class Of Warrant Or Right, Warrants Exercised", "documentation": "Class Of Warrant Or Right, Warrants Exercised" } } }, "auth_ref": [] }, "beat_ClassOfWarrantOrRightWarrantsExpired": { "xbrltype": "sharesItemType", "nsuri": "http://www.heartbeam.com/20240630", "localname": "ClassOfWarrantOrRightWarrantsExpired", "presentation": [ "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYScheduleofWarrantActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Expired (in shares)", "label": "Class Of Warrant Or Right, Warrants Expired", "documentation": "Class Of Warrant Or Right, Warrants Expired" } } }, "auth_ref": [] }, "beat_ClassOfWarrantOrRightWeightedAverageRemainingLife": { "xbrltype": "durationItemType", "nsuri": "http://www.heartbeam.com/20240630", "localname": "ClassOfWarrantOrRightWeightedAverageRemainingLife", "presentation": [ "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYScheduleofWarrantActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding", "label": "Class Of Warrant Or Right, Weighted Average Remaining Life", "documentation": "Class Of Warrant Or Right, Weighted Average Remaining Life" } } }, "auth_ref": [] }, "beat_ClinicalResearchOrganizationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.heartbeam.com/20240630", "localname": "ClinicalResearchOrganizationMember", "presentation": [ "http://www.heartbeam.com/role/COMMITMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Clinical Research Organization", "label": "Clinical Research Organization [Member]", "documentation": "Clinical Research Organization" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.heartbeam.com/role/CondensedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.heartbeam.com/role/CondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments (Note 7)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r36", "r67", "r291", "r344" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.heartbeam.com/role/COMMITMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r58", "r152", "r153", "r407", "r475", "r477" ] }, "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonClassAMember", "presentation": [ "http://www.heartbeam.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Class A [Member]", "documentation": "Classification of common stock representing ownership interest in a corporation." } } }, "auth_ref": [ "r526" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://www.heartbeam.com/role/CondensedStatementofChangesinStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "netLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r435", "r436", "r437", "r439", "r440", "r441", "r442", "r462", "r463", "r465", "r508", "r524", "r526" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.heartbeam.com/role/CondensedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r39" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.heartbeam.com/role/CondensedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r39", "r345" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.heartbeam.com/role/CondensedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r39" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.heartbeam.com/role/CondensedBalanceSheetsUnauditedParenthetical", "http://www.heartbeam.com/role/CondensedStatementofChangesinStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r4", "r39", "r345", "r363", "r526", "r527" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.heartbeam.com/role/CondensedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.heartbeam.com/role/CondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock - $0.0001 par value 100,000,000 shares authorized; 26,562,111 and 26,329,032 shares issued and outstanding at June\u00a030, 2024 and December\u00a031, 2023, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r39", "r293", "r433" ] }, "us-gaap_ConstructionInProgressGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionInProgressGross", "crdr": "debit", "presentation": [ "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Construction in progress", "label": "Construction in Progress, Gross", "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [ "r57" ] }, "us-gaap_ContractualObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractualObligation", "crdr": "credit", "presentation": [ "http://www.heartbeam.com/role/COMMITMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount to be paid to Clinical Research Organization (CRO)", "label": "Contractual Obligation", "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments." } } }, "auth_ref": [ "r461" ] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpensesAbstract", "presentation": [ "http://www.heartbeam.com/role/CondensedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Expenses:", "label": "Costs and Expenses [Abstract]" } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.heartbeam.com/role/COMMITMENTSDetails", "http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r109", "r110", "r167", "r172", "r278", "r282", "r288", "r412", "r414" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.heartbeam.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATION" ], "lang": { "en-us": { "role": { "terseLabel": "STOCK-BASED COMPENSATION", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r189", "r193", "r221", "r222", "r224", "r424" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.heartbeam.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.heartbeam.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.heartbeam.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Line Items]", "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": [ "http://www.heartbeam.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Table]", "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.heartbeam.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.heartbeam.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r449" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.heartbeam.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r450" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.heartbeam.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.heartbeam.com/role/CondensedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share, basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r101", "r116", "r117", "r118", "r119", "r120", "r121", "r125", "r127", "r130", "r131", "r132", "r135", "r238", "r241", "r254", "r255", "r285", "r302", "r416" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.heartbeam.com/role/CondensedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share, diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r101", "r116", "r117", "r118", "r119", "r120", "r121", "r127", "r130", "r131", "r132", "r135", "r238", "r241", "r254", "r255", "r285", "r302", "r416" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "NET LOSS PER COMMON SHARE", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r16", "r17", "r134" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost not yet recognized, period of recognition (in years)", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r223" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost not yet recognized, excluding options, amount", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r507" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost not yet recognized, options, amount", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": [ "r507" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.heartbeam.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONAssumptionsDetails", "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.heartbeam.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.heartbeam.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.heartbeam.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.heartbeam.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.heartbeam.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.heartbeam.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r447" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.heartbeam.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.heartbeam.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.heartbeam.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r447" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.heartbeam.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r452" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.heartbeam.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://www.heartbeam.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r447" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.heartbeam.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.heartbeam.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r451" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.heartbeam.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r447" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://www.heartbeam.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r447" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://www.heartbeam.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r447" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.heartbeam.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r447" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://www.heartbeam.com/role/CondensedStatementofChangesinStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r4", "r85", "r98", "r99", "r100", "r111", "r112", "r113", "r115", "r120", "r122", "r124", "r137", "r146", "r147", "r148", "r185", "r232", "r233", "r235", "r236", "r237", "r239", "r240", "r241", "r246", "r247", "r248", "r249", "r250", "r251", "r253", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r271", "r301", "r308", "r309", "r310", "r323", "r388" ] }, "beat_ExecutivesAndEmployeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.heartbeam.com/20240630", "localname": "ExecutivesAndEmployeesMember", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Executives And Employees", "label": "Executives And Employees [Member]", "documentation": "Executives And Employees" } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.heartbeam.com/role/CondensedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.heartbeam.com/role/CondensedStatementsofOperationsUnaudited", "http://www.heartbeam.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "verboseLabel": "Consulting service fees", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r47", "r368" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r47" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.heartbeam.com/role/CondensedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.heartbeam.com/role/CondensedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before provision for income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r45", "r69", "r71", "r286", "r299", "r418", "r419", "r467", "r469", "r470", "r471", "r472" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r149", "r150", "r151", "r257", "r258", "r259", "r305", "r307", "r373", "r410", "r427", "r523" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r150", "r151", "r257", "r258", "r259", "r305", "r307", "r373", "r410", "r427", "r523" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.heartbeam.com/role/CondensedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.heartbeam.com/role/CondensedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax provision", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r73", "r82", "r123", "r124", "r136", "r141", "r143", "r228", "r229", "r234", "r303", "r426" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://www.heartbeam.com/role/CondensedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Taxes paid", "label": "Income Taxes Paid, Net", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r12", "r103", "r230", "r231" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.heartbeam.com/role/CondensedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.heartbeam.com/role/CondensedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued expenses", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r2" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.heartbeam.com/role/CondensedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.heartbeam.com/role/CondensedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.heartbeam.com/role/CondensedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r2" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.heartbeam.com/role/CondensedStatementofChangesinStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToEquityForwardAgreements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToEquityForwardAgreements", "presentation": [ "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Incremental common shares attributable to dilutive effect of equity forward agreements (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Equity Forward Agreements", "documentation": "Additional shared included in the calculation of diluted EPS as a result of the potentially dilutive effect of equity forward arrangements using the reverse treasury stock method." } } }, "auth_ref": [ "r132", "r415" ] }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "calculation": { "http://www.heartbeam.com/role/CondensedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.heartbeam.com/role/CondensedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Interest Income (Expense), Nonoperating", "documentation": "Amount of interest income (expense) classified as nonoperating." } } }, "auth_ref": [ "r419", "r456", "r469" ] }, "beat_LesseeOperatingLeaseMonthlyRentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.heartbeam.com/20240630", "localname": "LesseeOperatingLeaseMonthlyRentExpense", "crdr": "debit", "presentation": [ "http://www.heartbeam.com/role/COMMITMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Monthly rent expense", "label": "Lessee, Operating Lease, Monthly Rent Expense", "documentation": "Lessee, Operating Lease, Monthly Rent Expense" } } }, "auth_ref": [] }, "beat_LesseeOperatingLeasePriorNoticeForCancellation": { "xbrltype": "durationItemType", "nsuri": "http://www.heartbeam.com/20240630", "localname": "LesseeOperatingLeasePriorNoticeForCancellation", "presentation": [ "http://www.heartbeam.com/role/COMMITMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, prior notice for cancellation", "label": "Lessee, Operating Lease, Prior Notice For Cancellation", "documentation": "Lessee, Operating Lease, Prior Notice For Cancellation" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://www.heartbeam.com/role/COMMITMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease commenced, initial period", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r511" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.heartbeam.com/role/CondensedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.heartbeam.com/role/CondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r9", "r31", "r32", "r33", "r34", "r35", "r36", "r37", "r106", "r145", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r243", "r244", "r245", "r260", "r343", "r417", "r445", "r478", "r514", "r515" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.heartbeam.com/role/CondensedBalanceSheetsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.heartbeam.com/role/CondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities and Stockholders\u2019 Equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r44", "r68", "r295", "r433", "r460", "r474", "r510" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.heartbeam.com/role/CondensedBalanceSheetsUnaudited", "http://www.heartbeam.com/role/CondensedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and Stockholders\u2019 Equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.heartbeam.com/role/CondensedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.heartbeam.com/role/CondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total Current Liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r33", "r88", "r106", "r145", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r243", "r244", "r245", "r260", "r433", "r478", "r514", "r515" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.heartbeam.com/role/CondensedBalanceSheetsUnaudited", "http://www.heartbeam.com/role/CondensedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Current Liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "beat_LiquidityGoingConcernAndOtherUncertaintiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.heartbeam.com/20240630", "localname": "LiquidityGoingConcernAndOtherUncertaintiesLineItems", "presentation": [ "http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liquidity, Going Concern, and Other Uncertainties [Line Items]", "label": "Liquidity, Going Concern, and Other Uncertainties [Line Items]", "documentation": "Liquidity, Going Concern, and Other Uncertainties [Line Items]" } } }, "auth_ref": [] }, "beat_LiquidityGoingConcernAndOtherUncertaintiesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.heartbeam.com/20240630", "localname": "LiquidityGoingConcernAndOtherUncertaintiesTable", "presentation": [ "http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liquidity, Going Concern, and Other Uncertainties [Table]", "label": "Liquidity, Going Concern, and Other Uncertainties [Table]", "documentation": "Liquidity, Going Concern, and Other Uncertainties [Table]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.heartbeam.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermPurchaseCommitmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermPurchaseCommitmentLineItems", "presentation": [ "http://www.heartbeam.com/role/COMMITMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Purchase Commitment [Line Items]", "label": "Long-Term Purchase Commitment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_LongTermPurchaseCommitmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermPurchaseCommitmentTable", "presentation": [ "http://www.heartbeam.com/role/COMMITMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Purchase Commitment [Table]", "label": "Long-Term Purchase Commitment [Table]", "documentation": "Disclosure of information about long-term purchase arrangement. Includes, but is not limited to, term of arrangement with supplier, minimum quantity required, milestone, period covered by arrangement, and committed amount. Excludes short-term purchase arrangement and unconditional purchase obligation." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r154", "r155", "r156", "r157", "r188", "r226", "r256", "r283", "r304", "r306", "r313", "r335", "r336", "r396", "r397", "r398", "r399", "r400", "r408", "r409", "r421", "r422", "r423", "r428", "r429", "r430", "r431", "r434", "r480", "r516", "r517", "r518", "r519", "r520", "r521" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r154", "r155", "r156", "r157", "r188", "r226", "r256", "r283", "r304", "r306", "r313", "r335", "r336", "r396", "r397", "r398", "r399", "r400", "r408", "r409", "r421", "r422", "r423", "r428", "r429", "r430", "r434", "r480", "r516", "r517", "r518", "r519", "r520", "r521" ] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NatureOfOperations", "presentation": [ "http://www.heartbeam.com/role/ORGANIZATIONANDOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "ORGANIZATION AND OPERATIONS", "label": "Nature of Operations [Text Block]", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": [ "r75", "r83" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.heartbeam.com/role/CondensedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.heartbeam.com/role/CondensedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r102" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.heartbeam.com/role/CondensedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flows From Financing Activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.heartbeam.com/role/CondensedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.heartbeam.com/role/CondensedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r102" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.heartbeam.com/role/CondensedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flows From Investing Activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.heartbeam.com/role/CondensedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.heartbeam.com/role/CondensedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r51", "r52", "r53" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.heartbeam.com/role/CondensedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flows From Operating Activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.heartbeam.com/role/CondensedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 }, "http://www.heartbeam.com/role/CondensedStatementsofOperationsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.heartbeam.com/role/CondensedStatementofChangesinStockholdersEquityUnaudited", "http://www.heartbeam.com/role/CondensedStatementsofCashFlowsUnaudited", "http://www.heartbeam.com/role/CondensedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net Loss", "verboseLabel": "Net loss", "terseLabel": "Net loss", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r46", "r53", "r70", "r86", "r96", "r97", "r100", "r106", "r114", "r116", "r117", "r118", "r119", "r120", "r123", "r124", "r129", "r145", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r238", "r241", "r255", "r260", "r300", "r365", "r386", "r387", "r443", "r478" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "RECENTLY ISSUED ACCOUNTING STANDARDS", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.heartbeam.com/role/CondensedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.heartbeam.com/role/CondensedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total other income", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r48" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.heartbeam.com/role/CondensedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other Income", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.heartbeam.com/role/ORGANIZATIONANDOPERATIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r420", "r468" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.heartbeam.com/role/CondensedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.heartbeam.com/role/CondensedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.heartbeam.com/role/CondensedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.heartbeam.com/role/CondensedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r71", "r418", "r467", "r469", "r470", "r471", "r472" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://www.heartbeam.com/role/COMMITMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rent expense", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r269", "r432" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" ], "lang": { "en-us": { "role": { "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements." } } }, "auth_ref": [ "r29", "r54", "r55", "r65" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.heartbeam.com/role/CondensedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.heartbeam.com/role/CondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r90" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.heartbeam.com/role/CondensedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.heartbeam.com/role/CondensedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r50" ] }, "us-gaap_PaymentsToAcquireShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireShortTermInvestments", "crdr": "credit", "calculation": { "http://www.heartbeam.com/role/CondensedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.heartbeam.com/role/CondensedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of short-term investments", "label": "Payments to Acquire Short-Term Investments", "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term." } } }, "auth_ref": [ "r49" ] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.heartbeam.com/role/CondensedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r38", "r170" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.heartbeam.com/role/CondensedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r38", "r345" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.heartbeam.com/role/CondensedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r38", "r345", "r363", "r526", "r527" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.heartbeam.com/role/CondensedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.heartbeam.com/role/CondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock - $0.0001 par value; 10,000,000 authorized; 0 shares outstanding at June\u00a030, 2024 and December\u00a031, 2023", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r38", "r292", "r433" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.heartbeam.com/role/CondensedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.heartbeam.com/role/CondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r455" ] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrivatePlacementMember", "presentation": [ "http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Private Placement", "label": "Private Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.heartbeam.com/role/CondensedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.heartbeam.com/role/CondensedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of equity, net of issuance costs", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r1" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.heartbeam.com/role/CondensedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.heartbeam.com/role/CondensedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of stock options", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r1", "r8" ] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "calculation": { "http://www.heartbeam.com/role/CondensedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.heartbeam.com/role/CondensedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of warrants", "label": "Proceeds from Warrant Exercises", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": [ "r457" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.heartbeam.com/role/CondensedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.heartbeam.com/role/CondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r3", "r270", "r287", "r298", "r433" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "PROPERTY AND EQUIPMENT, NET", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r3", "r78", "r81", "r297" ] }, "beat_PublicVenturesLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.heartbeam.com/20240630", "localname": "PublicVenturesLLCMember", "presentation": [ "http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Public Ventures, LLC", "label": "Public Ventures, LLC [Member]", "documentation": "Public Ventures, LLC" } } }, "auth_ref": [] }, "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted", "crdr": "credit", "presentation": [ "http://www.heartbeam.com/role/COMMITMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining commitment", "label": "Purchase Commitment, Remaining Minimum Amount Committed", "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations." } } }, "auth_ref": [ "r36", "r67" ] }, "us-gaap_PurchaseObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseObligation", "crdr": "credit", "presentation": [ "http://www.heartbeam.com/role/COMMITMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase commitments", "label": "Purchase Obligation", "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier." } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r154", "r155", "r156", "r157", "r186", "r188", "r216", "r217", "r218", "r226", "r256", "r280", "r281", "r283", "r304", "r306", "r313", "r335", "r336", "r396", "r397", "r398", "r399", "r400", "r408", "r409", "r421", "r422", "r423", "r428", "r429", "r430", "r431", "r434", "r437", "r476", "r480", "r509", "r517", "r518", "r519", "r520", "r521" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r154", "r155", "r156", "r157", "r186", "r188", "r216", "r217", "r218", "r226", "r256", "r280", "r281", "r283", "r304", "r306", "r313", "r335", "r336", "r396", "r397", "r398", "r399", "r400", "r408", "r409", "r421", "r422", "r423", "r428", "r429", "r430", "r431", "r434", "r437", "r476", "r480", "r509", "r517", "r518", "r519", "r520", "r521" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [ "http://www.heartbeam.com/role/CondensedBalanceSheetsUnauditedParenthetical", "http://www.heartbeam.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Domain]", "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r144", "r187", "r275", "r276", "r290", "r296", "r338", "r339", "r340", "r341", "r342", "r362", "r364", "r395" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyMember", "presentation": [ "http://www.heartbeam.com/role/CondensedBalanceSheetsUnauditedParenthetical", "http://www.heartbeam.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r107", "r108", "r275", "r276", "r277", "r278", "r290", "r296", "r338", "r339", "r340", "r341", "r342", "r362", "r364", "r395" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://www.heartbeam.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Line Items]", "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r144", "r369", "r370", "r373" ] }, "beat_RelatedPartyTransactionMonthlyAmountOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://www.heartbeam.com/20240630", "localname": "RelatedPartyTransactionMonthlyAmountOfTransaction", "crdr": "debit", "presentation": [ "http://www.heartbeam.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Monthly payment", "label": "Related Party Transaction, Monthly Amount Of Transaction", "documentation": "Related Party Transaction, Monthly Amount Of Transaction" } } }, "auth_ref": [] }, "beat_RelatedPartyTransactionNumberOfBoardMembers": { "xbrltype": "integerItemType", "nsuri": "http://www.heartbeam.com/20240630", "localname": "RelatedPartyTransactionNumberOfBoardMembers", "presentation": [ "http://www.heartbeam.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of independent Board of Directors members", "label": "Related Party Transaction, Number Of Board Members", "documentation": "Related Party Transaction, Number Of Board Members" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.heartbeam.com/role/CondensedBalanceSheetsUnauditedParenthetical", "http://www.heartbeam.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Axis]", "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r144", "r187", "r275", "r276", "r290", "r296", "r338", "r339", "r340", "r341", "r342", "r362", "r364", "r395", "r513" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.heartbeam.com/role/RELATEDPARTYTRANSACTIONS" ], "lang": { "en-us": { "role": { "terseLabel": "RELATED PARTY TRANSACTIONS", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r272", "r273", "r274", "r276", "r279", "r320", "r321", "r322", "r371", "r372", "r373", "r392", "r394" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.heartbeam.com/role/COMMITMENTSDetails", "http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r109", "r110", "r167", "r172", "r278", "r282", "r288", "r413", "r414" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.heartbeam.com/role/CondensedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.heartbeam.com/role/COMMITMENTSDetails", "http://www.heartbeam.com/role/CondensedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r227", "r410", "r419", "r522" ] }, "beat_ResearchAndDevelopmentExpenseExpectedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.heartbeam.com/20240630", "localname": "ResearchAndDevelopmentExpenseExpectedCost", "crdr": "debit", "presentation": [ "http://www.heartbeam.com/role/COMMITMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development expense, expected cost", "label": "Research And Development Expense, Expected Cost", "documentation": "Research And Development Expense, Expected Cost" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "beat_ResearchAndDevelopmentNumberOfClinicalStudySites": { "xbrltype": "integerItemType", "nsuri": "http://www.heartbeam.com/20240630", "localname": "ResearchAndDevelopmentNumberOfClinicalStudySites", "presentation": [ "http://www.heartbeam.com/role/COMMITMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of planned sites to carrying out the clinical study", "label": "Research And Development, Number Of Clinical Study Sites", "documentation": "Research And Development, Number Of Clinical Study Sites" } } }, "auth_ref": [] }, "us-gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "presentation": [ "http://www.heartbeam.com/role/CondensedStatementsofCashFlowsUnaudited", "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash (included in other assets)", "label": "Restricted Cash, Noncurrent", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r74", "r454", "r458" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember", "presentation": [ "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock units", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r16" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONScheduleofNonvestedRestrictedStockUnitsActivityDetails", "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "RSU\u2019s", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.heartbeam.com/role/CondensedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.heartbeam.com/role/CondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r41", "r60", "r294", "r311", "r312", "r319", "r346", "r433" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://www.heartbeam.com/role/CondensedStatementofChangesinStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r85", "r111", "r112", "r113", "r115", "r120", "r122", "r124", "r146", "r147", "r148", "r232", "r233", "r235", "r236", "r237", "r239", "r240", "r241", "r246", "r248", "r249", "r251", "r253", "r267", "r268", "r308", "r310", "r323", "r526" ] }, "beat_SaleOfStockAmountRemainingForFutureIssuanceValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.heartbeam.com/20240630", "localname": "SaleOfStockAmountRemainingForFutureIssuanceValue", "crdr": "debit", "presentation": [ "http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock, available for issuance under the ATM", "label": "Sale Of Stock, Amount Remaining For Future Issuance, Value", "documentation": "Sale Of Stock, Amount Remaining For Future Issuance, Value" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Domain]", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIESDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Shares issued in at the market (ATM) (in shares)", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "beat_SaleOfStockValueAuthorizedInTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://www.heartbeam.com/20240630", "localname": "SaleOfStockValueAuthorizedInTransaction", "crdr": "debit", "presentation": [ "http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock, maximum amount authorized", "label": "Sale Of Stock, Value Authorized In Transaction", "documentation": "Sale Of Stock, Value Authorized In Transaction" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": [ "r16" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r16" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock-Based Compensation", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r24" ] }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Nonvested Restricted Stock Units Activity", "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units." } } }, "auth_ref": [ "r62" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://www.heartbeam.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]", "label": "Related Party Transaction [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": [ "r27", "r28", "r369", "r370", "r373" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONAssumptionsDetails", "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONScheduleofNonvestedRestrictedStockUnitsActivityDetails", "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r190", "r192", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock Option, Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r6", "r7", "r61" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r64" ] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": [ "http://www.heartbeam.com/role/STOCKHOLDERSEQUITYTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Warrant Activity", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r22" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.heartbeam.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r446" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.heartbeam.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r448" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.heartbeam.com/role/CondensedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.heartbeam.com/role/CondensedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stock based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.heartbeam.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r424" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONScheduleofNonvestedRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r208" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONScheduleofNonvestedRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r208" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONScheduleofNonvestedRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Non-vested, beginning balance (in shares)", "periodEndLabel": "Non-vested, ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r205", "r206" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONScheduleofNonvestedRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Numbers of Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONScheduleofNonvestedRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Non-Vested, beginning balance (in dollars per share)", "periodEndLabel": "Non-vested, ending balance (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r205", "r206" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONScheduleofNonvestedRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant Date Fair value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONScheduleofNonvestedRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Shares vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r209" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONScheduleofNonvestedRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares vested (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r209" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free rate, maximum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free rate, minimum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend", "crdr": "debit", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected dividend yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend", "documentation": "Disclosure of the weighted average expected dividend for an entity using a valuation technique with different dividend rates during the contractual term." } } }, "auth_ref": [ "r217" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate", "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement." } } }, "auth_ref": [ "r216" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONAssumptionsDetails", "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONScheduleofNonvestedRestrictedStockUnitsActivityDetails", "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r190", "r192", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of options granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted", "documentation": "Net number of non-option equity instruments granted to participants." } } }, "auth_ref": [ "r5" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares authorized for issuance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r425" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options Additional Disclosures", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r199" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable, Weighted average exercise price (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r199" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Options cancelled (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r203" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.heartbeam.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r201" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average grant date fair value per share (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r211" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate intrinsic value, outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r23" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r197", "r198" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of options outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in dollars per share)", "periodEndLabel": "Ending balance (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r197", "r198" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.heartbeam.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONAssumptionsDetails", "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONScheduleofNonvestedRestrictedStockUnitsActivityDetails", "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options exercised (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r202" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options cancelled (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r203" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options granted (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r201" ] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement, Tranche One", "label": "Share-Based Payment Arrangement, Tranche One [Member]", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheTwoMember", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement, Tranche Two", "label": "Share-Based Payment Arrangement, Tranche Two [Member]", "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of share-based compensation arrangement vesting (as a percent)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": [ "r481" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected term (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r215" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable, Aggregate intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r23" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable, Average remaining contractual life", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r23" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average remaining contractual life", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r63" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.heartbeam.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r84", "r92", "r93", "r94", "r106", "r127", "r128", "r130", "r132", "r138", "r139", "r145", "r158", "r160", "r161", "r162", "r165", "r166", "r170", "r171", "r174", "r177", "r183", "r260", "r315", "r316", "r317", "r318", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r345", "r366", "r388", "r401", "r402", "r403", "r404", "r405", "r453", "r459", "r466" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.heartbeam.com/role/CondensedStatementofChangesinStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r4", "r39", "r42", "r43", "r85", "r98", "r99", "r100", "r111", "r112", "r113", "r115", "r120", "r122", "r124", "r137", "r146", "r147", "r148", "r185", "r232", "r233", "r235", "r236", "r237", "r239", "r240", "r241", "r246", "r247", "r248", "r249", "r250", "r251", "r253", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r271", "r301", "r308", "r309", "r310", "r323", "r388" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://www.heartbeam.com/role/CondensedBalanceSheetsUnauditedParenthetical", "http://www.heartbeam.com/role/CondensedStatementofChangesinStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r111", "r112", "r113", "r137", "r268", "r284", "r314", "r334", "r337", "r338", "r339", "r340", "r341", "r342", "r345", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r358", "r359", "r360", "r361", "r362", "r364", "r367", "r368", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r388", "r438" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://www.heartbeam.com/role/CondensedBalanceSheetsUnauditedParenthetical", "http://www.heartbeam.com/role/CondensedStatementofChangesinStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r111", "r112", "r113", "r137", "r144", "r268", "r284", "r314", "r334", "r337", "r338", "r339", "r340", "r341", "r342", "r345", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r358", "r359", "r360", "r361", "r362", "r364", "r367", "r368", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r388", "r438" ] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": [ "http://www.heartbeam.com/role/CondensedStatementofChangesinStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stock issuance upon exercise of warrants (in shares)", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": [ "r4", "r21", "r39", "r42", "r60", "r168" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.heartbeam.com/role/CondensedStatementofChangesinStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Common Stock under ATM, net of issuance costs (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r4", "r38", "r39", "r60", "r315", "r388", "r402" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": [ "http://www.heartbeam.com/role/CondensedStatementofChangesinStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stock issuance upon vesting of restricted stock units (in shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": [ "r4", "r38", "r39", "r60" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.heartbeam.com/role/CondensedStatementofChangesinStockholdersEquityUnaudited", "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock issuance upon exercise of stock options (in shares)", "negatedLabel": "Options exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r4", "r38", "r39", "r60", "r202" ] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": [ "http://www.heartbeam.com/role/CondensedStatementofChangesinStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stock issuance upon exercise of warrants", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": [ "r4", "r39", "r42", "r43", "r60" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.heartbeam.com/role/CondensedStatementofChangesinStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Common Stock under ATM, net of issuance costs", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r4", "r38", "r39", "r60", "r323", "r388", "r402", "r444" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.heartbeam.com/role/CondensedStatementofChangesinStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stock issuance upon exercise of stock options", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r4", "r39", "r42", "r43", "r60" ] }, "us-gaap_StockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockOptionMember", "presentation": [ "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options (excluding exercisable penny stock options)", "label": "Equity Option [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)." } } }, "auth_ref": [ "r437" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.heartbeam.com/role/CondensedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.heartbeam.com/role/CondensedBalanceSheetsUnaudited", "http://www.heartbeam.com/role/CondensedStatementofChangesinStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total Stockholders\u2019 Equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r39", "r42", "r43", "r56", "r347", "r363", "r389", "r390", "r433", "r445", "r460", "r474", "r510", "r526" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.heartbeam.com/role/CondensedBalanceSheetsUnaudited", "http://www.heartbeam.com/role/CondensedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 Equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.heartbeam.com/role/STOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "STOCKHOLDERS\u2019 EQUITY", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r59", "r105", "r169", "r171", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r185", "r252", "r391", "r393", "r406" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Axis]", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "presentation": [ "http://www.heartbeam.com/role/GOINGCONCERNANDOTHERUNCERTAINTIES" ], "lang": { "en-us": { "role": { "terseLabel": "GOING CONCERN AND OTHER UNCERTAINTIES", "label": "Substantial Doubt about Going Concern [Text Block]", "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern." } } }, "auth_ref": [ "r30" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.heartbeam.com/role/CondensedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental Disclosures of Cash Flow Information:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Axis]", "label": "Title and Position [Axis]" } } }, "auth_ref": [ "r473", "r512" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Domain]", "label": "Title and Position [Domain]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.heartbeam.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "beat_TripleRingTechnologiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.heartbeam.com/20240630", "localname": "TripleRingTechnologiesMember", "presentation": [ "http://www.heartbeam.com/role/COMMITMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Triple Ring Technologies", "label": "Triple Ring Technologies [Member]", "documentation": "Triple Ring Technologies" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "USE OF ESTIMATES", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r18", "r19", "r20", "r76", "r77", "r79", "r80" ] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingAxis", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting [Axis]", "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506" ] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingDomain", "presentation": [ "http://www.heartbeam.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting [Domain]", "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": [ "http://www.heartbeam.com/role/CoverPage", "http://www.heartbeam.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Warrants", "terseLabel": "Warrants", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r435", "r436", "r439", "r440", "r441", "r442" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.heartbeam.com/role/CondensedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average common shares outstanding, diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r126", "r132" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.heartbeam.com/role/CondensedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average common shares outstanding, basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r125", "r132" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "40", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205-40/tableOfContent" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r413": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r414": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r415": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "35", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-35" }, "r416": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r417": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r418": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r419": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r420": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r421": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r422": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r423": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r424": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r427": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r428": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r429": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r430": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r431": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r432": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r433": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r434": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r435": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r437": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r442": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r443": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r444": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r445": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r446": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r447": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r448": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r450": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r452": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r453": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r454": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r455": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r456": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r457": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r458": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r459": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r460": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r461": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r462": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r463": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r464": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r465": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r466": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r467": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r468": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r469": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r470": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r471": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r472": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r473": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r474": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r475": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r476": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r477": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r478": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r479": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r480": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r481": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r482": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r483": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r484": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r485": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r486": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r487": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r488": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r489": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r490": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r491": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r492": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r493": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r494": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r495": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r496": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r497": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r498": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r499": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r500": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r501": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r502": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r503": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r504": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r505": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r506": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r507": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r508": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r509": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r510": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r511": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r512": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r513": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r514": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r515": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r516": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r517": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r518": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r519": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r520": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r521": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r522": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r523": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r524": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r525": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r526": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r527": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 46 0001628280-24-037202-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-24-037202-xbrl.zip M4$L#!!0 ( F"#EEE$E7"$ZD &T#"0 1 8F5A="TR,#(T,#8S,"YH M=&WL?6EWXDB6Z/?Y%7K4]'3F.>#4QN:LXAW2)JO[]^?^^C!SEF?J![;F__%6[4/^J M4+?O6;;[],M?V]VKFYN__M_6?_W\?RJ5__WT\$6Y]OK1B+JAU14'DB9#QY9D""1W9_?(&]?_KNL!+0_LP'X.^+)^\Y M]>H/H4_< %,0D 9?KE: ; 86O*>%[CU^\Q;?ACLHUJSV?S KL:W+K\)(92\ M+_##Q0W C[.+#SQ3U^K+H*,"=/@=R0,+BYR]&R\_DH!.-@57+7OR0/KFV@=^ M,7VKO6HA;A 2MT]3<,^^>Q70=;6BZA5-GWPTL+.@"1_4/OSOUR_=_I".2&7^ MTQ:=VU*";[@P!>^E0X 92]2M?.N66C\#A5JMGTC+W^EK2;&M7TJ#"K!: M2P6@U>M-HZ[__&'FK3D^ACRN>H>B+ ME\ ">F??FWXD_F;@13[[BPF*R\BU0[;P8$C@8BGY?41)$/FTQ?_B%W_^,'LM M^1O?L?"^"-8P_[)8"%Y^ZU[G?1>@M8N+F+P3&-2V:/I6!F<2>OZ&GUUX'G^\ MIJXWLMVLUZX+FIE7?)A=_:I=!_0)B6X!BHCKR_AB+C"Z$3+S$A2/X9^YWF;9 M/NW#GK+7EUS-]FUR3*MU*VU"FJG MV2O)W\E'/LSL.QL,^J[!$.^&DR3_TX*/O8P=NV^'7[D.L6RXRNSL4FS_779# MV!(^<^60(+@;=$.O_[W]8H,82FZY\D:@H=CU-G_1SQ\RWS\!Q609QX$OEC15-#@8Z\/!*! .PMGVQOIF2I%P$-^X[_P98<3+&XT]%_X, ML@Q\9ESN6A<8!8DB37R;?37,VY9EHY(@SCVQK1OWBHSMD#A' _^=V^8[AO\# M#8GM4JM#?-=VGX*C ;QXKD-A6]NY[W J/"V"$22L.R2"TA,!0<*Z2\)(:!&P MM'.?ZIC9:#=Q!'WG_MNIZ)D=P7_G?N/12Z8= 5XZJNO&S HS:G7IJ!X6_M)1 M/1#@!7-4B]R:=%0WL; /$Z76I:,J.(*DHWH,6)*.ZMIZIBA[W9".ZF'A+QW5 M P%^YX[JX;9V[/[@_N1H874KQK'[@(>1H\7!?^>NX&G)T>( +QW5XZEV-J2C M*CB"I*-Z#%B2CNIZ>D8O3L^8TE$]+/REHWH@P OFJ!:YM6-W5 ^6Y#A ";IY M[![N7I,![WW[&39^[Y ^P^<;&'KS MTX$? EM& !]_C*?4;LF(\B^R=@#WT2,\^#M\*/)I\.7+U:ZKH*H5M9"SMZ:X M?O8Y(EF (EQ37,?^'"EB-\6/IK!Q@3:\P;*=*+2?:9?V(Q_,5AIT7OI.9%'K ML^^-4"E'(>O\=3=(-'#2CN?3:_8+9LF$4<[=&%]QDF&?JK AB--#[P%$=%78 M",>)H?\HU?[ M0>UA=&[MO"-7>T/M 71M[;@[Y,W4DFP%!V'#._<.<>'<6'-C<4-+RP<4-BIP^EQ\(Y>(&2XI" M^9&*7W%#':(@YC <4QO"AC?V9Z$EK[YQ^]Z(3@YN?/'Z+ ([^_U?J4M]XK1=JVV-P'0' M[!.,PW9>QO ^>I()L+J,SQP3D1PF*%^7$9UC(I(#J7<9 SHF(CF00W1L4:/- M;,!3(I0#V27'%FN2A'(@V^388E^24 YCGS3.(Q9W2H1R&!NE(6P0\0A0=AAK MH2%L:/$(4'88O=T0-CIY!"@[D 85-E9X!"@[D"Z3D;M\1 )&%R5^?PA4.-\=Z3UITR;G<\)'(@77UL4;MS)I$#V0;'%J\[9Q(YD"TB(W7'12:'L4>: M,DYW7&1R&)ND*6R43I*)0'9)4]C(H"03@6R3YG%'(\_02CCN6.09ZFMA(Y'" M(^Q FE/8N*#P"#N0#A,N2H<'(GMVB&VX;US+?K:MB#BIG@:=%]IGG4X"P%(2 MD#G-.0E-&1^;?/%W,'%M]VFNH2OK?T,":F&'''B$\S1;G$]< ,V=^Q;?2H+, M09#"1N,V)(_>#T^21V'DH:D[#\.M 8C9@W%F00?C-%6X)E/YG"BS,"0+&QUY MH [LRKK'>1K(X 'I(\,'GU[35^9-OND5H9S>XO E;)AB_U:$I)!,"A$V+G)2 M^"I.S>X\++)1M,%8%Q!:0?T.-77GX8;<]H:>HH?M[ TA/?,5(ZMZOCUVZ -8 MX3W:'[J>XSW9NS!T9^:PJD9!74 T53AG6Q!X"R'QA',\!47. 6*^FB9<\86( MR#E,!D73A"MY$!0YAXB7:,*YTH(@9S?-C31-.%?X#7A?.;9K]XF3)*;N_"?B MVO\ANVE^-PMU(/1&,5 7SKT4"NHBV%>:<(EVH5%T$"M+N-2Z4"C:7F-\L%\N M?1IXD=^G ?]S2(G%UF/9SZV?X3\,&7:_00W:-.OJ8[5I$DLEIJ;WFWI=HZ;5 MJ#;HO]#FFCX3A*\.(&5DNY4AM9^&X:59'8B+A_+0?$#2H!;"N^ M,;#_0^'%\ WVYX_XHZKZ$5!"DT5HNOJ7C[CUBD7[GL_PEUKI5NK]WK=&<7+>!RNYVK;P\WO9M.5VG?7BN= M_[WZK7W[:T>YNOOZ]:;;O;F[%7X+?Y!@"/9LZ+EEY?KBZD+1U:K9%'[9G^\> MOBH_@XQR/?08:$WOFS &K,@$3+6B^]_]'Q@X I Q"'C@%XF__AH MV<'8(:\@F=F^V$,?X[<_>F'HC2Y10#Y3/T0%$G^$?8]?GLK."Y7+SQ"D=&@E M7XXO7\"E#UF_-XWL*^J%MN2)[/N;U8M&??6K/K"5\=4! !"TOY2,4G+SF%@6 M4-^E/GY1M%F@.G2P .^_?5)[@]X-[X_6$9L^AJ"&3Z7F\[^$8%% -+[]8&. M/3\L*0//'Y$0E.=+>#FP7ZA5"?UH0HK@!__/3\VZ6?NXE!I#JR 8 OV6EM$U MPN- #/V/;^V'7N?ARS^5A\[]W4-/N?_VT/W6ONTIO3L%Y&P/A*FB&@^AR$CR ^.ZS;A\M^#))L'/GJ^$ M0ZK\F1"6PNTX!8QJ:BG)-@^!N?S<<<^6WN'NP"QO6/!+902O&.)C%8N\5E[! M?*Y0-^$5L'#^%KGT?W[2:NI'0RTK:/(6*<0/@5[/7UBQU":B:9.V;Q-'^09> MG6=1Y6MW8Y2KF[$-JP"PT3=8KE4&Q DF:L6,U8JY-[5R"/G3>VC?=F^8?MB- MZCAZI1%.""?1&@/?&RG_FOZ/$GKI/X]-?%YYHY$=8%A&^6R#S 0R?Z3^Y9&H MQ0Z+Z^#"^;H3]JUBQ$JKF)I:4^<96!$71<6 XX$^L6Y3;HAQM00DM5+KMPX8 MBI\Z[:]EY>;VZF)MS2\*K;[KO)!^J."N,$@SW:=" J4[IGT,1UJ*[2IV&"A7 M0V;OO5\'W08SWH_":C ;%]5F+9?9L/QW4\WWII6+:NS( .$TMZT)4A1+YK1 M.$OB&3)_'(\_XGJG]7B^UKJE#?A"? M;F&5J C?&%-GAX@>>;F)$Q?\&-^LWFB46F:]8C8:FEE=4!R+5LURUM,62QPSXC) 5L)3NP%3RE;]%OAU8-JNS!?DLLCIARY]A M2K:-5)XI(_JQ%5MM1! '9;@E0+MXN.A>*'&EO?_SH_^A-6"^/#2Y="(7\%_[SS>]Z/B=;'.KPN M&+E$N7*(3PH#.9/>=_X]F!FVVY_F=G1P"MMO.$W2S%@+Q/<>6'+._[/'W,R+ M 6R46LVJ>@#[0D!U$@,*W;E['\C0'A-'F1Q\5>X&H%5H4)QU>RIP YI2D*@V MB[35A(ENK"HC>;<^UZ'4;/N4S/"9"<8\%B+.WTX]T//G0LO8=%; MH]FLF*9I"*R8LJ,HT[#)__S4T+7ZQT#I48>.<9MQ^*^L@&WL1,@/"H)UEM36 M#YO].PK +GP]T$:[($5\.[3AC3[;,_6II8PC/X@P9A1Z"MS!+%9-?_?X'F40 MAGS;_?!RG;W6E^UUOV&D9O.B83;R1I'TQD73K H611)R44;]O$);K",%\@(E M_:'2=TA0H/H],E#XA(G [NOHT7/>!>_/%1!)Q)V1!'WI#XG[!#^XRH^A#;], MI6LN$Y;TOS_Y'BC\2KR/?I_2P>#CJ=AH*^T,/6UGQ)KJ5=,?&?M-[(P:3] ! MI%E+@PVBODNAO*[!++&48"D6!UP:3%!4+[4^==H]B1H1&*@3RZ9TXE-K@ !K M=Z_;R^M5-Y)6 _8_IP128RV9U,3*9Q_]AZ 0HI^#8VZB/W$\9$H=7>52YP^) M@?UQ0I9PT;7UA\* M+/T[6(&4)0#1>_:G11GOM/?*D 3*P'; [R:. Q>Q^ [=\3\C&YUQ\,$?:7P# MO'/BCQN8CN,59[%7GG+F$SR@IXZ7L>),L> JF.IXZ]BG?WRD%+ 1 M/?X;=H#WLUOA(5Q%_!ZL0PS8(M@B21 J356QR&MPD3N$?Q7Y/KR.%S.B= A) M& 43HM1+K7_2!>F%0H"^56Y0=F,[;&>J7)-0L(+ >=X=/J.= #M(8([ M3;4:EV-%#L\ =RL]Y1V6F=<_*KJA7\1WA$,[@"63,99E[9IC^8(GC$B#]_G9 M+ 49!$S,=1,V,[+9+";X,R8Z0#-1'-@;50CX) X $2D'T>"CW,S\50$85C(N M!".@5?B&GP@[P-L(0/!:1B4!+P/)BE!\4L J^1$.D\L7H#,H6YE%![;+BGA9 MH@G#WCILOP)0 M/7G^ZV*M*6^-P(#8CV^:5ISJ)K@W66)YF=([79+K+A/SN:T*]J9/40"?"((W MS[=6WS[@FIO6-T].B(F;3K96S8V9Y#V_LM=<\;>\B:%:;@RM$PFH'L[6&ZRP MJLI@HV2:@O8@R_5@#@<(#==C_D(4<(L,L,!/WV:[8 )(9>X?3Q4"*()2^GQ9NS68A'?"A2LG;>M9=E^XQUYGVE8 ME^G)0GXT]\V3A7K][:.%QU)AL8%7$ RIXTP8]!V0"+/.^;&=1=L7L )^&WA9 MB8)'KRJWP,5OKN#F6?PTUF3G(\ /K^9!6 8XT"+@K6U8/C' ?*+B12%C&N0> MPBZWHR=8,B"!GPY'MSHK5-Q)0+ODI$?!W-ICB3- M$A!YWP:U'_Q2NKG]G!'/8TAA.5XV>B2XFR)FEF+=:%2Q/%8RAR\$G0V*&-ZE M3N@7Z[1KY6I-+VN:EI!PLM26D,A<[M6FVUZ-/2YH+WWLTVX_TX5&6%-OESFN MZO01\AAX3A0N/L(AT6+G&+(Z/>5MX%6?-/ :^E-[ZHE6'GU*OE?((*3^)7%^ MD-< #3#9Y>LXNGS-=7H1I'HVXTCOVQI*J/7?WO4ZRD/GU_;#]_63.SKYW;WO*&9BMV=ECEV\-H]Z2;D<)S-5@T]1G$N8+]LQ@! M$ML-DN@@"'H<;%)Q/.][;-#RH8-!$B!$>Q@,)32-1I2X>!,0V2%+!Q1@'"2> @B/&!@4[?_ MBNOW(O ]2# LLW^11]L!W-XC"R$=#.8B3$ZRY<$W@+Q!*R%,V,KB19#^GY'-OP&/@R&B MQ"2I+)+DA=(;TF!R1P;1*DQ14P1@:J.X2%S;9#EE< =QP:DMVTPP3_X^-#TC8_4L>GSXCH" M2K\O_/CD@16ZL'&0DZ,57QC[%,_U+KWL,6P1)R/A@>NWW8@FEY +@#.!X3D" M+X"?L55JP*BM3R+$.IVF^%83&#[SB&/Z4!PP[N4I.H7!9)!%6B0(HM$X];=/ MTXE[WPX :]ZF/_(M\6EYXD*T.G[1L%"# N/AL#*:T- J'7C!+N-3Q?N#[ M8<\*3AI2;FY =\.&%*=]D4#M 5:A? 9)X?E!&J@4'%7PKN'#:\E%]@Q? MM7 M>B'I%<0+T-J)$&R[;@3R9O&5?Y\4,&!OL;B%VC7M\Q:_AL:\1B.NZ&#!FSF5 M@2N::(-4\QGXWZ_8ZQ>>YYXG$R]@UGD^+:/,Q/4D,A+E 4(>/HEDB\VE'"X! MB?4,M$3A+]:GA^\=: /F5&KK,1LA@3C*S;P5=PP!(,1R^GL0OF#K>A_*["Y"![X$^BE<"V#)Q84OP$7AI\H M& SOE3!?.]E[6)R8#RN1*LT)]G)3#F\4=Y?P(-O]Z %"CG3 MMNV1GEVDY'30034@AO9#3[FI?+ZY;=]>W;2_*#>W*,K;/3:L M8$$=;7#PZRRZAF7B?X=?7,"_Z^5&O;8$OSLX-"9>PL3N=(".PD!@(?: M/A&'I>&Z0THQ^L\R68Q.CG5'.(_CJ#>@&$>]?/6H5Q_7Z&'@=CX'DY:>AU Y MQO;>D%3 !U/ 2%R[\GEVT%Y@77*8B6HUE\>TA!$'1RJ:JG%O<)[M!!U]-ZUH M2?+'(;R.,M$5V"_)H5^>3T:EJ"3SJ=@MF%265OVQ"Q4@"_UTK'HI5/8K5!KS M0H65RP\]!ZN'XH(DI?-GA"5[AQ(RTG(YN)!I,-M36BY2R&P@9 QM7LA:P'L>IN>MIM&I@Q.)E-+;,[RVJR"3%-,[PEJC&HMI8ULQ+OQ/].0P5/ONV@#SIB8NO>]/K50,NTO]UGDH\%C(<4J09J$GIJ0ELR-+ MIFG&EHPFG:[3D$2 T"_TB3C)P]L=QG6AP_'=P04/;KZMNBI25TJ M/AUC.XZ;7V_;O6\/V!G__)2HKBU2\M(9K#OO7__6&8\".]O79&?[_:_E?#O; M\SHXI:(LZ9&# ;8D.MXZ&#=J82BK'>*O;D. MD^\FV'PO_";>W>!(*"^"=UAL\%6?8@_Q(1M314*R? ?'.KQ!O0 ;O:B1"\UF M]J5EKUK^NZG6BEO4ZOT5.P="-&,N>R9#TFV%64G8<67&MCLC0*1;?B; ,/)$ MBS;US ZQV780T)3Z7.&RO#E#(==4E.4',M;_SKZ#=H=PL:[BP8L<3Y?K(&H_ MYX0*>/X B9_,@TU:8P]V[A+T8ALL+)G"\;@*_3.RGXFS:- FZ,X#&54Y!OK^ M[WF*SK7%]-9\?*M0>_O9?L%P]V>?\&'/D6N'#^C"1H%5XG[I"_^A7ZF6%'!Z M[1%Q@E]*%6 "EXPHWEEY(F1\B732=BW\?YTID;3#*^+[KP".WXD3@8?,4SK@ M^+R$EVXTJE@>\Z7QM6AQ)_CA5_J@=@#]P0%&MK#6:@C#( 9*4HNG+>Y^."1B$.'[: M#9*)\"RAG8RH)K,6;78H7L\'M4Q9<=P,]8;"B0'=X7 &UF)5 ]P*C6W2#(ZI MEUI5T]R67;+)=F?Z9!WS5M++&P)X,WIIE%HUHR8(O13DCK#OFO6+AN"61<\+ ML7G;C'^YU+U<1?\Q&-8;LGB"G/&&))WC@7PF2!--]+JJ%62!K#T(\Q#&NR2V M[<7P-L1FJLS>;>A5X:EM2?L<\Q#M<[8.C(JPLB)UG]847//=^]X8EO/*G >, MN8TQAUQ67!INHP!/7/*\Z3!PH-X[Q W!_NLD<+VE&9:?J95:1ET5Q+'>L_(Z M<4)YTU/(12AZJ:57MW81Q(K '(>8Y.<$R.:.P7DXQF_(Q90??.NY_66NL&F4 M6M6M#2\9.1&00-Z0A^L2B D$LK7"%#%4(KH"0.Q6UYN9/ MA]/7B@3E];2RL$I.N$ 8[Q>9'H3;CG]UVL>(ABX"\V>;2=:1^WY9. -ZI# M%9SNSZ*..(5B64R\#7\*6!S5[O=A@V&@C,DK.VB$/$SZ?3^BJ8JI=[;;=R(+ M_L4.W\*E,<%DR'_GLZGR1C M%O6"5-_.:5$&;@4*8"V+?9BUB\-%/[@6S-)^&Q\!.UNYL[X.S"MP#*G\)!$6 MK?SR$J%YY%HOWYC@@K3.+C+ 8KWZ+/) WFADAZQGGO+NU@NI4G]?7!XHKY)Y M">Q+UW9^*84^'L^?.],_72H>[8=GX4/4[3.&CSFYRO%VZ/Q57KFV];YKDWV+ M)"+F@9+=S8_+//9#/$>\JA8W1_P(MG):7Z:BJKH0:@X_^M 7 '\7A4%(7&3GC,5K M>P'NZC7H0+1KP(TO1_&F[U)(J&!G4>Y9&6I9P=:BK&@CZ;,97]+8)6.+J,VZ M*>#C=HO?;MR3PFU&WZM5)38UH]1BVEK_*$@R5![-W6\3GRUHQQ2-=LYAJ).> M./6>NYW]]9;>XM_(:>S4JIL97V\IL,T64]O$\BI:_Z>6OJU5L\JRWVP0]-K87UK1U"!TM ML5U3T49PKA=O]Q8)9YW!V=";9=58K/A=2MXV P5O6[F%E3Q;42R;76[977E* M%['1,V_P^ O7&O.%AS)M_K56QT4U:;)W0H0=+0VE7\Q= 0>')5O5RO MRL[LXLC=?C\:1?Q H44'=M\.S](L?;>5Q U@_?"O>;9YH"&!+UD=XKL CR % M[&L.Z[P<5"^U3'!?&HO#/Q;*0:0]>U0TM2"!]T93#3"$L_L'[YVF1#&$!:B( M7EZ)H6QO$9]M<>H;MG(:Z!S8>9FI66HURG7U++I^28K;WK+>FN(:6"11+3>- MHN:!"5X6+=N_BU?&)H"ZW* '4JXV'C%6XCG.RVK23[A]00X G([P7O] 5=NU MMA?EVFYZAJZ!,T';@DBN.T>N6_\$62%P&+55^R/FGV,_WXP[;"84*' MJ:=B#*G31\@CF%M1N/P14>"IS5DQJ?_B:I&R[7Z#&K1IUM7':M,DEDI,3>\W M];I&3:M1;=!_Z5CFQ1\:^E/#[HE6'GU*OE?( #9X29P?Y#5 TDO3&1!9&NCS M\%H*E<%@9U#AQ Y\[OF$81-8D_IX%ZR)"+,69>BCF/OI;?QH!EBWK".@-^ B MDO$ F3^<-,\-^R?2A<-$C$A_Z[0?>I\Z[:]EY>;VZF(I]XJRWJN)&.I.1 Z" M_FY,.18#Y=VW1$"]%WX[[VY!.^P@K)"7_H4_4DL:&(N$NPJ_LLB(5F^ MGSF=@KXZ(\J)%&7J#G;ED'% +Y-_?$S:.]DN6QM[Z&/\LECTHNB8TW0,>OSR M5*I@^2=*EMC7C;\<7[Z 2Q\6?S?5B[K6R+RD7FB9OR][E:9?-)O9EY:]:OGO MIEJ3B]K_HLR5KWHCDK(RIM-&20*BSGCU01%09P7W#0*$@^BQ6S*@8 M:GF-PYXG"9*N_;(&0+8AEI2CO&Z<57"88#MPZXG@Z\C&WYZR2A(JEH M&RHZA^X$L2'N/BGQP/KMFN&?1 Y(KNQX\V8'K/O[E;K 2PZ?-6"-;-<.0I^% MRV2;^_-JX-U<'6V/"04;=\^022R!\P;;#5!=9=T493+P'G)8DC-$VEL>SM#4 MO;(&:V_8T!N2-21K",\:>^6,:JEEEFOJXGE=R1G"4(_DC)@S]LL:-60-0]WZ M)*L\4544L3S0@!*_/V2NE46?J>.-,95XEL>J"G1$$K@"YUQ/H;HAV]31#6F8 M1;62EF>I1"*DM^SV0BFIP3KC-R0EG20E[9&0FJ56M:S7MS9R)2&)2$A[I*2F M6FH99:VV>)[SO+N;&,:!SZAXD_15,M57GN365;DUQ>DHM@VMJ"B7I+BCI[@=$YQ1:C7+C7I1 W0EP1T]P>V:XLQ2 MJUXV:T6EN 2?6RE+;N3*CJE,Z1#BZ8L7!,K ]T:)=^2YF\V_7C=Q)IZ$SM4F M:L'M6=(F:B*J;]R^-Z((YKS"NKK, UJ_+90X"5=)0ZL\F=T146V94R.)Z,B) M:'\T5%_FIT@:.G(:VB,1-9:Y'GLG(NE;R)4=?&6GY5LL.2X4#JFO<)&QT3FA M=<2X?'[_SQ=49<8U:E,8*L[6J#=X]I &H6*O)F299'\C)9@ D@N$.(1YZ[F3 MM.PM#3,,AV:II1FRO.<4">:ME-YF% /KP):L6P>Y)=39>Q[SW: X@C^3)R8D+Q067Q50/'5-$O]V?=& M5_ .VXT ,--&TI\8&OA]/01[YR7T"="K[1+_]2:DHP!D/7[=]QR'27L>)-1TB,3:PKJ]9D;>+) M$>,14B.(\U:]K(M0;BV21R:?%^SY<_"4;B;^T-11.C._J-"ZFUAXQK&J3]2E M@_DQY0/[A5J5_U#?RY*-6JG%AGCJ'P7I*M>6!I-\I8@ M5"9YJ[@4W^%K9/9@4$K&%&EO&S'F;'2C (;0-N/+3=>Q M7$+H.F/-Q6BE9$W)FD?!FH5SA+$A;Q8L(DQD3$,RIF3,@^]M,\8LFB&J&_)E M\1*BAJQ970R4'IXU!0WA&+ 5RXL>'2IWLT9XYUQK^#BP5@8@U'E1G0"^S>%^&XT>J7\W8&([ MN)N"/58EZX3J4]*]OI_5QOIE8=&YU]LHM?1:N5JKE1O&&CI)5KF>!(?,A@+V MS"*KPHI%+KS7&NJ9;VJ21XY%QXY*,VMBO$5N-YB6-K0N18Q&N5& MS9 <>$@[1*W8M/&IE 7>3R++18Q[8+G'[-G%@J22D(UC]W!#UU+;C M;YE PA_'7F CDCY!% #Y)@Z2.BP%.? MFR>?^B^N%L61W6]0@S;-NOI8;9K$4HFIZ?VF7M>H:36J#?HO] OCAX;^E&*? M:.71I^1[A0Q@@Y?$^4%> R2]-)T!D<4+,FJPXGEX+87*8+ SJ'!B!^'L\8X> MER YJ8]WP9J(,&M1ACZJJI_>Q@^>1.TAHRO>@*LYQ@.DE85\H83 PB$L1K2_ M==H/O4^=]M>R?4M$V7OA-_KNQ@4Y[$7P#BLH*_2E3U$+H36D6"0D^7; M=-.<9H.=.&0"Z*Z;!UAN9M[ MM MA(3C@&$;%HOV'7%^?O0_M.Z);55LE_W[BHSM$'Z7D-T,LOU^-(K @Z,6 ^1L2NK1$X$4CP(N%,Z.S&(M4=>Y*[# MF<4&S;:O*,D>B26TI?2).,3M4Z6BM,>^[2A:AH&T;@YC[:-7)YS=T-/I@IO; MS_,) VXD,9FY?7:@RC)HAMXLJQEU&)O-H5M6,[)#WA:KW6+^_-M_DC MY;>L@]3ZZLYK:4?RSIGQCI&?=_(U(##JI5;5*#=KBP=* M)'=)[CHZ[LK7X\-B1Z-FM MIJFMUC1MZ]]1$+*"PIXW3>!A[N[&C;-V+-;'9-=52G0]4%!,@1W2+O6?[3Z] MA\UXU@/M>T\N>\OOQ(EH7KUEXM&3LFHN=GZ3U"@F-4IA(31Z"IQH))RLT,22 M%:>5@9NNEU%8/:_2[GTM*RYE9:%V$$0L-=?W@G"SX H.ULPNK=EC=9J ,_52JZJ6 10%>8@"1%E. MG+ V4[42/8?F^PWL\B4\S_1DBN47=:)1:M6+2EI(DI$?1FY2[A_43_62JVMB1S2_3LS=Y=F[?KXO#V M601W,TS?9QJ$V*,$+%^PR4+?[F-#DB".^]HRN+M+$_AA G%V6_L'\:U;&MX- M/GO^@-IAY&\0]VV46EJ]7F[H=4&\2AF'D&$BB1Z)'HD>B1X9T=S=_+PS"U9* M7U.B1Z)'HNL3NI8$*$_;:1]9GCDO\A69SO+OJYAU5XC:6U=T*,D?*QEF6U3I9L+>ZN%3UPKNX M2):4+'FF+*FKNSY;7S5*K6JUK#:+.CDAF58R[>DQ;2X74]?VUG.F:H*C62L; MC<7\]Z8]9R3G2LX](<[-P[@[[V13K99:C7)=+;@3V[Y9-M>H*CDX9)U7G?,X M#+FH=1>UW>"0(ZOKW&BBB"$GBLB)(D+"<-ID1$X4D1-%! :GG"@B)XKLC%6/ M8Z+(,1E$\WGO]/@08YTRR3-.6^O[G!)2Q=.=95VOE]6ZF3, L.?HVZH@VSF$ MR\XM\#7+!YNF?NNE5MYJ#$G7DJYW2=<['ZY1;91:>K5LUO(VY9"4+RE_ITG( M_0V^J#;C\6>+/+ T"2G)7Y+_3LE_(9>7@_P7*+RF@NE>;0I WN?3NJ'@ 1/R M3*D\\BO1/=!=JM=5WTZV\ M9I9:LM7R25),,0,K\D5):U4@)[.LUT3I BII2O:-.6KT%&G,[X;E:YSEZW*J MVRG-O#A!]W<7-GLA,R]JV#:[459U4<;&R!B+#($=-7KV92BOVQB_ACV\U:)Z MADCZD>Q]UNC9EU&\-GLW16+OLPA9[VWRQ0FZCKLPA'B1[!HII)7QE0DG0Y-N5=V]UU#J'EK8:/'*]+*3U^B1Z)'HF> MDT1/OE-%>QD^4M=*+:.L51>;!.3NZ2GI1RCZ60RX[H1^=&'HY[3BK>L/'LEN M1Y?3#Y331I:%8_@%S+27G2LX]/<[-Q;@;-%W,R:]UX%>MK.9N3B<8T^:=-\(W MA?VJ9T>^RH<.^5#,*$8-.&GL!:S1P:5/'1+:SW0ZN^4OI9FG8EI3IX^01R"M M*%S^R$(+[/T+ QW79,R"(OW?X:1?^I@\TS[I:7(*\H#[>!6LBPJQ%&?HH;W^R^PUJT*99 M5Q^K39-8*C$UO=_4ZQHUK4:U0?^E&:56CXTJ\@9<5KM8&$M:67B4 X_2OPL[ M,4S%]?(NE:TO4NZ7IAKDO16:.&6FI5]7(]8]Z%I'Q) M^0>L=-AFIDM.'L C&+5R0U\L5)(CC23Y'T+PK].*:SN:UTLMK5IN&G51Y/XY MG"F6PX[D:4F)'HF>_3L2!Q]VE%,]X3FLLF[FU4Z2&J6PD.C9ME/DD?E*2P,CREW?LJ9R9MDLPYS,RD!C^E!:"0S26/A+!D>SRAT5.D7;[I M.*M&K=3*.+@E249,DI$<+31Z"C2>-V;HND ,?3ZA6CE9Z."6;2&3A1H-L'++ M>E64:;HR8"'C24>-GGT9N>M.'FDT2ZVM9VU*ZI',+=&S-WMW7=YNJN+P]ED$ M=^5,(;%,X%W,%&IJI996KY<;^M9Y$QF'$%IM2O1(]$CT2/1(],BI0D+?=0YA M93E52#K\$CT2/1(]IX.>?.?:]C)5J*F76LUR-:,7J)PJ=-STLVX#Z.W(QQ"& M?$ZSS8!#$[4%Q.@I"3($2!X;3MAYP$ M(2=!" Q..0E"3H+8&:O*21#[F@1AK)\D/M2RK:K-<-V7#?!&H M1?9-SN2#S?*5NJJ66INE]R5=2[K>"5V;NTXLZJI6:NEFN2H'00A!'"=-^;DR M@.;>,H!@9P(/Z&6ML9BWD(,@)/D?1/#K.Q?\K-6V43=%D?OG< Q,#H*0!UPD M>B1Z]J]/WIB4*%AS=UTUP1>P37:CK.I;CXF1P1BAM:9$SZ%E0,&&\IJ-\'4- M>W:K>4LN)?U(]I;H.:!1O#9[ZR*Q]UD$K^6D"[$,X1U,NM U ]A*+U?EA..C MH3D939+HD>B1Z)'HD6'-XL.:8%3XQ-W0D#M!=V<7AMR5Y\+> _C.W8#_.[0? M'=JE?;@UM#>PXLQ2JU[6FW*"[['0FXQ^"(V>?04WUY $BY$0+.23:8QC(27) MZ4*C9U]QSHTXO280IY]#R'.K 632Z9(^L42/1(]$CU#HR==/8:'[\PXF2.E: MG;OKBSF7]2=(2?H1D7X6+<2=T$]#&/HYK9#IZKY[3-!K'U=T(<[I+LG)94O" MJ_H>._;I&E975\O-IEJN%N9M"37\(I>_?RBB%0.5(VSAI.4T2W M05W-/QU-LJ1D2CSKV M>&R6S7J.'H^2GU+$]I596M^\%<%BFS35D;G'PQ?YI06>E M=)0JI(\=*HG[BJ>$@ZQEX]K8;=*"VB$1):-!R4&MDOJI&'7J]!'R")B*PN6/ MB )/\W];I&3:M1;=!_@;9,'AI. M1M6,R1.M//J4?*^0 6SPDC@_R&N I)>F,R"R>$$F3A^H-=LNY1>!>LB0BS%F7HH\S[Z6W\X(&3'IL1Z0VXO&0\0%I9R!=*""P$ MAQG1*K]UV@^]3YWVU[)RQX/P+EW;=$ M8KT7?COO;EP0MUX$[[""Y11N=(R59Y(;3I<;]L,.U5,K MI#L.]9;JC8_A4I\"\OLVN.-NK/?P5_QW'RVC"(,5MJMX$[.(%&(6S8J4F7!! M?*F"D+O4+^KHXR>_,40F/S(HVQA1@9]4]AJ^()RA/1?2VGJ)!=AG;Y!9$NX M5J#+/[?+NXY]@;D$A&D(SJ@[&<5UO+7@6]ES<\D_+%O]-#_Z([<"J^%\.MVL MR^Y-ITA"^Z&A>D?9C"0FO 81?X&G9DE=#XC[!ZV8-Q""@8%L2UU(1+GWZ9C85F*1<*1[X9#Z2C_R?MD]!WUQ3_O]OW!CZUW1 =96AR.A[5IWB($V WR6SFF46MMW*Y)& MBXBTM']B:H(!4Q6%FHI4OL(+WW:_#UL!33LFKZR> H4OZ??]B$XELFPEMZF3 MN,@B"<#O.;R!-]H-7=B4ZZECYIN24SY_$"DST)Q>' M%>4^0R!(SR+19'%V%<'M5O'R-0R7(SV1G@VM7>5FL9;CWO>>;8M:GUZ_ 2IN MW$D]Q[2<(S=3Z9BI4K7%P["Y,U6'/WM3D"%]QO0H $$:2)":L1AY%H@@8_D_ M=Z)",WD!L)BE3MOG(:OBY2'W7^+_B[<9/!*EL6_!54KUOX\V<5D;Z/ M_/Z0\';J8Q^ML/"5.<;TS\@>8]7#F7G$V]E:LQH-/!56-]+SVGT IT_O8PC? M.\0-P8'I)$#.4EI8_M8XO%\B'>!]IDGSD$S:"!K8+]2J_(?Z7A8I52>='P6) MJIQ5@71:Q@9#SP\K(?5'X/6B(IT]5RO3/=N*V"X"N ?PO9F"-P^KU IC%9GQ M$5)E%T]0:SB@]5++*#>-YFG5[AY?F-&>."];AAG7]A6%Y*/#AQDG7F0ZJK/( M-XUB;.##AQ$+LH[/F-YV07 YI7AS>RF^_DO.^A M8C^[#/6=P-G>S[P%4&%G>P]]@O>\S^F"1 0P6($R0-P&A+>UH:R95YF=8((_ M)\,6^UX@_=(M_-(8V,A'-S%,<9C2I!5XAGXQU5(KHYNA=#M/@%JV)Y=\MHJI ME5JZ6:[7%BM;CK_4\,A$;7ID;< .J7ECQ(0L-BQ$O#+^N.,0[<2@MK)80B^U M%GU)655X L2R"VHQ2BU-+:J?O\R7%"(]MQKX?2:6QOJL\ >'9L(%>=(DIBG3 M)"=-15N1T2*Y%#(&>C^6J/!'8H5?X(GFD,9Q1%EY?$V:8\L\TH[5U9)@_B0P MN3)[9-; X%_T?Q,\'4(&;]7I7J:OCI?,"Z3SG(&@.@L$-1J+KHQDA(*K[_>? ME1)W96=G(]CQ@47EG14?67R/%2?,=,"":I\&H6_W<;0&_G9FL;^=U):@R,3_ MPYK89Y![;A@\3*",%]JN-?M#ZLY[V(AG+1XS[3L1 K?STF?-6AY(2#N# >V' MN24OFWRLZMN<.I+AQB-TC@4G2^Q 890;ZM9]V,2*;0JM(!#)9:X+Z!3767IA M,KG[$WVR71==3#R:PZA"'HC>@%MK.V36O+Q753$.5M8S2LB.R!C/15%'$,L] M6]8PWQCZMU_>T+"ZLIK1BD.R1L'EG?L_*"WNRJ3U,6-]3,R/CFNMM#VV3I ) M!Z73F&>PO5:HBJ04=)P!HFN+#?..3RD(8!5)ICU5IGUK?O-^N19KI^IE4]4D MVXIJL1FP%&TK;K/>X07EB&0_GJTZ MQ"?IHGD\;Q.5%4V5;SM/+&N+HJCR[=,+:]C?H*SG5'0[O"*^_PK@^)TX$14&60=6[=X#JDNM6F/.FUV'&KQ82Y,]EY(G!Q>W6Z*)44S?;8-\^7;O"ABXL2B]HT3B-H?0^V] M% %2!(B: VB>0@[@>-MU;5?=7UAVX !+.P?;L1N-QP[%7J1@0E[;0=_Q@@CL M16+@-5VT M&2DR!RY986.%MQTO&*+Q E-M'T)T;)+1@*G)@R/B/]DN#\_HLP3(^OM' MJ,Z\=$J97S:";V/A@>)Z(;P]])1PB!V6<00B#J:(7!*!50+_BOL*@5,?A"2D ML\.!YK<=?\MD@Q:]P&9^OD\=JE.'R&/@>=$X?)' M1(%G=6XX9.J_N%JD7KO?H 9MFG7UL=HTB:424]/[3;VN4=-J5!OT7SA7+7YH M.(F[CKN]KISV^U<*]]NV]^N;WKP MK\\WM^W;JYOV%Z7;:_[BCM9DQ'KI;30>" @*0D'1)J?A8M5\&XW@ M??U%LW2NFQ-!#_-N$(\N]MQ@JEI-KLEM-Z)6.XQ_PU=04,-CI ,_ M:]>_BU M?7OS_]J]F[M;I7U[K=S==Q[87]U$)<>+F>,+N!:_GQ>.3[X+WUB77_X=!:$] M>,V&O:YJ XWN1H9H.C(,)7[XB9(1,(S;OU#>(1)T]>/D=_8W(,7SF1Z-+U]Q M-1M??'^@)!/;@6('"E'ZQ+=LTE="VA^Z\.6G5R4V!< 2ZT^Y#WY M9#0!5N?JUP022O(D6!Y#$BK49=(506=16!Q_*7QZY('!Z?GQL<]D^98=L+9& M7A0&M@4&C3*DQ F'<)TJ X)'%,)7): A#M>Y4'KPVA0JM/I'@,4COPD,GWBW M&=N"%:=6BA#L#VVXVX*5@DGY-(Q7S)YG46]89)CQ-8R1^S8-B<_#Y&."*@3> M\SOL%6AF'FCCX>L$;+^GX99"W!@ CN;SA3)#A>Q[^ RN%]@W45LIG,+B*:U8 M0%YN #L#R^Z=-CZ&O6/^AN\W!7#*UH=F<-)<\A5;3L9-./D[J0)T':*= MZ,!&)J_ E?P@SQ27&F/;HH#6( 0YQ(LE8?D.H"L$@Y.;HA9UP%STX?WDR?6 M\?M\)QQE],\(/@)0"R)V#MAGUJM/+&8ZPJ6A%[#06N61H"G+L/@:@.D:K*7J M9D5-U@CP=9[;-X.GB%P9DD!YAD59#,+A$"@A13A(@/!+0.EWQ-RWB^Z%\MGS M+';AVH^>E+8%9J7-,(1LD%#BY^OVA!#[#F"-367!"2TA< 4X2&D,*!0 MV+IC<2H'NK;[M*S\&-K](>X+*-)UJ06_V+ &,#?QU)*5^DX9Z>61HC,*6T[+ MKN1=0/; K:RK:OS!(/E 'S'[Z@*Y(W+@]9K^A5$8+AK8-K!!3KK 2\\V_7$X M^%=70(R2;ER@.#*RA7L'F#MVH31*W\&]@7?6AJL".@3'T^\(G9W<_MYP6:* M1H_4G]A,[E.7OV>V\ 0@V,?BDQ^>;X'TG,0NU*F!52VU/)%US9/)A MSE[:CG#6,WQQM( 0U+;< 5#T#4W?;O08A$!"($JNO>@Q;#^"W?"K!_B\\D" M^6X/'O[DL(DV"<9J&29Q;=$D_O7NYO97]$JN.@^Q3=S[K?, W@G\T&O?W/9N M.F\8QYOB=IE1S5:9L79]:?Q$'+V%6BEZ_#?8&BBBB>(R!D0-X]O!=[AHPP(( MU_>@Y/FPL-AX($]4&5&+V2AF+=@49<5.FM7!-E3HCK(&'MQPROX4Y8]&-C] MR&'W3EX!LBS#8"0I UL!%^@[#?E+QAY:B?BK2U&/>XKWB M0,'(9VSI]GD4L ML\W2D/W,AU0 H)X >"D@\$,I"[8_+I&)TMG+\/,9F4MVG'H%XS4(X#,43'WE M%8@+B YI!?\SGK@E^ 1]0>L3"_-*[:K&YYB MBQ5@;2I.ZZ56\V*Q]%H!Q#IL^Y^8KD6P0 M3LT#DS?0+FIH+@ M"&#-.$@FF.HH5DD8HFQ!YRM^]PKW-9'UW-IZ\MC>N&([ /\NK238%V/?N0<- MLWPEKXK.^7>6$EG\E-FS3+5U@44"I?T$GCC3 XF/=?_[_*6)R\54SGWTZ(#) M\SMW,J2!7?T'Y*?:"LC",?29BQ 7=WTCL8 M$8RI.(X2C9EZ!I9\>D(R#;<5.^9L0\Q:(G<>*0DO$1QW S8CB\F7=@2ZWP>< M6#=N#US0@']@O6+PE$QJ8#'XDEQB+)?8=+PAB8M8L_BPS\8A*FR$WH6217D' M9X@>&A_*#_S/<@>);7(!+?75"=T49A)7JA.,B-T)/RF=JEEI5M0R@R7"; M.$IL]A6%)708@]T:VGIVG]_8(ZVYTE??),P-;&X"$+QR2Z+07MWM?SL ]3S!Y[56GSX ? *W8J$OLEI9RY=E^T MUR,-L\'P(1%P3B8S/K!VU@@]0GD M/,^SPZ*&]C@ 3(6VHWR^;J=B=6#N,)Z-#G*K+E!<3T'.\G$E*? G@&$9A/U,.\%@M.YCJ/$M! M_1%Z4[X"KR6.DX0&?WB1 _Z#_1WEP9 \8W1PL@=B/5,?2(&R!NGXQK1J92%9 MV'6FP;C+Z)! ;*11 MQ^:OMA//!&TKT&F1 X0Z9'0TZ\7@3AGMO67OSU.'4IR(7C.26-LFDKB74@+% MV#"2>.<_$=?^#X/L%8@+CZ58X ]PBN]3N;.[P>>$"+L3&IP>B8*[NP )1A%N MV.:G9 "-]_ ^D*S!8CRRGA'3JVN+\]/E9MK=YP.YN;P69<E;UWEUW;[OO2>6S:+W^*1=;# HGY< M*> JX-Z,%$VM_(,]]!"!NFM45 /?_, #[9)112HZPFH.]!7>%A3:S9D8PV7, %X)![&3.F1))L8X=FS4Q MHEST#W$MD<]S)DE@]4)YR[:*64JM&RX0L PL%A^CB?_,P]5336(CJ]FCMSPKP 86AZ$CG':I)@4YL4E=Q^0U6':"?F*R%L /2P_W>78/$]'QG1.O[9%.,U'X M713]F,VA?T:X:+X$_MW-E'?L#SXRQ9 HTW]'+M< $VVZD"&*WTE<%\OE,E^- M$(S/?V!8$YS+= _#K+[^5E;POTKG']]N?F]_P1IZ M5LX"AG7OX>8*Z^SQ^J*Y,&<<'(U%S8*\2X4EXG*F1 #NPDIC/V!R#BN%03(X M-I *LLHS3808-Z1!LOKVD^VR>HX0K<]7+KU2*0<0%0[FMG\,T;R,^VE8O#1Q M(;U_H4P""K'9S#_'I- D=.R\3LMG4FOG,2,TG?RI9=P'8]8.65T-WUP0HM4_ MXC(O;NV.<6TTT^9BM)B.P"!RP+/U+(_NLG7985(K[6*@@U50XE(^4PN=".6: MOT^Y<9/8[-6T*#!59WHS;X?'GYG(_G1W$:YHZ$N?%0=RS2B-#8[\:65)IOF)D1%CE>0RB)'+X2-SOB?X![16#&>NH)^9X M'!F$E6Q1F[%AS\VW$V]U$[NI9B?>XLKA))Z)VB58&->TK UN%O0+2B#E$O7? M GHWZ, K,38_/053KQZI]/[6[6"\#P3US==VKY-Q]NF4 B#<$9\XQYEF34:\ M(0Y(E/<3-%MR@.N0$3L?M0EFS:<&/XJL$?D.]FO"#(S!TW563+\0GK+BH0FT MW9#ODV3'3'QB/A9A34+>B0L&EB]^>=DS_"M67%'"9/DRNW79QP%9LCK?[8<0\$6[-]YF)C46;(*Y8?I+7ETX@O'_ (Y&]?S+3&4WI>SR-6E9N M.[USL9P1>:W[[)9PZ%TS+K:0T_L>F)S,! 9++AI%/)1KX2&TOAV?$KE._;6J MUQR:ATX_?@4_QLABI6#QXJ(KN %E1(%E@*>>XP*6A'7P"3J(' 4/G4W"QEQ$ MS1J^/+J,]>84#/-H$K&=OLE/:G4RWYEU+'!Q.V7%917@'CL+"4H,U@Y> C.E ML/R!YYAY%)LK.]L' &+]*)K&/XCO8PT?88>06'Q[DM5.%L>%#3\6F(;W5Y1E MU&66.0^OC(GM\[A(+%B9S9=42V?9R9EE4RMV.CUWR"IL)CF!BNU6X+$G'TFD M8&/Y*O6=&_<^_LJOOA>LV50V92_72RVCOJ12+4E0( (\D('L_,&T^)_)=/0E M,.;$\PP.Z2=%HL":>(SA0KE:!I5$-R1AJ]3AB31>67DH+R;B:C>^_16 /UOF MQ9T61@,6YXM#6.@=XB.5!O?49_6$2[5'(T-[-(Y1>_#2A*F6D#G=UI>[;EC;CU$XK2V;EK,//8<%/.,0'E\I MM2H$"^.>:.IPWK1$/OT\Z\X -@E^]30+A1F2KA'H[ C8 IKF4/ $*$"O,':G M/19*3M7]9D(Q?70Q!FOJ#%1LZTWZ=P%0T*[@A/!,V;FJ;!+""G9>3C!BQ0G6 M\FTDV30>OF8UP/;+3.4\+TE"DX__*['[^%_P!/\'1E;CGX+8D8:M!4F=PPPT M$AC$0)F24EQFR^MKD=1#NY+L-X;MCEQAP:AOM1_6B-.]&"7W+6;0LT!8NWNE MZ#6UHJD5LUK1C#+0#-96!TP$@(4/;LZ$PGRZD!!,_*P8:8E44!*I\,@(C@=_ M.$71V)J;4M3:7D/.\RIOG>>_UFJ+!RWFP#RM,MH)L ^13NWVA]2*\!Q+&Y"T$JO#%9CU MV?=&5TQ$QG6S\Z;_HM'?4!>-_H8JCM'_9@1[>FB4M60*HM$(BQY0 OY@::*T ML&,YDQSB-2F[2%R\!8J: IL5@BT0T *-<5:[S*@4FZD>7G4JX>PJQ>JR4DR MM>R]4LQ8KH^9A'I;)G%#?,( ;, ,P-$AXX!>)O_X&+?=NK1=!@WVT,>X=U[, M-4@J)SI9 M-P@.NH.[EJUD[G=3?7/M:X%!,RY,LYKK57M:5'WEJ[+'.^EFUG@GW_O!_SV= M>;KFX)SUL+CR9<=C:2PPL^ (SP1W&(^8.[AUMM/\#RB 0=+6F(TTS$&==[OW=+;Y?T>\H8:&EKN;515 ;>A MEUK5-IHH1!ZVJEXWF8B=80<9,2H8JFJ$$#.$U M\X?P:@*&\)KZ$3#4.<0(>EY(G".Q! KR8W)H'-1'UJVZWNNAQT,1M-65\M.6C;KHI17YSPA]M"YZMSVOOQ3N>EVOW6NTYV0 MN[WV[77[X;J[6" OW!F0O"=)O5#Y)PV5MN6QAJT9G7/O-MS)J3O&MW MO[UGKZ^H=:44SX6,6]OA$^]ZWACX46^H[R^5FQ&.)8A[EX1>?!NK,TJ>G#8' M!XF<-+0"L%I!TL"/-]+EC0M3?57BOB[\W7A2RY^^/!XO&913G;V2N1/4'1(V MNFSZ+AQ:1/MLN: M$/R-P 7_5=&2XSZX139L)-[F6X]4XQFO? 0@L7BA%CXVLL-)M\>D>8/E47[0 MGK=KG#;LC<9\3FX08YEW[HT'.*2!8<.+%F8W3/:9T:DF#=S%(Y GP'!5SG"3 M_FDIA@-6FG#2A&2:2NG&98-W>^0%EL#9)%#J9A:?3&^=Y0^XQ)DC'K6XG!EL M_H80/U96 L [PR6VADNW9L#>&,C6./;!Q>GA9'J,-O4&94QLZV)F.T5R0#YR MMB=S\J;M2)+SO=-CE,EATS5HO2BRWOG92A$H/NESFDQYRR!WLZ+JR9RU*\^: MSO^8(?-D$$4;_K12&F($=\#_&V"CJ3Z='/!E$VO'<--TKL1%,M:MAW.^RY.A_!\_QWI"9$[3>7R@W SRYS-83\WF0 ML2'BSJVHK-BA,@*6X,_@(Z/8M&.=)R>@G+1.FVZ/X3T^#!@D?Z5?OKYPB;7@ M1*1,!!7[+([PW9%LR77F,#X.A>Z(D9_7B:&?UXNKV[J[__=O?ENO/0C6F!=4OK_7.OH[+9TH[ I6,ZYX_V MPT/[ME=0=\\-#W-GDT12>7#G/^"",\87-9NBA ^V.)T]Z:N&>@XE=ZK!Y'Q# M#&7QL/:BPYTAJC2='_@ZAF.@IGI1UQK%G%K4+YK-[$L'/$HI%Y5G4>8ZAT[/ MZG3=;=(@B0E@'FX_UY.&?\1M)1@HDM82\8$[RGX<@R:B$CQ3\+!_3UMV.O: M*N^8U[3.2<23!%,[F3?.8 ,.#"A@;&""#@K_[1WS!,&/Q=#I^SQG6S5XCWC3&[MC3925SC^X&X0 MF[VQU9O"1L[TIJ&JA2V1#1#/7%]G2AVYUZ<56-6UYU*'+#&X/8D+5^_UWUN! M>VTP"\:^46 EA04K&43/Q1[Q/^D]&B23^R;>;1:#Z$4N6-Q6M;JC%++ M!%?M!#@WJY9IW64=!8UG1V1JVML$G%B0;6X\/B1VXQV7$VUU#(NC&IFQ#WN&UU;)QZU6EJ&ZS!=9+K7I3?ULZGEVCG$376$OY3)XG6=%U M=H6LCK7V!,"S%OG ?J%6Y3_4][*T>:/48CD3_:,@YRGD :5=&+#:9@;L,L-P M(U)K2E([-E*+\271(]%SE@??.B]CV]_08CF;9AC;6"P,O#F4B*86ID1D;Y5# MD],^[97-.PY_S'V%X[E#;A'.25J:+=YR\T-(O+14B=) MG;2F3EISI/UV^?IUS,1IKEQK['C).9/Y.5>/(SG!R&T'D^\&>-:< MN@$#Y0/O]7'E!6' /*E/)*#6/7EEA^T7SJL:^N*,8?AMR4'FRJ=VMW.M7-U] MO>_<=MN]F[O;?1YCCA>6L5Q=O&.V3):W>=\ UHX*0YE)?Y0@=;HX.18^HG32 M> #NU15^[!A;PV#_A&>JW#NP YQFS[HG\(8N-@[Z!A2SQ]SD&)Y"HG#H^;!2 M*YDK/_"]4=XIXS7]C>#AE,+2--A&.^>)]3CX]+I A&T<_

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end XML 47 beat-20240630_htm.xml IDEA: XBRL DOCUMENT 0001779372 2024-01-01 2024-06-30 0001779372 us-gaap:CommonClassAMember 2024-01-01 2024-06-30 0001779372 us-gaap:WarrantMember 2024-01-01 2024-06-30 0001779372 2024-08-12 0001779372 2024-06-30 0001779372 2023-12-31 0001779372 us-gaap:RelatedPartyMember 2024-06-30 0001779372 us-gaap:RelatedPartyMember 2023-12-31 0001779372 2024-04-01 2024-06-30 0001779372 2023-04-01 2023-06-30 0001779372 2023-01-01 2023-06-30 0001779372 us-gaap:CommonStockMember 2024-03-31 0001779372 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001779372 us-gaap:RetainedEarningsMember 2024-03-31 0001779372 2024-03-31 0001779372 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001779372 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001779372 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001779372 us-gaap:CommonStockMember 2024-06-30 0001779372 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001779372 us-gaap:RetainedEarningsMember 2024-06-30 0001779372 us-gaap:CommonStockMember 2023-03-31 0001779372 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001779372 us-gaap:RetainedEarningsMember 2023-03-31 0001779372 2023-03-31 0001779372 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001779372 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001779372 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001779372 us-gaap:CommonStockMember 2023-06-30 0001779372 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001779372 us-gaap:RetainedEarningsMember 2023-06-30 0001779372 2023-06-30 0001779372 us-gaap:CommonStockMember 2023-12-31 0001779372 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001779372 us-gaap:RetainedEarningsMember 2023-12-31 0001779372 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-06-30 0001779372 us-gaap:CommonStockMember 2024-01-01 2024-06-30 0001779372 us-gaap:RetainedEarningsMember 2024-01-01 2024-06-30 0001779372 us-gaap:CommonStockMember 2022-12-31 0001779372 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001779372 us-gaap:RetainedEarningsMember 2022-12-31 0001779372 2022-12-31 0001779372 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-06-30 0001779372 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001779372 us-gaap:RetainedEarningsMember 2023-01-01 2023-06-30 0001779372 beat:PublicVenturesLLCMember us-gaap:PrivatePlacementMember 2024-05-02 0001779372 beat:PublicVenturesLLCMember us-gaap:PrivatePlacementMember 2024-04-01 2024-06-30 0001779372 beat:PublicVenturesLLCMember us-gaap:PrivatePlacementMember 2024-06-30 0001779372 us-gaap:StockOptionMember 2024-01-01 2024-06-30 0001779372 us-gaap:StockOptionMember 2024-04-01 2024-06-30 0001779372 us-gaap:StockOptionMember 2023-04-01 2023-06-30 0001779372 us-gaap:StockOptionMember 2023-01-01 2023-06-30 0001779372 us-gaap:RestrictedStockMember 2024-04-01 2024-06-30 0001779372 us-gaap:RestrictedStockMember 2024-01-01 2024-06-30 0001779372 us-gaap:RestrictedStockMember 2023-01-01 2023-06-30 0001779372 us-gaap:RestrictedStockMember 2023-04-01 2023-06-30 0001779372 us-gaap:WarrantMember 2024-04-01 2024-06-30 0001779372 us-gaap:WarrantMember 2024-01-01 2024-06-30 0001779372 us-gaap:WarrantMember 2023-01-01 2023-06-30 0001779372 us-gaap:WarrantMember 2023-04-01 2023-06-30 0001779372 2023-01-01 2023-12-31 0001779372 beat:A2022EquityPlanMember 2024-05-31 0001779372 beat:A2022EquityPlanMember 2024-06-30 0001779372 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001779372 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001779372 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001779372 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001779372 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001779372 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001779372 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001779372 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-06-30 0001779372 us-gaap:RestrictedStockUnitsRSUMember 2024-06-30 0001779372 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2024-04-01 2024-06-30 0001779372 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-01 2023-06-30 0001779372 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-06-30 0001779372 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-06-30 0001779372 us-gaap:RestrictedStockUnitsRSUMember us-gaap:GeneralAndAdministrativeExpenseMember 2024-04-01 2024-06-30 0001779372 us-gaap:RestrictedStockUnitsRSUMember us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-01 2023-06-30 0001779372 us-gaap:RestrictedStockUnitsRSUMember us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-06-30 0001779372 us-gaap:RestrictedStockUnitsRSUMember us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-06-30 0001779372 us-gaap:GeneralAndAdministrativeExpenseMember 2024-04-01 2024-06-30 0001779372 us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-01 2023-06-30 0001779372 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-06-30 0001779372 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-06-30 0001779372 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-01 2024-06-30 0001779372 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001779372 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-06-30 0001779372 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001779372 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-01 2024-06-30 0001779372 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001779372 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-06-30 0001779372 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001779372 us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-01 2024-06-30 0001779372 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001779372 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-06-30 0001779372 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001779372 beat:ExecutivesAndEmployeesMember 2023-01-01 2023-06-30 0001779372 beat:ExecutivesAndEmployeesMember us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2023-01-01 2023-06-30 0001779372 beat:ExecutivesAndEmployeesMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2023-01-01 2023-06-30 0001779372 2024-04-30 0001779372 2024-04-01 2024-04-30 0001779372 us-gaap:RelatedPartyMember 2024-04-01 2024-04-30 0001779372 us-gaap:EmployeeStockOptionMember us-gaap:RelatedPartyMember 2024-04-01 2024-04-30 0001779372 us-gaap:RelatedPartyMember 2024-04-01 2024-06-30 0001779372 2024-01-31 2024-01-31 0001779372 2024-02-01 0001779372 beat:TripleRingTechnologiesMember 2022-03-31 0001779372 beat:TripleRingTechnologiesMember 2024-04-01 2024-06-30 0001779372 beat:TripleRingTechnologiesMember 2024-01-01 2024-06-30 0001779372 beat:TripleRingTechnologiesMember 2023-04-01 2023-06-30 0001779372 beat:TripleRingTechnologiesMember 2023-01-01 2023-06-30 0001779372 beat:TripleRingTechnologiesMember 2024-06-30 0001779372 beat:ClinicalResearchOrganizationMember 2024-03-08 0001779372 beat:ClinicalResearchOrganizationMember 2024-04-01 2024-06-30 0001779372 beat:ClinicalResearchOrganizationMember 2024-01-01 2024-06-30 0001779372 beat:ClinicalResearchOrganizationMember 2024-06-30 shares iso4217:USD iso4217:USD shares beat:segment pure beat:director beat:site 0001779372 --12-31 2024 Q2 false 10-Q true 2024-06-30 false 001-41060 HEARTBEAM, INC. DE 47-4881450 2118 Walsh Avenue Suite 210 Santa Clara CA 95050 408 899-4443 Common Stock BEAT NASDAQ Warrants BEATW NASDAQ Yes Yes Non-accelerated Filer true true false false 26562111 9157000 16189000 544000 636000 9701000 16825000 370000 256000 55000 50000 10126000 17131000 0 2000 1420000 1194000 1420000 1194000 1420000 1194000 0.0001 0.0001 10000000 10000000 0 0 0 0 0.0001 0.0001 100000000 100000000 26562111 26562111 26329032 26329032 3000 3000 55090000 52759000 -46387000 -36825000 8706000 15937000 10126000 17131000 2246000 1828000 4602000 4303000 2844000 1484000 5272000 3165000 5090000 3312000 9874000 7468000 -5090000 -3312000 -9874000 -7468000 134000 158000 312000 178000 134000 158000 312000 178000 -4956000 -3154000 -9562000 -7290000 0 0 0 0 -4956000 -3154000 -9562000 -7290000 -0.19 -0.19 -0.16 -0.16 -0.36 -0.36 -0.52 -0.52 26566832 26566832 19690251 19690251 26538863 26538863 13910365 13910365 26329032 3000 53966000 -41431000 12538000 1040000 1040000 50000 76000 76000 5252 8000 8000 177827 -4956000 -4956000 26562111 3000 55090000 -46387000 8706000 8227074 1000 25462000 -26322000 -859000 702000 702000 17666666 2000 24268000 24270000 88026 103000 103000 8750 -3154000 -3154000 25990516 3000 50535000 -29476000 21062000 26329032 3000 52759000 -36825000 15937000 2247000 2247000 50000 76000 76000 5252 8000 8000 177827 -9562000 -9562000 26562111 3000 55090000 -46387000 8706000 8009743 1000 24559000 -22186000 2374000 1095000 1095000 17872955 2000 24762000 24764000 88026 103000 103000 12500 7292 16000 16000 -7290000 -7290000 25990516 3000 50535000 -29476000 21062000 -9562000 -7290000 2247000 1095000 -92000 -152000 210000 -1094000 -7013000 -7137000 98000 0 0 3939000 -98000 -3939000 76000 24764000 8000 103000 0 16000 84000 24883000 -7027000 13807000 16239000 3594000 9212000 17401000 9157000 17401000 55000 0 9212000 17401000 16000 0 0 0 ORGANIZATION AND OPERATIONS<div style="margin-top:12pt;text-align:justify"><span style="color:#201f1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">HeartBeam, Inc. (“HeartBeam” or the “Company”)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> is a cardiac technology company focusing on developing and commercializing higher resolution ambulatory Electrocardiogram (“ECG”) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company’s ability to develop higher resolution ECG solutions is achieved through the development of the Company’s proprietary and patented Vector Electrocardiography (“VECG”) technology platform. HeartBeam’s VECG is capable of developing three-dimensional (3D) representations of cardiac electrical activity by displaying the spatial locations of ECG waveforms that demonstrated in early studies to deliver diagnostic capability equal or superior to traditional hospital-based ECG systems.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has validated this technology and is seeking U.S. Food and Drug Administration (“FDA”) clearance of its initial telehealth products. The Company filed a 510(k) submission in 2023 for its initial product, a patient-held VECG device, which is planned, with a second submission, to become an ambulatory device, carried by patients, which can synthesize a 12L ECG for physician review.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#201f1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was incorporated in 2015 as a Delaware corporation. The Company’s operations are based in Santa Clara, California and operates as one segment.</span></div> 1 GOING CONCERN AND OTHER UNCERTAINTIES<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is subject to a number of risks similar to those of early stage medical device companies, including dependence on key individuals and products, the inherent uncertainties with regulatory approvals, the difficulties inherent in the development of a commercial market, the potential need to obtain additional capital, competition from larger companies, other technology companies and other technologies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has incurred losses each year since inception and has experienced negative cash flows from operations in each year since inception. As of June 30, 2024 the Company has a cash and cash equivalents balance of approximately $9.2 million. Based on its current business plan assumptions and expected cash burn rate, the Company believes that the existing cash is insufficient to fund operations for the next twelve months following the issuance of these financial statements. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> May 2, 2024, the Company entered into a Sales Agreement (“PV Sales Agreement”) with Public Ventures, LLC, as sales agent (“Public Ventures” or “Agent”), pursuant to which the Company may sell up to an aggregate of approximately $17 million of shares of the Company’s common stock. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There were 50,000 shares issued under the At The Market (“ATM”) during the three months ended June 30, 2024. As of June 30, 2024, there was approximately $16.9 million available for issuance under the ATM.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company’s continued operations will depend on its ability to raise additional capital through various potential sources, such as equity and/or debt financings, strategic relationships until FDA clearance is obtained for the Company’s initial telehealth product and sufficient revenue can be generated to achieve positive cash flow from operations. The Company expects no material commercial revenue in 2024. Management can provide no assurance that such financing or strategic relationships will be available on acceptable terms, or at all, which would likely have a material adverse effect on the Company and its financial statements.</span></div>The accompanying unaudited condensed financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that may result should the Company be unable to continue as a going concern. 9200000 17000000 50000 16900000 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BASIS OF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PRESENTATION</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed unaudited financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("US GAAP") and in conformity with the instructions on Form 10-Q and Rule 8-03 of Regulation S-X and the related rules and regulations of the Securities and Exchange Commission (“SEC”) and have been prepared on a basis which assumes that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the unaudited interim condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results of operations for the periods presented. The interim operating results are not necessarily indicative of results that may be expected for any subsequent period. The accompanying condensed unaudited financial statements should be read in conjunction with the Company’s audited annual financial statements and notes thereto included in the Company’s Form 10-K filed with the SEC on March 20, 2024 (“2023 Annual Report”). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CASH, CASH EQUIVALENTS AND RESTRICTED CASH</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash deposits. The Company maintains its cash in institutions insured by the Federal Deposit Insurance Corporation (“FDIC”) and has cash balances in accounts which exceed the federally insured limits as of June 30, 2024 and December 31, 2023. The Company has made a deposit to the bank for their credit cards in the amount of $55,000 and is classified as restricted cash included in other assets as of June 30, 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">USE OF ESTIMATES</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with US GAAP,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be based on amounts that differ from those estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">PROPERTY AND EQUIPMENT, NET</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Property and equipment are stated at cost less accumulated depreciation. Depreciation of property and equipment is calculated using the straight-line method over the estimated useful lives of the assets. The Company regularly evaluates the estimated remaining useful lives of the Company’s property and equipment, net, to determine whether events or changes in circumstances warrant a revision to the remaining period of depreciation. Maintenance and repairs are expensed as incurred. As of June 30, 2024, property and equipment, net represents construction-in-progress of $370,000 related to tooling development that has not been placed into service. Construction-in-progress amounts are not subject to depreciation as such assets are not yet available for their intended use.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LOSS PER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COMMON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SHARE</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share excludes the effect of dilution and is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted net loss per share is computed by giving effect to all potential shares of common stock, including stock options and warrants to the extent dilutive. Basic net loss per share was the same as diluted net loss per share for the three and six months ended June 30, 2024 and 2023 as the inclusion of all potential common shares outstanding would have an anti-dilutive effect.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In accordance with ASC 260-10-45-13, exercisable penny options are included in the calculation of weighted average basic and diluted earnings per share. As of June 30, 2024, 182,169 penny options have been included in the calculation of weighted average basic and diluted earnings per share. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of awards outstanding as of June 30, 2024 and 2023, which are not included in the computation of basic and diluted weighted average shares: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.596%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.447%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three and Six months ended<br/>June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options (excluding exercisable penny stock options)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,993,356 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,851,383 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283,411 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,470 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,152,397 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,152,397 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,429,164 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,250,250 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RECENTLY ISSUED ACCOUNTING STANDARDS </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Not Yet Adopted as of June 30, 2024:</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2023, the Financial Standards Accounting Board (FASB) issued Accounting Standards Update (ASU) 2023-07 "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures" which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 is effective for the Company’s annual periods beginning January 1, 2024, and for interim periods beginning January 1, 2025, with early adoption permitted. The Company does not expect that the updated standard will have a significant impact on the Company’s financial statement disclosures.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2023, the FASB issued ASU 2023-09 "Income Taxes (Topics 740): Improvements to Income Tax Disclosures" to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. ASU 2023-09 is effective for the Company’s annual periods beginning January 1, 2025, with early adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on the Company’s financial statement disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2024, the FASB issued ASU 2024-02 “Codification Improvements – Amendments to Remove References to the Concepts Statements.” This amendments to the Codification that remove references to various Concepts Statement. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2024. Early application of the amendments in this update is permitted for all entities, for any fiscal year or interim period for which financial statements have not yet been issued (or made available for issuance). If an entity adopts the amendments in an interim period, it must adopt them as of the beginning of the fiscal year that includes that interim period. The Company is currently evaluating the impact that the adoption of this standard will have on the Company’s financial statement disclosures.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BASIS OF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PRESENTATION</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed unaudited financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("US GAAP") and in conformity with the instructions on Form 10-Q and Rule 8-03 of Regulation S-X and the related rules and regulations of the Securities and Exchange Commission (“SEC”) and have been prepared on a basis which assumes that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. </span></div>In the opinion of management, the unaudited interim condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results of operations for the periods presented. The interim operating results are not necessarily indicative of results that may be expected for any subsequent period. The accompanying condensed unaudited financial statements should be read in conjunction with the Company’s audited annual financial statements and notes thereto included in the Company’s Form 10-K filed with the SEC on March 20, 2024 (“2023 Annual Report”). <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CASH, CASH EQUIVALENTS AND RESTRICTED CASH</span></div>The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash deposits. The Company maintains its cash in institutions insured by the Federal Deposit Insurance Corporation (“FDIC”) and has cash balances in accounts which exceed the federally insured limits as of June 30, 2024 and December 31, 2023. 55000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">USE OF ESTIMATES</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with US GAAP,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be based on amounts that differ from those estimates.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">PROPERTY AND EQUIPMENT, NET</span></div>Property and equipment are stated at cost less accumulated depreciation. Depreciation of property and equipment is calculated using the straight-line method over the estimated useful lives of the assets. The Company regularly evaluates the estimated remaining useful lives of the Company’s property and equipment, net, to determine whether events or changes in circumstances warrant a revision to the remaining period of depreciation. Maintenance and repairs are expensed as incurred. 370000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LOSS PER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COMMON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SHARE</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share excludes the effect of dilution and is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted net loss per share is computed by giving effect to all potential shares of common stock, including stock options and warrants to the extent dilutive. Basic net loss per share was the same as diluted net loss per share for the three and six months ended June 30, 2024 and 2023 as the inclusion of all potential common shares outstanding would have an anti-dilutive effect.</span></div>In accordance with ASC 260-10-45-13, exercisable penny options are included in the calculation of weighted average basic and diluted earnings per share. 182169 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of awards outstanding as of June 30, 2024 and 2023, which are not included in the computation of basic and diluted weighted average shares: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.596%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.447%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three and Six months ended<br/>June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options (excluding exercisable penny stock options)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,993,356 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,851,383 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283,411 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,470 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,152,397 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,152,397 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,429,164 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,250,250 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 5993356 5993356 2851383 2851383 283411 283411 246470 246470 5152397 5152397 5152397 5152397 11429164 11429164 8250250 8250250 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RECENTLY ISSUED ACCOUNTING STANDARDS </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Not Yet Adopted as of June 30, 2024:</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2023, the Financial Standards Accounting Board (FASB) issued Accounting Standards Update (ASU) 2023-07 "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures" which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 is effective for the Company’s annual periods beginning January 1, 2024, and for interim periods beginning January 1, 2025, with early adoption permitted. The Company does not expect that the updated standard will have a significant impact on the Company’s financial statement disclosures.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2023, the FASB issued ASU 2023-09 "Income Taxes (Topics 740): Improvements to Income Tax Disclosures" to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. ASU 2023-09 is effective for the Company’s annual periods beginning January 1, 2025, with early adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on the Company’s financial statement disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2024, the FASB issued ASU 2024-02 “Codification Improvements – Amendments to Remove References to the Concepts Statements.” This amendments to the Codification that remove references to various Concepts Statement. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2024. Early application of the amendments in this update is permitted for all entities, for any fiscal year or interim period for which financial statements have not yet been issued (or made available for issuance). If an entity adopts the amendments in an interim period, it must adopt them as of the beginning of the fiscal year that includes that interim period. The Company is currently evaluating the impact that the adoption of this standard will have on the Company’s financial statement disclosures.</span></div> STOCKHOLDERS’ EQUITY<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">WARRANTS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of warrant activity during the six months ended June 30, 2024:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>average exercise<br/>price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>remaining life (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>intrinsic value<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and exercisable - December 31, 2023</span></div></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,152,397 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.71 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.35</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$792</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and exercisable – June 30, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,152,397 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.71 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.85</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of warrant activity during the six months ended June 30, 2024:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>average exercise<br/>price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>remaining life (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>intrinsic value<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and exercisable - December 31, 2023</span></div></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,152,397 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.71 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.35</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$792</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and exercisable – June 30, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,152,397 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.71 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.85</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 5152397 5152397 4.71 4.71 P3Y4M6D P3Y4M6D 792000 792000 0 0 0 0 5152397 5152397 4.71 4.71 P2Y10M6D P2Y10M6D 1158000 1158000 STOCK-BASED COMPENSATION<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At the June 2024 annual stockholders’ meeting the 2022 Equity Incentive Plan was amended to increase the number of authorized shares from 5,900,000 shares to 8,900,000.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">STOCK OPTIONS</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock option activity during the six months ended June 30, 2024:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>options<br/>outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>exercise<br/>price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average<br/>remaining<br/>contractual life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>intrinsic value<br/>(in thousands)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding – December 31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,092,525 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,945 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,252)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.54 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options cancelled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,748)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding – June 30, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,175,525 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,692 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable – June 30, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,748,660 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,687 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company estimates the fair values of stock options using the Black-Scholes option-pricing model on the date of grant. For the six months ended June 30, 2024 and 2023, the assumptions used in the Black-Scholes option pricing model, which was used to estimate the grant date fair value per option, were as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.628%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average Black-Scholes option pricing model assumptions:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.89% - 128.74%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.23% - 111.73%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.02 - 7.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.71 - 6.07</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% - 4.60%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.54% - 3.80%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average grant date fair value per share</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.81 - $2.48</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.73 - $3.38</span></div></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">RESTRICTED STOCK UNITS</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of RSU’s awards activity:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six months ended June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numbers of Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Vested at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,881 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,357 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(177,827)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at the end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283,411 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.38 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">STOCK BASED COMPENSATION</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock-based compensation expense:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.115%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,338,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSU’s</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total general and administrative</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744,000 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623,600 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,621,000 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">924,600 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  RSU’s </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,000 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,800 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">626,000 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,800 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,040,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702,400 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,247,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,095,400 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the six months ended 2023, the Company granted 2,208,000 options to various executives and employees. Sixty percent (60%) of these options vest based on FDA Clearance for marketing of HeartBeam’s synthesized 12L product and the remaining forty percent (40%) vest monthly over a period of 48 months. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company calculated the fair value for each of these grants using the Black-Scholes option pricing model and the performance-based options are expensed beginning from date of grant to the expected FDA clearance, which is based on management’s probability assessment performed on a quarterly basis. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2024, total compensation cost not yet recognized related to unvested stock options and unvested RSUs was approximately $6.4 million and $0.6 million, respectively, which is expected to be recognized over a weighted-average period of 2.4 years and 1.08 years, respectively.</span></div> 5900000 8900000 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock option activity during the six months ended June 30, 2024:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>options<br/>outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>exercise<br/>price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average<br/>remaining<br/>contractual life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>intrinsic value<br/>(in thousands)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding – December 31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,092,525 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,945 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,252)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.54 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options cancelled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,748)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding – June 30, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,175,525 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,692 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable – June 30, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,748,660 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,687 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 6092525 2.22 P8Y8M12D 2945000 114000 2.27 5252 1.54 25748 2.41 6175525 2.23 P8Y4M24D 3692000 1748660 1.90 P7Y4M24D 1687000 For the six months ended June 30, 2024 and 2023, the assumptions used in the Black-Scholes option pricing model, which was used to estimate the grant date fair value per option, were as follows:<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.628%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average Black-Scholes option pricing model assumptions:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.89% - 128.74%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.23% - 111.73%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.02 - 7.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.71 - 6.07</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% - 4.60%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.54% - 3.80%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average grant date fair value per share</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.81 - $2.48</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.73 - $3.38</span></div></td></tr></table></div> 1.2589 1.2874 1.1023 1.1173 P6Y7D P7Y P5Y8M15D P6Y25D 0.0450 0.0460 0.0354 0.0380 0 0 1.81 2.48 1.73 3.38 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of RSU’s awards activity:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six months ended June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numbers of Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Vested at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,881 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,357 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(177,827)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at the end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283,411 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.38 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 217881 3.12 243357 2.26 177827 3.13 283411 2.38 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock-based compensation expense:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.115%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,338,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSU’s</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total general and administrative</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744,000 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623,600 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,621,000 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">924,600 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  RSU’s </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,000 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,800 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">626,000 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,800 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,040,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702,400 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,247,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,095,400 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 602000 507200 1338000 707200 142000 116400 283000 217400 744000 623600 1621000 924600 287000 78800 607000 170800 9000 0 19000 0 296000 78800 626000 170800 1040000 702400 2247000 1095400 2208000 0.60 0.40 P48M 6400000 600000 P2Y4M24D P1Y29D RELATED PARTY TRANSACTIONS<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the course of business, the Company obtains accounting services from CTRLCFO, a firm in which an executive of the Company has significant influence. On December 29, 2023, this executive, informed the Company of his plans to retire from his position as of February 1, 2024 and as such ceased to be a related party as of February 1, 2024. The Company had balances due to this firm amounting to approximately $2,000 as of December 31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During April 2024, the Company entered into consulting agreement with one of the independent Board of Directors to provide business development consulting services. For these consulting services, the Company agreed to pay $5,000 per month as remuneration and granted 70,000 options to vest during over a period of 36 months. During the three months ended June 30, 2024, the Company recognized $24,500 related to these consulting services, which includes stock based compensation expense of $9,500.</span></div> 2000 1 5000 70000 P36M 24500 9500 COMMITMENTS <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease Obligations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Prior to February 1, 2024, the Company was in a month-to-month lease agreement for its headquarters. The agreement was for an undefined term that could be cancelled at any time, given one month’s notice by either party. The Company’s monthly rent expense associated with this agreement was approximately $1,800. This headquarters lease was in the name of the Company’s Chief Executive Officer, and the cost was reimbursed monthly to CEO until January 31, 2024 when the Company terminated the month-to-month lease, and entered into a new lease in name of the Company with the same landlord. The new lease commenced on February 1, 2024, for initial period of 3 years. The Company performed an assessment and concluded that amount of operating lease right-of-use, or ROU assets was below the Company’s capitalization thresholds set in accordance with ASC 842. For the three and six months ended June 30, 2024 rent was approximately $5,400 and $10,440, respectively. For the three and six months ended June 30, 2023, rent expense was approximately $4,000 and $8,000, respectively.</span></div><div style="text-align:justify"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:106%">Professional Services Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the Company entered into a professional services agreement with Triple Ring Technologies, Inc. (“TRT”), a co-development company, to assist in the design and development of the Company’s telehealth complete solution 3D vector ECG collection device for remote heart attack or MI monitoring. This agreement was followed by several amendments. The agreement with TRT includes a commitment totaling $1.7 million. For the three and six months ended June 30, 2024, the Company has expensed approximately $0.1 million and $0.2 million, respectively. For the three and six months ended June 30, 2023, the Company has expensed approximately $0.4 million and $0.6 million, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2024, the Company has a remaining commitment of $0.2 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:106%">Clinical Research Organization</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 8, 2024, the Company has entered into an agreement with Clinical Research Organization (CRO) to perform certain services related to project set up, clinical trial management and monitoring during next six months. As per terms of the agreement, the Company will pay CRO approximately $0.5 million for these services. Additionally, the Company has signed a Clinical Study Agreement with first of five sites to carry out the clinical study for which CRO will act as Company sponsor in relation to payment for these services. The total cost of the clinical trial including the CRO cost is expected to approximate $0.8 million. For the three months and six months ended June 30, 2024, the Company has expensed $0.3 million and $0.7 million based on actual services performed by the CRO and clinical sites, of which $0.2 million was accrued as of June 30, 2024. As of June 30, 2024, the Company has a remaining commitment of $0.1 million.</span></div> P1M 1800 P3Y 5400 10440 4000 8000 1700000 100000 200000 400000 600000 200000 500000 5 800000 300000 700000 200000 100000